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According to international studies, the incidence of post-
radiation sarcoma (PRS) is less than 1% (68, 94, 122). 
This incidence is reported to have increased in recent 
years (94) and may continue to increase with the 
incorporation of radiotherapy in the multidisciplinary 
treatment of an increasing spectrum of malignant disease, 
and with an increasing number of patients surviving longer 
than the latent period necessary for the development of a 
postradiation sarcoma (108). In certain conditions (for 
example carcinomas of the breast and anus and 
retinoblastoma) radiotherapy is used so that extensive 
mutilating surgery may be avoided. It may also be used to 
improve the chances of local control ( for example in some 
cases of carcinoma of the breast) without having a known 
effect on long term survival. 
It is important that rare but severe complications of 
radiotherapy are reported and taken into account when 
weighing up the benefits and disadvantages of various 
modalities of treatment such as radiotherapy and surgery. 
As it is not possible to substantiate a 100% cause and 
effect relationship between oncogenesis and irradiation 
( 10 0) , the term "postradiation sarcoma" has been used in 
this report, as has been done in others (121, 122). 
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Statistical evidence for the relationship between 
irradiation and oncogenesis does exist (43, 51, 113). The 
mechanism of induction of postradiation sarcomas remains 
unclear as there has been difficulty in achieving 
radiation-induced transformation of human cell lines in 
vitro (8). Radiotherapy regimens used in patients who have 
developed postradiation sarcomas have not been well 
described (27, 49). Dose levels at which these tumors are 
most likely to occur have not been clearly established. 
Conflicting reports exist. These tumors either occur in 
low dose areas on the edge of the field ( 11 7) or in high 
dose areas (14, 114, 47). According to an hypothesis based 
on experimental work in mice, an increasing incidence of 
leukemia may be noted after irradiation with increasing 
dose until cell kill at high doses causes a fall in 
incidence ( 3 8) • 
extrapolated to 
This hypothesis could possibly be 
postradiation sarcomas but the peak 
incidence may not necessarily occur at the same dose level 
as for leukemia. 
This report from Groote Schuur therefore sets out to review 
cases of postradiation sarcomas, including malignant mixed 




of Groote Schuur Hospital and the 
(Frere Hospital, East London and 
Port Elizabeth) or known to have 
occurred in patients initially treated in these hospitals. 
It aims [1] to establish the features of the initial 
malignancy as well as the latent period for the development 
of postradiation sarcoma, 
and the outcome of the 
accurately as possible 
postradiation tumors have 
describe possible risk 
12 
the type of postradiatiop tumor 










predisposition to the development of malignancy, repeated 
courses of radiotherapy, surgery as part of the treatment 
of the initial tumor, and chemotherapy. 
Questions regarding the genesis of postradiation sarcomas 
cannot be answered by a review of 20 cases, even when 
combined with an analysis of literature. This review aims 
to add relevant information to the body of data from which 
the final answers may come. In view of the late diagnosis 
often made in cases of postradiation sarcoma (25, 94) the 
review also aims to heighten awareness of the condition so 
that it may be more often reported at a curable stage. 
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2. MATERIALS AND METHODS 
2.1. INCLUSION CRITERIA 
Possible cases of PRS, including MMMT, 
for malignancy at Groote Schuur 
in patients treated 
or the affiliated 
hospitals, or presenting to these hospitals with second 
malignancy, were identified by discussion and 
correspondence with members of the Radiation Oncology 
Departments. Cases were included in the study if the 
patient had developed a sarcoma in a previous radiotherapy 
field (regardless of the latency period) and if the 
histology differed from that of the primary tumor. If the 
postradiation tumor was an aggressive fibromatosis without 
histological evidence of malignancy and without metastases 
the case was not included. 20 cases which fulfilled the 
criteria for inclusion were identified. As the computerised 
database available did not allow a method of ensuring that 
all cases have been included in this study, the incidence 
rate for PRS could not be calculated. 
2.2. DOCUMENTS AND SPECIMENS REVIEWED AND METHODS OF REVIEW 
The clinical notes and, where available, diagrams, 
photographs of the postradiation tumors and radiological 
studies were reviewed. Histological specimens of the 
postradiation tumors (19 cases) and of the initial tumors 
(9 cases) were reviewed with a pathologist. Further 
immunocytochemical studies were obtained where indicated to 
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elucidate the diagnosis further. The postradiation tumors 
were graded as low, moderate or high grade according to the 
criteria of the number of mitoses, the extent to which 
tissue resembled normal tissue and the presence of 
necrosis. Clinical notes, x-rays and histological 
specimens as well as radiological studies were obtained, if 
this was at all necessary and feasible, from other 
institutions at which the patients had been treated. 
Note was made of other complications of radiotherapy 
experienced by the patients and where possible of evidence 
of radiation damage to tissue on x-rays and in pathological 
specimens. In some cases the entire specimen was of tumor 
tissue and damage to normal tissue could not be 
ascertained. 
2.3. CALCULATION AND PRESENTATION OF RESULTS 
2.3.1. CONVERSION FACTORS 
It is indicated in the text or on the tables if a 
conversion factor has been applied. Where doses were 
prescribed in Gray for Co-60 or 20MV beams, no conversion 
was required for tumors in soft tissue or bone. A factor 
of O. 957 had already been taken into account for C0-60 
prescriptions in Gray. Further reduction of this factor to 
0. 925 for postradiation tumors in bone was not considered 
necessary for this study. Doses for Tantalum-182 and 
Radium also required no conversion. For 250kV, HVL 3.5mmCu 
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irradiation, where it is indicated that f-factor conversion 
was applied a factor of 1. 05 was used for bone and O. 956 
for soft tissue. For the 220kV beam a factor of 1.5 was 
used for bone and 0.948 for muscle. 
factor of 4.67 was used (52, 102). 
For I-125 in bone a 
The f-factor gives dose in rads and this was subsequently 
converted to Gray (Gy) . ( 10 0 rads is equal to 1 Gy.) 
It must be noted that the f-factor does not take into 
account the radiobiological differences of the beams as 
this is virtually impossible to quantify in such a study. 
Therefore it has been specified for each case which beam 
was used. In cases where more than one course of 
radiotherapy was used, doses have sometimes been added 
together for the purposes of the study, even when different 
modalities were used in the same patient. 
Prescribed doses have been described as target volume doses 
(the minimal dose covering the target volume), central 
doses (the dose on the central axis at the midpoint of the 
patient in the case of parallel opposed fields) or given 
(applied) doses. In patients who had had radium insertions 
for carcinoma of the cervix the dose at Manchester Point A 
(a point estimated to be 2cm from the vaginal fornix) has 
been calculated. When necessary "prescribed doses" were 
actually obtained from the isodose charts. For example in 
case 19 two courses of radiotherapy were administered, one 
using a single field with a given dose and one using 
parallel opposed fields with a central dose. 
charts were used to determine the maximum dose. 
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The isodose 
Prescribed doses are described in the units used at the 
time of prescription as far as possible, as conversion 
factors vary according to the tissue being considered. In 
the Groote Schuur Radiation Oncology Department 
orthovoltage radiation is prescribed in Roentgen (R), which 
indicates exposure in air, and megavoltage and Radium 
treatment in Gray (absorbed dose). 
Field sizes are described in length by breadth. 
2.3.2. CASE REPORTS 
Results are first presented as case histories. 
2.3.3. BODY DIAGRAMS AND ISODOSE CHARTS 
The postradiation tumor was drawn onto a body diagram if 
information about the external beam radiotherapy was 
available ( 19 cases) . External beam radiation field ( s) 
were reconstructed on the body diagram to indicate the 
position of the postradiation sarcoma in the field(s). 
Where all radiation details were available (18 cases) 
isodose charts were reconstructed at one to four levels 
through the postradiation tumor. (In small tumors only one 
17 
level was necessary). 
charts. 
These included off-axis .isodose 
If necessary standard anatomical drawings were used in the 
construction of diagrams (123). Isodose charts with 
postradiation tumors superimposed have been used previously 
in our department (69). 
Using the clinical notes, diagrams, photographs, and where 
available radiological studies such as ultrasound scans, 
angiography and CT scans, drawings of the postradiation 
tumors were superimposed on the isodose charts. An 
estimate was made of the dose range in the tissue in which 
the tumor had developed and the point at which growth was 
likely to have been initiated. 
taken as the centre of the 
( In most cases this 
tumor. In patients 
was 
who 
developed secondary tumors in the uterus a point at the 
site of a normal uterus was taken. Where the main bulk of 
the tumor did not lie at the centre of the tumor a point in 
the main mass was taken.) A representative diagram was 
chosen for each patient for inclusion in the report. 
In three cases where radiological studies were no longer 
available, the tumor was reconstructed from descriptions 
onto the normal scan of another patient and transferred to 
the isodose charts. In two of these cases, the patient had 
been less than a year old at the time of radiotherapy and 4 
years old at the time of development of the postradiation 
tumor. The tumor as described in the older child was 
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reconstructed on the scan of a child of less than a year of 
age (i.e. involved areas were demarcated) so that it could 
be seen whether involved structures lay in the radiation 
field and what dose these structures had received in the 
infant. 
2.3.4. TABULATION OF RESULTS 
Results were tabulated with reference to the sex of the 
patient; age at which the initial radiotherapy was given; 
the type and site of the initial malignancy (described in 
this report as the primary tumor); radiotherapy modalities, 
dose and fractionation regimens; the latent interval 
(calculated from the start of the first radiation treatment 
course to the presentation of the second primary, whether 
or not it was recognized as a postradiation tumor at this 
time); the age at the presentation with the postradiation 
tumor; the tissue in which the postradiation tumor 
developed (bone or soft tissue); site (trunk, head and neck 
or extremity with a more specific site mentioned); the dose 
received in the tissue in which the sarcoma or MMMT 
developed (dose range and point); the pathological type and 
grade of the postradiation tumor; the treatment of the 
postradiation condition and outcome of this condition 
(calculated from the time of presentation with the 
postradiation tumor). If there was a significant delay in 
diagnosis of the postradiation tumor after presentation 
(more than approximately 1 month) the outcome has been 
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reported in the case history from the time of diagnosis as 
well as the time of presentation. 
2.3.5. STATISTICS 
Where indicated in the Results section groups were compared 
with regard to latency and with regard to the dose point at 
which the PRS is estimated to have developed. Mean and 
median ages for certain groups and median survival were 
also calculated. The package used was Microsoft Excel 4.0 
using the Statistical Analysis Toolpak. The test for 
comparing groups was a two sample t-test assuming unequal 
variances. 
Results are thus presented as brief case reports, with a 
diagram of the radiation field and PRS on a body outline 
for each patient, and where available a representative 
isodose chart. Tables and further description of results 
are included after the case histories. 
3. RESULTS 
3.1. CASE REPORTS 
Case 1: Primary Tumor: Carcinoma Cervix 
Postradiation Tumor: Malignant Mixed Mullerian 
Tumor Uterus 
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A 57-year-old patient presented in 1986 with a stage 2A 
squamous carcinoma of the cervix. A course of C0-60 
radiotherapy was commenced in December 1986 utilising 15 by 
16cm anterior and posterior fields and 15 by 9cm right and 
left lateral fields. A target volume dose of 2. OOGy per 
fraction was achieved 5 times a week in 27 fractions to a 
total dose of 54. OOGy. 
treatment was 43 days. 
The duration of external beam 
A vaginal cylinder and ovoid 
containing 55mg of radium were then inserted for 32 hours 
achieving a dose of 17. 6Gy at Manchester point A. The 
total summated dose at Manchester point A was 71.6Gy. The 
total duration of treatment was 48 days. At follow-up the 
patient was noted to have radiation proctitis and vaginal 
adhesions. 
In December 1992, 6 years after the commencement of 
radiotherapy, the patient was noted to have an enlarged 22-
week size uterus. Ultrasound showed a central lower 
abdominal mass which was solid and cystic. Aspiration 
biopsy in February 1993 produced cells with features of 
papillary cystadenocarcinoma. Hysterectomy was performed 
21 
in February 1993. The cavity of the uterus was filled by a 
large tumor mass measuring 6 by Berns. Omental metastases 
were present. Histological diagnosis was of an 
infiltrating malignant mixed mullerian tumor. This was of 
high grade. Radiation-induced desmoplastic response was 
present in the myometrium. The patient was not given 
furt:-.er active treatment. In June 1993, 4 months after 
hysterectomy, she was noted to have a local recurrence. 







that month, 6 
postradiation tumor 





As this was a uterine tumor it probably developed in an 
area between the coccyx and the symphysis pubis (the 
location of a normal uterus) and not at the central point 
of the mass at the time of presentation. On isodose curves 
through the central axis (3cm superior to the symphysis 
pubis) the tumor lies in an area which received from 60 to 
lOOGy. On curves taken 1.5cm inferior to the central axis 
it lies between 58 and lOOGy (fig 1). 
The tumor is estimated to have developed in tissue which 
received between 58 and lOOGy, probably in an area which 
received approximately lOOGy. 
Case 2: Primary Tumor: Carcinoma Cervix 
Postradiation Tumor: Malignant Mixed Mullerian 
Tumor Uterus 
22 
A 40-year-old patient presented with a stage 2 squamous 
carcinoma of the cervix in May 1977. A course of Co-60 
radiotherapy to the pelvis was commenced in May 1977 
utilising 15 by 15cm anterior and posterior fields and 15 
by 9cm left and right lateral fields. A target volume dose 
of 2.00 Gy was delivered 5 times a week in 27 equal 
fractions with adjustment of the last fraction achieving a 
total dose of 54. OOGy. The duration of treatment was 42 
days. An intracavitary radium insertion was performed 
thereafter using a tandem and ovoids containing 75mg of 
radium and achieving a dose of 19.5Gy at Manchester point A 
from the radium insertion and a total of 73.5Gy at point A. 
The total duration of treatment was 47 days. The patient 
complained of dyspareunia on follow-up and was noted to 
have vaginal adhesions. 
The patient failed to attend appointments after 1979 until 
June 1993, 16 years and 1 month after the commencement of 
radiotherapy, when she returned comp laing of lower 
abdominal pain and dysuria. She was noted to have a 
suprapubic mass the size of an 18 week pregnant uterus. On 
scan a 12cm cystic mass was noted. She underwent 
laparotomy, subtotal hysterectomy and bilateral salpingo-
oophorectomy in June 1993. The endometrial cavity was 
noted to be filled with a polypoid tumor mass. On 
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microscopic examination this was found to be a malignant 
mixed mullerian tumor. The tumor infiltrated through the 
wall of the myometrium into the outer third. It was high 
grade. Inflammatory cells attributable to prior 
irradiation have been noted in the specimen. The patient 
refused chemotherapy and in September 1993, 3 months after 
presentation with the postradiation sarcoma, returned to 
her home elsewhere in the country. She was lost to follow-
up. 
This was a uterine tumor and therefore developed in tissue 
of the uterus in its position at the time of radiotherapy. 
On isodose curves through the central axis 
to the symphysis pubis) the tumor at 
(2.5cm superior 
the time of 
presentation was situated between 45 and lOOGy (fig 2). At 
a level 1cm superior to the symphysis pubis it was also 
situated between the 45 and lOOGy curves. It is therefore 
estimated to have developed in this dose range, probably in 
tissue which received approximately 60Gy. 
Case 3: Primary Tumor: Carcinoma Cervix. 
Postradiation Tumor: Malignant Mixed Mullerian 
Tumor Uterus 
A 37-year-old patient presented in October 1972 with a 
stage 2B squamous carcinoma of the cervix. A course of 
Co-60 radiotherapy was commenced in October 1972 utilising 
8 fields. 15 by 15cm anterior and posterior and 15 by 8cm 
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left and right antero-lateral fields were used initially. 
A dose of l.45Gy was applied to each field 5 times a week 
for 15 fractions with adjustment of the last fraction 
achieving a total given dose of 21.SOGy to each field and a 
total target volume dose of 30.lOGy. Commencing on the day 
after the fifteenth treatment two radium insertions were 
performed 1 week apart using a tandem and ovoids containing 
75mg of radium in both cases. At each insertion the radium 
was left in situ for 36 hours achieving a total dose at 
Manchester point A from both insertions combined of 
37.44Gy. Treatment to the pelvic sidewalls commenced the 
day after the first radium had been removed. Treatment was 
by means of 15 by 15cm left and right anterior and 
posterior wedged fields. A dose of 2. 00 to 2. llGy was 
applied to each field 5 times a week for 11 fractions to 
the left and 12 to the right fields achieving a total given 
dose on the right of 22. SOGy and on the left 25. OOGy to 
each field. The target volume dose from the external beam 
treatment was 57.50Gy and the maximum dose 67.80Gy. 
Overall a total dose of approximately 94.94Gy was achieved 
at point A. The total duration of treatment was 43 days. 
The patient later developed radiation cystitis (cystoscopy 
revealed marked radiation changes) and radiation enteritis. 
Small bowel enema showed features of radiation enteritis 
involving the ileum including an area of constant 
narrowing. Radiation change was noted in both iliac bones. 
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In June 1986, 13 years and 8 months after commencement of 
the radiotherapy, the patient was referred back to the 
radiotherapy department with a solid lower abdominal mass. 
CT scan revealed a well-defined 9 by 6cm central pelvic 
mass which could not be separated from the uterus and which 
appeared to be compressing the bladder inferiorly with some 
anterior displacement. Aspiration biopsy did not reveal 
malignant cells and Pap smear was normal. She was assessed 
as having haemato- or pyometria secondary to cervical 
stenosis from previous radiotherapy and no further 
investigations were performed until June 1987. At this time 
the patient complained of right iliac fossa pain and 
constipation. Ultrasound showed an 11cm mass resembling 
fibroids with possible calcification. IVP showed a large 
soft tissue density pelvic mass and mild obstructive 
changes. A presumptive diagnosis of pyo- or haematometria 
was again made and the patient was taken to theatre for 
this to be drained. The cervix could not be located and 
the Pouch of Douglas was inadvertantly opened. A 
laparotomy was performed and a "multifibroid" uterus with 
multiple thick fibrotic adhesions was found. Through a 
combined vaginal and abdominal procedure the cervix was 
located and dilated and the uterus drained. Necrotic 
material and blood were obtained. Necrotic tissue and 
curettings were examined and she was diagnosed as having a 
malignant mixed mullerian tumor of the uterus. This was a 
high grade tumor. Palliative subtotal hysterectomy and 
bilateral salpingo-oophorectomy were performed in July 
1987. The tumor was thought to infiltrate the bladder at 
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surgery. On macroscopic examination it was noted to extrude 
through ruptured areas which appeared surgical in origin. 
Histologically it was noted to invade almost to the serosa. 
Post-operatively the patient received chemotherapy 
(Cisplatinum, Epirubicin and Cyclophosphamide 4 weekly) . 
After the fifth cycle a pelvic mass was noted. 
Chemotherapy was given for 8 cycles. It was discontinued 
in January 1988 when she was noted to have vaginal bleeding 
and tumor at the vault. A course of 20MV radiotherapy was 
commenced in February 1988 utilising 10 by 12cm anterior 
and posterior fields to the lower pelvis and vagina. A 
central dose of 28Gy was achieved in 8 fractions 3 times a 
week. The disease continued to progress locally and the 
patient died in June 1988, 2 years after presentation with 
the postradiotherapy tumor and one year after the diagnosis 
was made. 
This is a uterine tumor and probably developed in tissue 
lying between the symphysis pubis and coccyx. At the level 
of the central axis, 2cm above the symphysis pubis, tumor 
at the time of diagnosis was situated between the 50 and 
60Gy dose levels. Tumor from the larger bulk lying more 
superiorly has also been superimposed on central axis 
isodose curves. It lies between 60 and 10 OGy (fig 3) . 
Therefore it is estimated that this tumor developed in 
tissue which received from 50 to lOOGy, probably in an area 
which received lOOGy. 
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Case 4: Primary Tumor: Carcinoma Cervix 
Postradiation Tumor: Malignant Mixed Mullerian 
Tumor Uterus 
A 55-year-old patient presented with a stage 3B poorly 
differentiated squamous carcinoma of the cervix in 1957. 
She underwent two intracavity radium insertions of which 
the details have been lost. A course of of 220kV, 
1. 5mmCu radiotherapy was then commenced in November 
HVL 
1957 
utilising four fields (right and left anterior oblique and 
right and left posterior oblique). A dose of 200R was 
applied ~o each field 5 times a week. The anterior fields 
received 18 fractions to a total of 3600R and the posterior 
19 fractions to a total of 3800R, the two final fractions 
to the posterior field being given on the same day. The 
total target volume dose was approximately 3 7 8 3R. The 
duration of external beam treatment was 28 days. 
At a routine visit in March 1974, approximately 16 years 
and 4 months after the commencement of radiotherapy, the 
patient complained of abdominal pain and swelling. She was 
noted to have a mass· the size of a 14 to 16 week pregnant 
uterus arising from the pelvis. Ultrasound showed a large 
cystic mass in the midline. Barium enema showed the colon 
to be displaced in the sigmoid area by a large soft-tissue 
density pelvic mass. Liver scan showed patchy uptake 
throughout the liver. Chest X-ray showed no metastases. 
The tumor increased rapidly in size over two weeks and the 
patient was subjected to laparotomy in April 1974. An 
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irresectable tumor arising from the pelvis was foun9. The 
uterus was 20 weeks size. Tumor tissue was bursting 
through the myometrium. There was parametrial involvement 
to the pelvic sidewalls. Adhesions were noted around the 
liver. Biopsy only was performed. On histological 
examination this was diagnosed as a malignant mixed 




Only stromal sarcoma is noted in the uterine 
probably because insufficient material is 
The diagnosis is as noted on the basis of 
malignant glands in the broad ligament. The differential 
diagnosis would be stromal sarcoma of the uterus with an 
adenocarcinomatous component in the broad ligament. Chest 
x-ray showed a large rounded opacity with fluid levels in 
the retro-cardiac region. This may have been due to a 
hiatus hernia which was evident on Barium swallow but lung 
metastases were not excluded. Therefore the patient was 
assessed as possibly having spread to lung and liver. 
It was decided that the patient should commence 
chemotherapy with Actinomycin D and Vincristine. After the 
first injection of Actinomycin D she developed confusion 
and vomiting. She died in May 1974, 2 months after 
presentation with the postradiation tumor, before she was 
due for re-assessment for further chemotherapy. 
As details of the doses achieved by the radium insertions 
have been lost an estimate of the dose at which this tumor 
developed is not possible. Fig 4 shows the situation of 
the tumor at presentation in relation to the external beam 
fields. 
Case 5: Primary Tumor: Carcinoma Cervix 
Postradiation Tumor: Rhabdomyosarcoma of the 
Uterus 
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This 35-year-old patient presented in March 1983 with a 
Stage 3B carcinoma of the cervix. A course of 20MV 
radiotherapy was commenced in May 1983 utilising 17 by 16cm 
anterior and posterior and 17 by 11cm right and left 
lateral fields to the pelvis. A target volume dose 
{minimum tumor dose) of 2.88Gy was delivered 3 times a week 
for 16 fractions and a final fraction of 2.50Gy to achieve 
a total target volume dose from external beam therapy of 
48.45Gy. The duration of external beam radiotherapy was 57 
days. Two days after the completion of external beam 
treatment the patient underwent a radium insertion. A 
tandem and two ovoids containing 75mg of radium were 
inserted for 35. 5 hours achieving a dose of 23. 08Gy at 
Manchester point A from the radium insertion and a total 
summated dose at point A of 71.53Gy. The total duration of 
treatment was 60 days. 
In May 1988 the patient complained of post-coital bleeding 
and dyspareunia and was noted to have a frozen pelvis. In 
March 1988 she complained of lower backache. CT scan 
showed no evidence of lymphadenopathy or definite tumor 
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recurrence. Loops of small bowel appeared closely applied 
to the region of the uterus. In March 1993, 9 years and 10 
months after commencement of the course of radiotherapy, 
the patient was admitted to hospital with a rectal 
stricture. Rectal biosy showed radiation changes. CT scan 
showed a large midline cystic structure with a soft tissue 
rim in the pelvis which was thought to represent a fluid-
filled uterus. Bilateral hydronephrosis was noted . 
• 
In September 1993 the patient was referred back to the 
Radiotherapy Department with a smooth hard pelvic mass. CT 
scan was compared to one done in March 1993. This showed 
an enlargement of the mass previously noted but no 
hydronephrosis. The patient did not attend clinic again 
until October when she was seen again complaining of lower 
abdominal pain and the passing of fresh blood per rectum. 
Sigmoidoscopy showed a bleeding rectal stricture. 
Laparotomy was advised to establish the nature of the mass. 
The patient was reluctant to consent to this. In December 
1993 the vaginal vault, previously described as a fibrosed 
tube, was noted to have broken down. Biopsy of a vault 
mass showed features of a rhabdomyosarcoma. The 
differential diagnosis included the rhabdomyosarcomatous 
component of a carcinosarcoma. On review this has been 
confirmed to be a high grade rhabdomyosarcoma. 
1994 the patient complained of haematuria, 
In January 
dysuria and 
difficulty in passing urine as well as incontinence and 
suprapubic pain. Cystoscopy revealed slough, possibly due 
to tumor. Vaginal examination revealed an extensive mass 
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vagina. The patient was treated invading the 
symptomatically. She died in August 1994, 17 months after 
a mass was noted on CT scan and 8 months after histological 
diagnosis of the postradiation sarcoma. 
autopsy was refused by the family. 
Permission for 
On isodose curves 5.5cm above the central axis, 
approximately 2cm below the superior tumor, the tumor is 
situated between 47 and 48Gy. On isodose curves at a level 
through the central axis, 1.5cm above the symphysis pubis, 
it lies between 40 and 62Gy (fig 5). This is a uterine 
tumor and therefore developed in tissue of the uterus in 
its position at the time of radiotherapy. It is estimated 
to have developed in tissue receiving between 40 and 62Gy, 
at a point receiving approximately 50Gy. 
Case 6: Primary Tumor: Carcinoma Cervix 
Postradiation Tumor: Leiomyosarcoma of the 
Abdominal Wall 
A 40-year-old woman presented in September 1985 with a 
Stage 2B squamous carcinoma of the cervix. A course of Co-
60 radiotherapy was commenced in September 1985 utilising 
16 by 14.5cm anterior and post.~ior fields to the pelvis. 
A central dose of 2.85Gy was achieved 4 times a week for 17 
fractions to a total central dose of 48.45Gy. The duration 
of external beam treatment was 33 days. After 5 external 
beam treatments a vaginal cylinder contairiing 95mg of 
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radium was inserted for 10 hours due to bleeding achieving 
a dose from the cylinder of 4Gy at Manchester point A. A 
tandem and single ovoid containing 55mg of radium were 
inserted for 6 hours after the completion of external beam 
treatment achieving a dose of 3. 3Gy at point A from this 
insertion. Overall a summated dose of 55.75Gy was achieved 
at Manchester point A in a total of 37 days. 
In May 1989 thickening of the skin and superficial muscle 
thickening were noted in the irradiated area. In December 
1993, 8 years and 3 months after the commencement of 
radiotherapy, the patient complained of a mass in the left 
lower quadrant which had been present for 5 months and was 
painful. Fibrosis and a small area of darkening with skin 
tethering were noted in the irradiated area. There was no 
obvious mass palpable but CT scan showed a mass lesion just 
above the level of the acetabula. There was no plane of 
cleavage between this lesion and the rectus femoris muscle. 
Aspiration biopsy failed to reveal a diagnosis and further 
investigations were not undertaken until the patient 
returned in January 1994. At this time an 8 by 8cm 
irregular mass was noted in the abdominal wall with a 2cm 
area of skin infiltration. Biopsy showed this to be a 
leiomyosarcoma. The tumor was high grade. No surgery was 
possible and the patient was treated symptomatically with 
analgesics. She is alive with disease at the time of 
reporting, 9 months after the presentation with sarcoma in 
December 1993. 
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On isodose curves the tumor lies in an area which received 
between 20 and 52Gy (fig 6). It is thought to have grown 
at a moderate dose point of 50Gy. 
Case 7: Primary Tumor: Low Grade Stromal Sarcoma of the 
Uterus 
Postradiation Tumor: Fibrosarcoma of the Soft 
Tissues of the Pelvis 
A 19-year-old patient underwent dilatation and curettage in 
1958 for menorrhagia. Curettings showed features of 
possible endometrial sarcoma but stromal endometriosis 
could not be excluded. On review there was found to be 
malignancy in this specimen which was suspicious of stromal 
sarcoma. The patient subsequently underwent myomectomy and 
further dilatation and curettage. Specimens showed no 
malignancy. The patient presented to our Radiotherapy 
Department in July 1959 with a pelvic mass. Biopsy of 
tumor protruding through the cervix showed features of 
probable endometrial sarcoma. On review a diagnosis of low 
grade stromal sarcoma has been made. 
In July 1959, when the patient was 20 years old, a course 
of 250kV, HVL 3, 5mmCu radiotherapy was commenced to the 
lower abdomen utilising four 25 by 12,5cm fields (left and 
right anterior oblique and left and right posterior 
oblique). An applied dose of SOR was given initially and 
was increased daily in increments of lOR until llOR was 
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achieved. The maximum tumor dose was increased from 65R to 
143R and the target volume dose from 55R to 121R. After 16 
fractions the patient's separation changed. The same 
applied dose was used achieving a daily maximum tumor dose 
of 165R and a target volume dose of 148.5R. After a 
further 5 fractions fields were reduced to 15 by lOcms. A 
further 6 fractions were given of applied dose 200R 
achieving maximum tumor dose 220R and target volume dose 
200R. Treatment was given 5 times a week for a total 
duration of treatment of 4 0 days. The total applied dose 
was 3300R, the total maximum tumor dose 4160R and the 
target volume dose 3647R. The size of the mass decreased. 
The patient underwent total abdominal hysterectomy and 
bilateral salpingo-oophorectomy in November 1959 and a 
diagnosis of stromal endometriosis was made. On review 
this has been noted to be the same tumor as in the previous 
specimen (stromal sarcoma) but of modified appearance. The 
patient remained well on follow-up and was discharged from 
the clinic in December 1986. 
In November 1989, 30 years and 4 months after the 
commencement of radiotherapy, the patient presented to a 
private clinic with a history of lower abdominal pain, 
urinary frequency and dyspareunia. She was found to have a 
tender fixed pelvic mass of about 15 by 20cm. Ultrasound 
showed a solid mass and confirmed the clinical 
measurements. CT scan showed a central solid mass between 
the bladder and rectum. On intravenous pyelogram the right 
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kidney and ureter were non-functioning. Cystoscopy showed 
a possible area of bladder infiltration. Laparotomy 
revealed an inoperable tumor arising from the pelvis with 
the appearance of seedlings on the anterior surface of the 
rectus muscle. Histology showed an undifferentiated 
sarcoma with metastasis to muscle. 
In June 1990 treatment with a neutron beam was commenced at 
another institution for a 7 by 7cm tumor with pelvic 
spread. It is uncertain whether chemotherapy had been 
given prior to this. 3 angled wedged fields were utilised. 
A target volume dose of 7.8Gy was achieved in 6 fractions 
treating 3 times a week. The course was repeated to 
reduced fields 8 weeks later as there was minimal response 
and the tumor had remained inoperable. At follow-up the 
patient appeared well. She had occasional diarrhoea and a 
cystic mass was palpable fixed to the pelvic sidewall. CT 
scan showed virtually no change and surgery was not 
recommended. 
The patient subsequently presented to a surgeon in another 
city with a large pel vie mass. A complete resection was 
performed in June 1991. There was infiltration of the 
peritoneum, vault of the vagina, bladder base and small 
bowel with obstruction of the latter and the right ureter. 
Histology showed a moderate grade fibrosarcoma. On review 
the histological appearance of the postradiation tumor 
(fibrosarcoma) is different from that of the initial tumor 
(low grade stromal sarcoma). 
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The patient was subsequently noted to have metastases in 
the abdominal wall and para-aortic nodes as well as 
increased tumor in the pelvis. She died in November 1991, 
2 years after the presentation with the postradiation 
sarcoma. 
On isodose curves at the level of the central axis (through 
superior tumor) the tumor is situated in an area which 
received between 30 and 40.3Gy. 4cm below the central axis 
(mid-tumor) it lies between 30 and 4 OGy (fig 7) . 6. 2cm 
below the central axis it lies between 32 and 39.lOGy. The 
tumor appears to have developed in tissue which received 
between 30 and 40Gy, probably in tissue receiving 
approximately 38Gy. 
Case 8: Primary Tumor: Carcinoma Breast 
Postradiation Tumor: Pleomorphic Sarcoma of the 
Chest Wall 
A 27-year-old woman who had in 1985 been treated with 
conservation surgery and radiotherapy and subsequently 
mastectomy for a carcinoma of the right breast, underwent 
wide local excision and axillary clearance for a Tl node 
negative ductal carcinoma of the upper outer quadrant of 
the left breast in July 1987. A course of Co-60 
radiotherapy was commenced in August 1987 utilising 17 by 
8cm planned tangential fields to the left breast. A target 
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volume dose of 2.4Gy was achieved 4 times a week in 16 
equal fractions to a total dose of 38.4Gy. A lOMeV 
electron boost was then commenced to the scar utilising a 6 
by 10cm field. A dose of 4. SGy four times a week was 
applied for five fractions to achieve a total dose of 11.25 
Gy at the 90% isodose from the booster field. The total 
duration of treatment was 40 days. 
In July 198 9, 1 year and 11 months after commencement of 
radiotherapy to the left breast, a 2 by 1cm mass was 
excised from under the breast. Pathologic diagnosis was 
that this was a malignant fibrous histiocytoma but on 
review it has been described as a high grade pleomorphic 
sarcoma. At the time of the last report, in September 
1994, 5 years and 2 months after her presentation with the 
postradiation tumor, the patient was well and free of 
sarcoma recurrence. A recurrent carcinoma in the left 
breast had however been recently excised and she had 
commenced Tamoxifen. 
On an isodose curve the tumor lies in a moderate dose area 
which received 38Gy (fig 8). 
Case 9: Primary Tumor: Carcinoma Breast 
Postradiation Tumor: Sarcoma of the Axilla 
A 52-year-old woman underwent radical mastectomy for a Tl 
node positive carcinoma of the left breast in February 
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1976. A course of Co-60 radiotherapy was commenced in 
March 1976 to the left supraclavicular and superior 
internal mammary nodes utilising an 18 by 15cm anterior 
"inverted L" field and a 5 by 12cm posterior 
supraclavicular field. A dose of 2.25Gy for 16 fractions, 
followed by 2. 65Gy for 8 fractions and then 1. 50Gy for 1 
fraction was applied five times a week to the anterior 
field to a total applied dose of 58.7Gy. A dose of 0.95Gy 
was applied 5 times a week to the posterior field for 8 
fractions with adjustment of the last fraction to a total 
dose of 7. 5Gy. A dose of 52. 85 Gy was achieved at the 
apical node. The duration of treatment was 37 days. 
In 1983 the patient developed pain in the left shoulder and 
chest wall. X-ray in September showed increased density in 
the clavicle and ribs compatible with radiation change. CT 
scan showed an increase in left axillary soft tissue. In 
January 1984, 7 years and 10 months after commencement of 
radiotherapy, a 3 by 3cm left axillary mass was noted. 
Aspiration cytology showed malignant cells and the patient 
was treated with Tamoxifen for presumed recurr~nce of the 
breast carcinoma. The disease progressed on this treatment 
and on subsequent chemotherapy (Cyclophosphamide, 
Methotrexate and 5-Fluorouracil). Biopsy in May 1984 
showed features of a sarcoma. The tumor is of moderate 
grade but there is insufficient material for a more 
specific diagnosis to be made on review. A course of Co-60 
radiotherapy in hyperbaric oxygen was commenced to the 
axillary mass utilising anterior and posterior opposing 
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fields. A total central dose of 3 6Gy was given in 9 
fractions with treatment twice a week. The duration of 
treatment was 29 days. There was initial regression on 
irradiation but three months after completion of treatment 
the lesion was noted to have recurred. It continued to 
progress. Lymphoedema of the left arm, fungation of the 
tumor and bleeding were noted. The patient died in July 
1985, 18 months after presentation with the axillary mass 
and 14 months after diagnosis of a sarcoma. 
The tumor appears to have developed on the edge of the area 
protected by lead, in tissue which received between 20 and 
35Gy, probably in an area which received approximately 30Gy 
(fig9). 
Case 10: Primary Tumor: Carcinoma of the Breast 
Postradiation Tumor: Leiomyosarcoma 
Clavicular Area 
of the 
A 68-year-old woman with a history of surgery for an 
ovarian tumor (details unknown) underwent modified radical 
mastectomy in September 1972 for a Stage 2 carcinoma of the 
right breast. This was followed two weeks later by 
excision of slough and skin graft. A course of C0-60 
radiotherapy was commenced in October 1972 to the internal 
mammary and supraclavicular areas utilising a 16 by 21cm 
"inverted L" anterior field and a 6 by 10cm supraclavicular 
posterior field. A dose of 2Gy for 2 fractions and then 
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2.5Gy for 23 fractions with adjustment of the last fraction 
was applied five times a week to the anterior field to a 
total applied dose of 60Gy. A dose of l.15Gy was applied 
five times a week for 15 fractions to the posterior field 
with adjustment of the last dose to a total applied dose of 
18Gy. A dose of 55Gy was achieved at the apical node. The 
duration of treatment was 33 days. 
In 1984 the patient was noted to have dermatomyositis 
secondary to liver metastases diagnosed on ultrasound. She 
was treated with hormonal agents until April 1985 when 
these were discontinued due to disease progression. 
In September 1985, 12 years and 11 months after 
commencement of radiotherapy, the patient was noted to have 
a swelling in the right clavicular area. A tumor was 
incompletely resected in November 1985 and shown on 
microscopic examination to be a spindle cell sarcoma. On 
review this has been diagnosed as a leiomyosarcoma in spite 
of a negative desmin stain. (The tumor contains cigar-
shaped cells running in sheets interspersed with striated 
muscle. Fibrillar cytoplasm is noted) . Radiation change 
with fibrosis and muscle lysis as well as vascular changes 
in surrounding normal tissue have also been noted in this 
tumor. It was a high grade tumor. 
Six months after resection the tumor recurred in the region 
of the scar. Treatment was symptomatic. The patient died 
in June 1986, 9 months after presentation with the 
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postradiation tumor. The cause of death is not noted and 
is uncertain in view of the possible presence of metastases 
from the breast carcinoma. 
4cm above the central axis the superior tumor lies between 
55 and 64. 54Gy. At a level 1cm above the central axis 
(approximately through mid-tumor) 
the 55 and 64. 3 9Gy dose levels 
the 
(fig 
tumor lies between 
10) . 2cm below the 
central axis the inferior tumor lies between 10 and 58Gy. 
The tumor is estimated to have grown in tissue which 
received from 10 to 64Gy, and probably in tissue which 
received approximately 60Gy. 
Case 11: Primary Tumor: Bilateral Retinoblastoma 
Postradiation Tumor: Osteosarcoma of the Maxilla 
An 8-month-old child was referred to Groote Schuur Hospital 
in January 1969 having undergone enucleation of the right 
eye for retinoblastoma in October 1968. Multiple tumors 
were noted in the left eye. X-ray of the skull and orbits 
did not show any bony abnormality. 
A course of 250kV, HVL 3. 5mmCu photon radiotherapy was 
commenced in February 1969 to both orbits utilizing 5 
fields: 1) 5 by 4cm left lateral posterior - 100% 2) 5 by 
3cm left lateral anterior -25% 3) 5 by 3cm left anterior -
25% 4) 5 by 5cm right lateral - 100% and 5) 5 by 3cm right 
lateral oblique - 100%. A maximum tumor dose·of 3686R was 
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achieved in 21 equal fractions of 175.SR. The target 
volume dose (minimum tumor dose) of 3119R was achieved in 
21 equal fractions of 148.SR. Treatment was given five 
times a week. The duration of treatment was 29 days. 
O. 6mg of triethanomelamine was administered intravenously 
on the days of the fifth and 12th fractions and 4 days 
after treatment had been completed. The lesions did not 
regress and the patient subsequently received two 
injections of intravenous Endoxan. 
In June 1969 two Tantalum-182 wire ophthalmic applicators 
were applied to the left eye. 1) One with two ellipses of 
tantulum, one weak and one strong, of mean diameter 6 and 
5mm, was applied to the upper temporal quadrant. The dose 
rate at 2mm (inclusive of SR/hr from the other applicator) 
was 12 6R/hr. 2) One with an outer rectangle of one weak, 
one strong wire about 13 by 10mm and an inner circle of 4mm 
diameter with one weak and one weaker wire was applied to 
the lower nasal quadrant. The dose rate for the lower 
nasal applicator (inclusive of 2R/hr from the other 
applicator) was 138R/hr. The duration of application was 
146,5 hours and the dose at the surface of the upper 
temporal applicator was 18459R. The dose at the surface of 
the lower nasal applicator was 20217R. 
In April 1970 left enucleation was performed as there was 
thrombotic glaucoma with secondary vitreous haemorrhage and 
no useful vision in the eye. The lens was cataractous. 
Histological assessment of the eyeball showed no evidence 
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of viable tumor. There was focal calcificatign and 
degeneration of collagen. 
In September 1972, 3 years and 7 months after the 
commencement of the initial course of radiotherapy, the 
child presented with a swelling of the left palate. X-ray 
of the facial bones showed opacification of the left 
maxillary antrum with apparent erosion of the lateral wall. 
The floor of the orbit was eroded. Biopsy of the gingiva 
showed features of osteosarcoma. This was a high grade 
tumor. Necrosis is evident in the specimen. Examination 
under anaesthaesia revealed swelling and elevation of the 
floor of the left orbit, medial displacement of the lateral 
wall of the nose and ulceration and tumor of the left upper 
gingiva in the region of the absent left molar. There was 
a hard swelling of the left half of the hard palate not 
crossing the midline and of the anterior maxillary wall. 
A course of Co-60 radiotherapy was commenced. Initially a 
single 5 by 5cm anterior field to the left maxilla was 
utilised. A dose of 2.00Gy was given per fraction 5 times 
a week. After 5 fractions, when planning had been 
completed, a 5 by 6cm left anterior field and a 5 by 7cm 
left lateral oblique field were utilised. A tumor dose of 
44Gy was given in 22 equal fractions of 2.00Gy each 5 times 
a week. There was a rest period of 17 days after 10 
fractions due to an acute reaction. The duration of the 
entire course of radiotherapy (3 fields) was 52 days. The 
total maximum tumor dose was 62.00Gy and the target volume 
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dose (minimum tumor dose) 52.00Gy. Five intravenous 
injections of 125µg Actinomycin D were given during the 
course of radiotherapy. When treatment was recommenced 
after the rest period, weekly Vincristine was administered 
until the end of treatment (3 injections) and 3 times 
thereafter .A week after the last Vincristine injection 5 
daily injections of 185ug Actinomycin were administered. 
Maxillectomy was performed in January 197 3. The mass had 
been noted to have decreased in size. At surgery the 
surgeon's opinion was that the tumor was extending up and 
over the orbital floor. No residual tumor was seen on 
histological examination of the surgical specimen. 
Fibrosis from previous radiotherapy has been noted in this 
specimen. 
In March 1973 extension of tumor in the left orbit was 
noted. X-ray showed opacification of the orbit. No 
further active treatment was possible. The child died in 
June 197 3, 9 months after he presented with the 
osteosarcoma. 
At a level 1.5cm inferior to the central axis of the field 
the superior tumor lies between 10 and 40Gy. 1cm inferior 
to this at the inferior field margin, at a level between 
superior and mid-tumor, the tumor lies between 20 and 33Gy. 
1cm inferior t~ this level, below the inferior field 
margin, the mid-tumor lies between 5 and 7. 7Gy (fig 11). 
The tumor lies in tissue which extends from that even 
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further inferior to the external beam field margin, where a 
minimal dose will have been received, to tissue which 
received 4 OGy. It is estimated to be likely to have 
developed in tissue which received 8Gy. 
Case 12: Primary Tumor: Bilateral Retinoblastoma 
Postradiation Tumor: Osteosarcoma Orbital Bones 
A 5-month-old girl was referred in May 1976 with the 
diagnosis of bilateral retinoblastoma. Skull x-ray and 
tomograms of the orbits and optic canals were normal. She 
had undergone enucleation on the right. Two nodules were 
present on the left retina. A course of 250kV, HVL 3 SmmCu 
photon radiotherapy was commenced in May 1976 utilising 4 
by 4cm fields to the right and left head. Three fractions 
of 140R achieving a central dose of 150R per fraction were 
applied. The dose was then increased to 190R (central dose 
230R) for 2 fractions to compensate for a public holiday. 
A further 14 fractions of 140R and a final fraction of 70R 
were then applied. Treatment was given 5 times a week. 
The total applied dose to each field was 2830R. A total 
central dose of 3000R was achieved. The duration of 
treatment was 39 days. 
4 days after the completion of radiotherapy the patient was 
commenced on chemotherapy with CCNU and Vincristine. 
46 
In January 1977, 2 months after completing chemotherapy, 
progression was noted in the left eye and chemotherapy was 
changed to Dibromodulcitol and Procarbazine. This 
chemotherapy was continued with interruptions until April 
1978. In May 1977 progression was noted on the left and in 
June an Iodine-125 applicator with four 1.80mCi sources and 
one 0.95mCi source was applied to the posterior aspect of 
the left globe. A dose of 45Gy over 150.5 hours was given. 
The tumor did not respond. In October 1977 a course of Co-
60 radiotherapy was commenced utilising a 3 by 2.5cm field 
to the left lateral orbit. A dose of 14.60Gy was given in 
two fractions over five days with the sensitizer Ro-07-0582 
orally before each treatment. In February 1978 gross 
recurrence was noted and the patient was again treated with 
Co-60 radiotherapy utilising a 3 by 3cm field to the left 
eye. A dose of 14.00Gy was given in 2 equal fractions over 
4 days with the sensitizer Ro-07-0582 before each 
treatment. In April 1978 left enucleation was performed 
due to progression. 
In December 1980, 4 years and 7 months after commencement 
of the first course of radiotherapy, a mass was noted in 
the left zygoma. X-rays of the skull and facial bones 
showed left retro-orbital sclerosis and a possible sphenoid 
edge mass. The left zygomatic arch was expanded and 
sclerotic. A bone biopsy in January 1981 showed this to be 
an osteogenic sarcoma. The tumor is high grade. No active 
treatment could be offered. The disease progressed and the 
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patient died in May 1981, 5 months after presentation with 
the postradiation tumor. 
At the level of the central axis, approximately midway 
between superior and mid-tumor, the tumor lies between 35 
and 60Gy. 1cm inferior to this, at approximately the level 
of mid-tumor, it lies between 20 and 50.3Gy (fig 12). 2cm 
inferior to the central axis the tumor lies between 20 and 
27.lGy. It is estimated to have developed in tissue 
receiving between 20 and 60Gy, probably in approximately a 
50Gy dose area. 
Case 13: Primary Tumor: Bilateral Retinoblastoma 
Postradiation Tumor: Pleomorphic Sarcoma of the 
Orbital Soft Tissues 
A 28-month-old female underwent left enucleation for a 
retinoblastoma involving the optic nerve in September 1972. 
Multiple lesions were present in the right eye. X-ray of 
the skull and orbits showed no abnormality except 
enlargement of the left optic foramen with possible erosion 
of the cortical margin inferiorly. 
A course of 250kV, HVL 3. SmmCu photon radiotherapy was 
commenced in October 1972 utilising five fields to the 
orbits and the right retina: 1) 4 by 2cm left lateral; 
2) 4 by 6cm left anterior oblique; 3) 4 by 4cm left 
anterior; 4) 4 by 2cm right anterior; 5) 4 by 5cm right 
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lateral. A maximum tumor dose of 3630R in 19 fractions of 
182R and a final fraction of 172R was achieved and a target 
volume dose (minimum tumor dose) of 3300R. Treatment was 
given 5 times a week. The duration of treatment was 30 
days. Cyclophosphamide was commenced during radiotherapy 
and continued each 2 weeks for 6 weeks. 
By October 1973 the disease on the right had progressed and 
in May 1974 right enucleation was performed for 
retinoblastoma. 
In 1974 the patient was commenced on treatment for 
pulmonary tuberculosis. 
In August 1977, 4 years and 10 months after commencement of 
radiotherapy, the patient was noted to have a mass in the 
left orbit and zygoma. Tomograms showed a soft tissue mass 
in the left orbit and destruction of bone. CT scan showed 
a retro-orbital mass on the left eroding through the 
postero-lateral aspect of the wall of the orbit. There was 
a small portion of tumor in the left middle cranial fossa. 
This has been assessed by a radiologist as being primarily 
a soft tissue tumor. The patient was initially treated 
with chemotherapy (Cyclophosphamide and Vincristine) on the 
assumption that the retinoblastoma had recurred. The 
initial biopsy was inadequate for a definite diagnosis. 
Overall features of repeat biopsy were of pleomorphic 
sarcoma. In view of the radiological evidence of bone 
destruction by the tumor it was decided to treat it as an 
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osteogenic sarcoma. Treatment was changed to Vincristine, 
high dose Methotrexate and Adriamycin and given for two 28-
day cycles. Response was noted but there was subsequent 
progression clinically and on CT scan. Chemotherapy was 
discontinued. The patient died in February 1978, 6 months 
after presentation with the postradiation tumor. At 
autopsy pleomorphic sarcoma was found to have destroyed the 
left temporal lobe of the brain. It had extended through 
the greater wing of the sphenoid, and into the pharynx and 
left maxillary sinus. 
CT scans showing the postradiation tumor have been 
superimposed on the contours taken at the time of 
radiotherapy. At the level of the central axis mid-tumor 
lies between 10 and 37Gy (fig 13). 1cm inferior to the 
central axis it lies between 10 and 37Gy. The inferior part 
of the tumor is in the region of the inferior field. At 
the inferior field level the tumor lies between 10 and 28 
Gy. The tumor is estimated to have grown between less than 
lOGy and 37Gy at a point which received approximately 35Gy. 
Case 14: Primary Tumor: Wilms' Tumor 
Postradiation Tumor: Osteosarcoma of the Iliac 
bone 
In March 1975 a 4-year-old child presented with a 9 by 15cm 
mass in the right abdomen. Intravenous pyelogram showed a 
non-functioning right kidney. A course of 250kV, HVL3.5mm 
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Cu photon radiotherapy was commenced in March 1975 to the 
right abdomen utilising 20 by 12.5cm anterior and posterior 
parallel opposed fields. The fields extended from the 
superior margin of the tenth thoracic vertebral body to the 
superior iliac crests and 2cms to the left of the midline. 
A dose of 130R was applied to each field for 9 fractions 
and SOR for 1 fraction 5 times a week to acheive a total 
applied dose of 1250R to each field and a total central 
dose of 1200R. The duration of treatment was 15 days. 
Incomplete resection of a Wilms' tumor was performed 6 days 
later. On the 13th postoperative day 250kV, HVL 3, 5mmCu 
photon radiotherapy was recommenced utilising 14 by 13cm 
anterior and posterior parallel opposed abdominal fields. 
The field centres were the same as for the preoperative 
applied to each field for 13 fields. A dose of 114R was 
fractions and 154R for 1 fraction to achieve a total 
applied dose of 163 6R to each field and a total central 
dose of 1800R. Treatment was given 5 times a week. The 
duration of this course was 18 days. 
Chemotherapy with Vincristine, Actinomycin D and Adriamycin 
was commenced preoperati vely and continued for a 68-week 
course. 
In February 1992, 16 years and 11 months after the 
commencement of radiotherapy, the patient presented with a 
2-month history of a mass in the right iliac fossa. The 
mass measured 10 by 10cm. The right leg was moderately 
swollen. Ultrasound showed an inhomogeneous mass with a 
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suggestion of necrosis in it. It measured 9. 7 by 4. 2 by 
6. 6cm and appeared fixed to the ileum. X-rays showed a 
large mass which appeared to arise from the right ileum and 
had the appearance of a large osteosarcoma. A number of 
slightly flattened and deformed lumbar and thoracic 
vertebrae were noted to probably be due to radiotherapy in 
childhood. A biopsy specimen from the ileum showed 
features of osteosarcoma. This is a high grade tumor. 
The patient was commenced on chemotherapy with Cisplatinum 
and Adriamycin for 2 cycles 4 weeks apart. There was no 
response to this chemotherapy and treatment was changed to 
chemotherapy with Cyclophosphamide, Vincristine, Adriamycin 
and Dacarbazine for 2 cycles 1 month apart. There was no 
response to treatment. The patient died in August 1992, 6 
months after presentation with the sarcoma. 
Isodose curves through the superior iliac crest at the 
inferior border of the field show the iliac bone to have 
been in an area which received approximately 10 to 13Gy 
( fig 14) . The tumor is estimated to have grown in bone 
which received approximately 12Gy. 
Case 15: Primary Tumor: Carcinoma Parotid 
Postradiation Tumor: Osteosarcoma of the Mandible 
A 17-year-old female underwent excision of a tumor at the 
left angle of the jaw in December 1967. (She·had also had 
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surgery for the swelling 10 years previously.) 
Histological examination showed a mucoepidermoid carcinoma 
of salivary gland origin with involvement of a lymph gland. 
The specimen shows low-grade tumor. A course of Co-60 
radiotherapy was commenced in March 1968, when the patient 
was 18 years old, to the left parotid area utilising a 10 
by 7cm left lateral and a 10 by 5cm left anterior field. A 
dose of 2.50Gy was given to each field 3 times a week for 
16 fractions achieving a maximum tumor dose of 3.25Gy and a 
minimum (target volume dose) of 3.00Gy per fraction. The 
total maximum tumor dose was 60.00Gy and the target volume 
dose 48.00Gy. The duration of treatment was 37 days. 
In February 1975, 6 years and 11 months after the 
commencement of radiotherapy, the patient was admitted to 
the radiotherapy ward with massive swelling of the right 
face. The history was of 2 months duration. The lesion 
extended from the right temporal fossa 5cm above the right 
zygomatic arch to the left lower third molar and from the 
right external auditory meatus posteriorly. It was 
assessed as being a T4 tumor. It crossed the midline in 
the floor of mouth. It was deep to the masseter and 
bulging into the mouth. 
right and left neck. 
radiotherapy was noted. 
Small nodes were noted in the 
Pigmentation from previous 
On the basal view of skull x-rays 
a large soft tissue tumor was noted in the region of the 
mandible on the right. Panorex showed a moth-eaten 
appearance to the right mandible and a poorly-defined 
periosteal reaction. There was a large soft tissue mass 
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apparently in the region of the angle of the mandible and 
extending mainly into the oral cavity. Biopsy showed this 
to be an osteosarcoma. The tumor is high grade. 
Methotrexate and Vincristine were administered once. The 
tumor continued to grow and fungated externally. The 
patient bled from the mouth. She was sent home in March 
1975 and subsequently died. The date of death is 
uncertain. 
At the superior edge of the field the bone containing 
superior tumor lies at 12Gy. At the central axis, through 
mid-tumor, the bone lies at 16Gy. The tumor in the body of 
the mandible lies between less than 8Gy and 16Gy if isodose 
curves of the field edge are superimposed on this area (fig 
15). The tumor appears to have developed in bone which 
received from less than 8Gy to 16Gy. It is thought to have 
developed initially in the body of the mandible. Therefore 
it probably developed from a point which received 
approximately 12Gy. 
Case 16: Primary Tumor: Synovial Sarcoma the Thigh 
Postradiation Tumor: Osteosarcoma of the Femur 
This 21-year-old patient was referred to our institution in 
March 1976 after excision of a mass in the left thigh. The 
histology report was that it was a soft part sarcoma. 
Review of the specimen led to the report that it was an 
undifferentiated malignant tumor, probably a sarcoma. At a 
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later review with immunocytochemical tests a diagnosis of 
synovial sarcoma has been made. 
A course of Co-60 radiotherapy in hyperbaric oxygen was 
commenced to the left thigh in April 1976 utilising 30 by 
11cm anterior and posterior fields to the left thigh. A 
central dose of 4.5Gy was given twice a week for 10 
fractions to a total central dose of 45. OOGy. After 7 
fractions the patient refused hyperbaric oxygen and was 
treated in air. 
days. 
The total duration of treatment was 33 
2 weeks after completion of radiotherapy the patient 
received chemotherapy with Vincristine and Methotrexate. 
The patient failed to return to clinic until November 1976 
when he presented with an ulcer on the right leg which was 
not malignant. At that time he received further 
chemotherapy (Vincristine, Methotrexate and Adriamycin). 
He was subsequently unable to attend further appointments 
as his employer would not release him from his duties. At 
follow-up appointments in April 1977 and April 1978 he was 
noted to be clinically free of recurrence. In April 1984 
the patient was referred back to our institution with a 
lesion which clinically appeared to be a local recurrence 
with sepsis and bleeding. Biopsy specimens did not reveal 
malignancy but pseudoepitheliomatous hyperplasia, fibrous 
tissue with degenerative cells and radiation changes in 
vessels. 
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In 1987 the patient presented to another institution with 
an adenocarcinoma of the upper lobe of the right lung which 
was treated by means of lobectomy. He also received 
treatment for tuberculosis. In November 1992 he presented 
with symptoms due to recurrence of the bronchial carcimoma. 
Bronchoscopy revealed a fungating mass of the right 
bronchus intermedius which on histological examination was 
again found to be a poorly differentiated adenocarcinoma. 
Symptoms were controlled by means of palliative 
radiotherapy. 
In July 1993, 1 7 years and 3 months after commencement of 
the course of radiotherapy to the left thigh, the patient 
returned to the same institution with a history of 
approximately 2 months of swelling of the left thigh, pain 
and stiffness of the left knee. X-ray of the left femur 
and knee showed a large osteosarcomatous lesion of the 
shaft of the femur and underlying osteoporosis of the 
bones. Biopsy showed a poorly differentiated osteosarcoma 
which on review of the report appears to have been high 
grade although grade is not specifically mentioned. The 
specimens could not be obtained for review. The patient 
was assessed for palliative amputation. Bone scan in 
September revealed intense uptake in the left femur and 
diffuse metastases in the spine, pelvis and skull. The 
features were those of an osteogenic sarcoma of the left 
femur and widespread metastases. Chest x-ray showed 
diffuse metastases in the right lung and CT scan multiple 
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pulmonary metastases and mediastinal lymphadenopathy. The 
patient died on 23 October 1993, 3 months after 
presentation with the postradiation tumor. Amputation had 
not been performed. The cause of death is ucertain in view 
of the presence of incurable bronchus carcinoma. 
The bone at the level of the superior field border, through 
the superior tumor, lies between 38 and 39Gy. At a level 
7.5cm above the central axis, through the main tumor bulk, 
the bone lies between 42 and 47Gy (fig 16). At the level 
of the central axis (mid tumor extent in bone) the bone 
lies between 45 and 47Gy. The tumor is estimated to have 
grown between 38 and 47Gy in an area which received 
approximately 45Gy. 
Case 17: Primary Tumor: Giant Cell Tumor of the Pelvic 
bones 
Postradiation Tumor: Postradiation Sarcoma in the 
Site of a Previously Irradiated Giant Cell Tumor. 
A 37-year-old male presented in 1977 with an extensive 
osteolytic bone lesion involving the right ileum and 
extending into the right superior pubic ramus. Open biopsy 
at the junction of the right superior pubic ramus with the 
ileum had shown tumor totally within the periosteum of the 
pelvis. Provisional histological diagnosis was of a grade 
2 giant cell tumor of bone but the final diagnosis was of 
possible aneurysmal bone cyst - diagnosis uncertain. On 
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review the most likely diagnosis is thought to be grade 2 
giant cell tumor. 
A course of Co-60 radiotherapy was commenced in December 
1977 utilising 13 by 9cm anterior and posterior parallel 
opposed fields to the right pelvis. 24 fractions of 2.20Gy 
and a single fraction of 3.25Gy were applied to each field 
5 times a week. A total applied dose of 5 6. 05Gy and a 
total central dose of 50.00Gy were achieved. 
of treatment was 38 days. 
The duration 
Subsequent x-rays showed some ossification in the lesion. 
In October 1980 the patient complained of pain in the right 
hip. X-rays were unchanged. 
In February 1981, 
of radiotherapy, 
3 years and 2 months after commencement 
x-rays showed evidence of radiological 
recurrence. Angiography showed features of a malignant 
vascular tumor of the right ileum and superior and inferior 
pubic rami with extension into the obturator foramen and 
further extension into the pelvis adjacent to the 
ileopectineal line. CT scan showed the lesion to involve 
the acetabulum and extend into the right superior pubic 
ramus. There was extension into the ischium with loss of 
cortex on the medial aspect and extension of soft tissue 
into the right obturator muscle which was displaced 
medially. 
In March 1981 the vascular supply to the tumor was removed 
by embolisation. 
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In March 1984 the lesion was still unchanged. In July 1984 
the patient complained of sciatic pain on the right and 
increased disablilty. X-rays and CT scan showed an 
increase in the size of the lesion. Biopsy of the lesion 
in October 1984 showed malignant fibrous histiocytoma. On 
review this has been diagnosed as a postradiation sarcoma 
in the site of a previously irradiated giant cell tumor. A 
more specific diagnosis could not be made. In view of the 
absence of non-osteoclastic giant cells the diagnosis of 
malignant fibrous histiocytoma cannot be confirmed. The 
specimen is very desmoplastic with fibrosis in response to 
the initial radiotherapy. Lung tomograms showed multiple 
metastases. The patient was treated with 2 cycles of 
chemotherapy with DTIC, Vincristine, Adriamycin and Endoxan 
one month apart. His condition deteriorated rapidly. Tumor 
was palpable over the right iliac spine and there was a 
palpable mass on the chest. He received radiotherapy to a 
painful area. A single fraction of Co-60 radiotherapy was 
given to a 15 by 22cm posterior pelvic field. He received 
a dose of 6.00 Gy. He died in January 1985, 3 years and 11 
months after presentation with the postradiation sarcoma. 
1cm from the superior border of the initial radiation 
field, at the level of the superior tumor, the bone in 
which the tumor grew lies between 30Gy and 54.50Gy. At the 
level of the central axis (approximately mid-tumor) the 
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tumor lies between 45 and 55Gy (fig 17). The tumor appears 
to have developed in bone which received between 30 and 
55Gy, probably in an area which received approximately 
48Gy. 
Case 18: Primary Tumor: Giant Cell Tumor of the Humerus 
Postradiation Tumor: Osteosarcoma of the Humerus 
A 19-year-old patient was referred to our institution in 
June 1949 with an osteoclastoma of the right humerus 
adjacent to the elbow (diagnosed on the basis of clinical 
and radiological features). A course of 220kV, HVL 1.5mm 
Cu radiotherapy was commenced in June 1949, when the 
patient was 20 years of age, utilising 15 by 7. 5cm right 
and left lateral fields to the right humerus. A dose of 
10 OR was applied to each field. For the first and last 
fractions the dose was SOR. Treatment was given 5 times a 
week for 21 fractions achieving a total applied dose of 
2000R. The duration of treatment was 30 days. 
On x-ray 
suspected. 
in January 1950 extension 
A second course of 
of the lesion was 
220kV, HVL 1.SmmCu 
radiotherapy was commenced in February 1950 utilising 15 by 
7. 5cm right and left lateral fields. lOOR was applied to 
each field 5 days a week for 20 fractions achieving a total 
dose of 2000R applied to each field. The total duration of 
this course of treatment was 28 days. The total central 
dose in this patient (from both courses of treatment) was 
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5000R. The patient appears to have been followed up at 
another hospital. An x-ray in April 1950 showed increased 
rarefaction. An x-ray in March 1951 apparently showed some 
improvement. In February 198 6 the patient was referred 
back to the orthopaedic surgeons with symptoms of lateral 
scar entrapment. An x-ray showed cystic and sclerotic 
change with osteoarthritis of the elbow joint. 
In January 1992, 42 years and 7 months after commencement 
of radiotherapy, the patient presented with a pathological 
fracture of the distal right humerus. She had fallen and 
injured her arm in December 1991. An x-ray showed a 
supracondylar fracture and a lytic bone tumor. Needle 
biopsy in April 1992 revealed a sarcoma of bone, thought to 
probably be an osteosarcoma. On review this has been 
confirmed as a high grade osteosarcoma. Aspiration 
revealed malignant cells consistent with a sarcoma. Bone 
scan in April 1992 showed features in keeping with a 
primary bony tumor of the distal humeral epiphysis and 
metaphysis with encroachment on the most distal diaphysis. 
There was no convincing evidence of metastatic bone 
involvement. In April 1992 the patient underwent a right 
above elbow amputation. At that time her symptoms were of 
increasing swelling of the right elbow, increasing pain of 
the elbow and stiffness. The arm was flexed at 90 degrees. 
There was minimal function of the right hand. Chest x-ray, 
CT scan and marrow biopsy did not show metastases. The 
patient did not wish to have adjuvant chemotherapy. 
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At follow-up in November 1993 an x-ray of the right arm 
stump showed generalised osteopaenia of the right shoulder 
girdle and right arm stump. She was well and clear of 
recurrence at her last visit in April 1994, 2 years and 3 
months after presentation with the postradiation tumor. 
Isodose curves through the central axis are representative 
of those through the superior tumor. Superior tumor has 
been superimposed on these curves and show the bone in 
which the tumor grew to lie between the 75 and 79Gy dose 
leve~s. Curves through the inferior border of the field 
are representative of the area of the main tumor bulk. The 
bone here lies between the 60 and 61.98Gy dose levels (fig 
18). The tumor is estimated to have grown between 60 and 
79Gy at a point which received approximately 62Gy. 
Case 19: Primary Tumor: Fibromatosis of the Buttock 
Postradiation Tumor: Osteosarcoma of the Pelvis 
and Left Femur 
A 10-year-old girl underwent incomplete excision of a tumor 
in the left buttock in November 1972. Histological 
features were of an extra-abdominal desmoid tumor or a low-
grade fibrosarcoma. On review a diagnosis of fibromatosis 
has been made due to low cellulari ty, the absence of the 
herring-bone pattern of fibrosarcoma, a pushing rather than 
an infiltrating border, the abscence of muscle invasion and 
mitotic figures and the presence of myxoid change. X-ray 
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had shown no bony erosion but a mass in the region of the 
left buttock and hip. The left ileum was narrowed in the 
vertical dimension and grooved laterally. It was thought 
that this might be due to a pressure defect caused by the 
mass. 
A course of Co-60 radiotherapy was commenced in November 
1972 utilising first a 10 by 10cm field to the posterior 
left sacro-iliac region. A dose of 2.00Gy was applied for 
8 fractions 5 times a week. The field size was then 
reduced to 10 by 8cm and a dose of 2.25Gy was applied for a 
further 8 fractions. The total applied dose was 33.75Gy. 
The duration of treatment was 22 days. 
In May 1973 early erosion of the right greater trochanter 
was noted. In September 197 3 there was noted to be no 
evidence of disease locally and x-ray was reported to be 
normal. 
In February 1975 a 17 by 15cm mass was noted in the 
buttock. X-ray showed a defect in the medial aspect of the 
left ileum, which was not thought to be malignant. There 
was a relative decrease in the size of the left ileum 
attributable to previous radiotherapy. The tumor was 
assessed as being inoperable because of attachment to the 
underlying iliac bone. Drill biopsy was performed. All 
slides were reviewed and the final diagnosis was that this 
patient had a desmoid tumor or fibromatosis. A course of 
Co-60 radiotherapy was commenced in March 1975 utilising 26 
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by 18cm parallel opposed fields to the left pelvis. ,A dose 
of 3 .20Gy was given to each field twice a week for 10 
fractions with adjustment of the last fraction to acheive a 
total applied dose of 31. 90Gy. A total central dose of 
45.00Gy was achieved. There was complete overlap of the 
previous field. Treatment was given in hyperbaric oxygen. 
The total duration of treatment was 34 days. The maximum 
significant posterior dose from both courses of 
radiotherapy •,,as 80Gy. 6 days after the completion of 
radiotherapy the patient was commenced on chemotherapy with 
Vincristine, Cyclophosphamide and Actinomycin. 
SO-week course of chemotherapy. 
This was a 
In July 1975 x-ray showed osteoporotic changes in the left 
hemipelvis and the acetabulum pushed inward by the head of 
the femur. In September 1975 the patient was noted to have 
had haemorrhagic cystitis following Cyclophosphamide but no 
measurable tumor mass. Intravenous pyelogram performed in 
June 1976 because of haematuria showed radiation necrosis 
of the head of the left femur, bladder calcification on the 
left and a hydronephrotic left kidney. Irregularity on the 
left side of the bladder due to radiation damage was noted. 
In September 1976 the patient underwent osteotomy and 
application of a pin and plate to the left femur because of 
a slipped femoral epiphysis. Marked fibrosis was noted in 
the irradiated area. This pin was later removed. 
In June 1980, 7 years and 7 months after the commencement 
of radiotherapy, a routine follow-up x-ray showed a large 
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lytic area in the left iliac bone adjacent to the 
acetabulum with a break in the cortex medially. Bone scan 
showed a photopaenic area in the left pelvis in keeping 
with previous radiotherapy. A focus of increased activity 
was noted in relation to the left side of the pelvis. Open 
bone biopsy was performed. The patient was diagnosed as 
having a sarcoma. The histological appearances were highly 
suggestive of a malignant fibrous histiocytoma. CT scan 
showed a large left-sided hydronephrosis associated with a 
large mass of suspected glands extending downwards and 
paravertebrally into the pelvis. There was also 
involvement of the left transverse process of the fifth 
lumbar verterbra, the proximal sacrum and the left ileum. 
Cauda y there was obvious bone destruction of the left 
half of the sacrum, and of the left inominate bone. The 
overlying mass in that area formed a part of the huge 
paravertebral mass which displaced the kidney. The lesion 
was too extensive for surgery and further radiotherapy 
could not be given. 
In July 1981 the patient was noted to have a 7 by 8cm mass 
posteriorly above the iliac crest. CT scan showed a large 
left loin tumor mass which incorporated the psoas muscle 
and extended inferiorly to involve the iliacus muscle. The 
left ischium showed extensive lesions in keeping with tumor 
or previous radiotherapy. There was also involvement of 
the left erector spinae muscles and obstruction of the left 
ureter. Excision biopsy of the mass in the posterior 
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lumbar area showed a well-differentiated fibrous reaction 
with no evidence of malignancy. 
In December 1981 there was noted to be further lysis of the 
head and neck of the femur with a previously placed pin 
protruding beyond the femoral head. There was also a 
pathological subcapsular fracture on the left. There was 
deep induration in the left iliac fossa attributable to 
radiotherapy. Hip replacement surgery was not feasible due 
to extensive tumor involving the head of femur. The 
patient was admitted to hospital for traction. Rebiopsy in 
December 1981 showed osteosarcoma. In January 1982 the 
patient underwent a Girdlestone procedure to the left hip. 
The patient developed septicaemia and died in July 1982 
with pulmonary metastases, gross fungation of the local 
tumor, gangrene of the left foot and anaemia. This was 2 
years and 1 month after presentation with postradiation 
malignancy. 
At autopsy features of septicaemia were noted with left-
sided hydroureter, hydronephrosis, pyonephrosis and 
pyelonephritis; constriction of left ureter distal end by 
fibromatosis/tumor; fibromatosis/malignant fibrous 
histiocytoma/osteosarcoma involving the left femur and left 
hemipelvis with erosive destruction; bilateral lung 
metastases; atrophic breasts, ovaries and uterus; and 
resolving haemorrhagic cystitis. At this time previous 
biopsies were reviewed and it was thought that the tumor 
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was originally an aggressive fibromatosis but after 
recurrence and radiotherapy the appearance was that of a 
malignant fibrous histiocytoma. At autopsy as mentioned 
there were sections containing malignant cartilage and 
osteoid production indicative of a chondroblastic 
osteosarcoma. On further review a single diagnosis of 
osteosarcoma has been made. The diagnosis 
fibrous histiocytoma was presumably made 
of malignant 
initially as 
osteoid could not be seen in the earlier specimens. 
As this was an osteosarcoma with bone involvement it is 
assessed as being a bone tumor. However there was 
extensive soft tissue involvement and assessment of the 
area in which the tumor developed has not been limited to 
bone. At the superior border of the second ( longer) 
radiotherapy fields the tumor (superior tumor) lies between 
30 and 38.14Gy. Isodose curves through the superior border 
of the initial fields (mid-tumor) show the tumor lying 
between 40 and 75Gy (fig 19). Curves through the central 
axis (inferior tumor) show a small amount of tumor between 
40 and 70Gy. It is estimated to have grown between 30 and 
75Gy, in tissue which received approximately 60Gy. 
Case 20: Primary Tumor: Benign Tumor Alveolus 
Postradiation Tumor: Osteosarcoma of the Maxilla 
A 5-year-old child underwent surgery in 1934 or 1935 at 
another institution for a lesion of the· right upper 
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alveolus initially thought to be malignant. Radium pellets 
or needles were inserted. A diagnosis of a benign 
condition (possibly fibroma or angioma) was then made and 
the radium was removed. Details are not available. At the 
age of 13 the patient underwent extensive plastic surgery 
to correct a mid-facial deformity. 
In December 198 7, approximately 53 years after the 
irradiation, the patient presented to our hospital with a 
locally advanced tumor of the right maxilla. She gave a 
history of retro-orbital pain, proptosis and a nasal 
discharge, infra-orbital and right nasal paraesthesia and 
some diplopia as well as some nasal obstruction. The 
symptoms dated from October 1987. The right nasal cavity 
was obliterated by a bony hard mass covered with mucosa and 
the mass covered the fenestration in the mouth. Full eye 
movements were present. X-rays showed new bone formation 
in the sphenoid and ethmoid bones, an opaque left antrum 
and extensive anterior middle cranial fossa new bone 
formation. CT scan showed proptosis of the right eye. 
There was marked new bone formation involving the right 
ethmoidal sinus and the spheniodal sinus and projecting 
into the right orbit. There was also some new bone 
formation projecting from the right frontal bone into the 
right frontal lobe. There was in addition some soft tissue 
attenuation in the right antrum and an opaque left antrum. 
These latter changes had the appearance of mucosal 
thickening. 
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Biopsy (right palate/antrum and right lateral nasal wall) 
showed features of fibrous dysplasia with osteosarcomatous 
changes. Palliative right total maxillectomy was 






apex, and across the roof of the ethmoids in the nasal 
cavi t /. Macroscopically tumor was noted within areas of 
necrosis. Histological features were in keeping with the 
diagnosis of osteosarcoma. On review osteosarcoma in 
fibrous dysplasia has been noted and also fibrosis without 
features of fibrous dysplasia i.e. radiation-induced 
fibrosis. The osteosarcoma is moderate grade. The patient 
returned to Harare for further treatment. She received 2 
cycles of chemotherapy (Methotrexate, Vincristine and 
Adriamycin). She elected to discontinue chemotherapy after 
an episode of neutropaenia, thrombocytopaenia and 
septicaemia although she did feel the tumor had diminished 
in size. In June 198 8 she attended a hospital in the 
United Kingdom. CT scan showed increase in the size of the 
tumor. There was extensive bony destruction with a retro-
orbital and maxillary mass. She received further 
chemotherapy (5 Fluorouracil, Adriamycin and 
Cyclophosphamide) and was referred for packing of the 
fungating tumor within the maxilla. A course of 
radiotherapy was commenced in July 1988 utilising anterior 
and lateral fields to the right face. A dose of 40Gy was 
achieved to the right side of the face in 20 fractions over 
30 days. She returned to Southern Africa where further 
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debulking surgery was done. She died in December 1988, a 
year after presentation with the postradiation tumor. 
Fig 20 shows the position of the postradiation sarcoma. 
The radiation dose in the area of postradiation tumor 
development cannot be assessed as no radiotherapy details 
are available. 
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3.2. TABULATION AND FURTHER ANALYSIS OF RESULTS 
Results are tabulated on Tables 1 and 2 (Addendum 2). On 
Table 1 cases are listed according to primary tumor type, 
and on Table 2 according to radiation modality. 
20 cases were reviewed of patients who developed 
postradiation sarcomas or MMMT. Patients presented with 
the sarcoma from September 1972 to June 1993. 
3.2.1. AGE AT PRESENTATION WITH PRIMARY TUMOR AND SEX 
Ages are described in years except for the subgroup of 
retinoblastoma patients. 
Sixteen patients were female and four male. The age at the 
time of the radiotherapy commencement was a mean of 28 
years with a range of O years (5 months) to 68 years. The 
median was 24 years. 
(patients under the 
In the paediatric group of six cases 
age of 15 at the time of initial 
presentation) the mean age was 4 years and the range O (5 
months) to 10 years. The median age was 3 years. In the 
adult group (fourteen cases) the mean age was 38 with a 
range of 18 to 68. The median was 37. In the 
retinoblastoma group (three patients) the mean 
14 months presentation with 
range 5-29 months. 
retinoblastoma was 





In seven cases the initial tumor was of the female 
reproductive tract (six 
stromal sarcoma of the 




one low grade 
patients had 
retinoblastoma, 
one a unilateral Wilms' tumor, one a parotid carcinoma and 
one a soft tissue sarcoma. In four patients the condition 
for which the original radiotherapy had been given was a 
benign one (two giant cell tumors, one fibromatosis, and 
one unknown, possibly angioma or fibroma). 
3.2.3. TREATMENT OF PRIMARY TUMOR 
Twelve patients had been treated with cobalt radiotherapy. 
One of these had also received treatment with a 250 kV beam 
and I-125 seeds. Four of the patients treated with cobalt 
therapy had also had radium insertions and one had received 
an electron boost as part of the initial radiotherapy, but 
this was not at the site in the field at which the 
postradiation sarcoma developed. Four other patients had 
received treatment with a 250 kV beam. One of these also 
underwent a Tantalum-182 insertion. Two had received 
treatment with a 220 kV beam and one of these had two 
radium insertions. One patient had been treated on the 
linear accelerator with a 20 MV beam and with a radium 
insertion and one had been treated with radium pellets or 
needles at another institution. 
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In thirteen cases the treatment of the initial condition 
included surgery (including case 17 who underwent open 
biopsy). The surgery did not necessarily affect the site 
of postradiation tumor development. Two patients (cases 10 
and 19) had more than one operation which may have affected 
the site of tumor development. The six patients who 
received chemotherapy for the primary tumor were in the 
group who had surgery. Three received Cyclophosphamide. 
If one or more implants were inserted during or at the end 
of a course of external beam therapy the radiotherapy is 
considered as one course. Five patients (cases 11, 12, 14, 
18 and 19) received more than one course of radiotherapy 
and a further case (8) could possibly be considered in this 
group as the site of tumor development was exposed to 
direct treatment and also received scatter from a course of 
radiotherapy to the opposite breast. 
3.2.4. LATENCY 
The mean latent period was 14 years and 2 months with a 
range of 1 year 11 months to 53 years. The median was 9 
years. 
In paediatric cases ( 6 cases), the mean latency was 15 
years 1 month and the range 3 years 7 months to 53 years. 
The median was 6 years 2 months. In adults (14 cases) the 
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mean was 13 years 10 months with a range of 1 year 11 
months to 42 years 7 months. The median was 11 years 5 
months. In the retinoblastoma patients (3 cases), the mean 
latency was 4 years 4 months (with latent periods of 3 
years 7 months, 4 years 7 months and 4 years 10 months) and 
the median 4 years 7 months. In the non-retinoblastoma 
patients the mean latency was 15 years 11 months with a 
range of 1 year 11 months to 42 years 7 months. The median 
was 11 years. The difference in latency between the adult 
and paediatric groups was not significant (p > 0. 05) but 
the latency of the retinoblastoma patients was 
significantly shorter than that of the non-retinoblastoma 
patients (p < 0.05). 
In patients treated with megavoltage beams alone (Co-60 and 
20MV) (seven cases) the mean latency was 8 years 3 months 
with a range of 1 year 11 months to 17 years 3 months. The 
median was 7 years 7 months. In patients who received 
orthovoltage (250 or 220kV) treatment alone (four cases) 
the mean latency was 23 years 8 months with a range of 4 
years 10 months to 42 years 7 months. The median was also 
23 years 8 months. The difference was not significant 
(p > 0.05). 
In patients who received megavoltage therapy with or 
without brachytherapy (twelve cases), the average latency 
was 9 years 3 months and the range 1 year 11 months to 17 
years 3 months. The median was 8 years 1 month. In those 
who received orthovoltage treatment with or without 
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brachytherapy (six cases) the average was 19 years 1 month 
and the range 3 years 7 months to 42 years 7 months. The 
median was 16 years 8 months. Again this difference was not 
statistically significant (p > 0.05). 
In patients who received brachytherapy with or without 
external beam therapy (nine cases), the mean latency was 14 
years and 7 months with a range of 3 years 7 months to 53 
years. The median was 9 years 10 months. In patients who 
received no brachytherapy (11 cases) the mean latency was 
13 years 10 months with a range of 1 year 11 months to 42 
years 7 months. The median was 7 years 10 months. This 
difference was not statistically significant (p > 0.05). 
In patients in whom the prescribed dose was more than 60Gy 
(six cases) the mean latency was 15 years 11 months with a 
range of 6 years to 42 years 7 months. The median was 11 
years 9 months. In patients prescribed for less than 60Gy 
(twelve cases) the mean was 9 years 11 months with a range 
of 1 year 11 months to 30 years 4 months. The median was 7 
years 5 months. The difference was not statistically 
significant (p > 0.05). 
In the MMMT group (four cases) the mean latency was 13 years 
4 months and the range 6 years to 16 years 1 months. The 
median was 14 years 11 months. In the pure sarcoma group 
(sixteen cases) the mean was 14 years 6 months with a range 
of 1 year 11 months to 53 years. The median was 8 years 1 
month. In the two patients with abnormal bone 
75 
prior to irradiation (two giant cell tumors) the latency 
periods were 3 years 2 months and 42 years 7 months. 
Postradiation tumors developing in bone (nine cases) had a 
mean latency of 17 years 3 months (range 3 years 7 months 
to 53 years) and a median of 7 years 7 months, and those in 
soft tissue (eleven cases) 11 years 8 months (range 1 year 
11 months to 30 years 4 months). The median was 9 years 10 
months. This difference was not statistically significant 
(p > 0. 05) . 
3.2.5. AGE AT PRESENTATION WITH SECONDARY TUMOR 
The age of the patients in years at the presentation with 
the sarcomas was a mean of 42 years with a range 4-81 
years. The median was 46.5 years. 
3.2.6. TISSUE AND SITE OF SECONDARY TUMOR 
The tissue in which the sarcoma developed was soft tissue 
(including uterus) in eleven patients and bone in nine 
patients. 
In eight of the patients who had received megavoltage 
therapy (C0-60 or 20MV beam) with or without brachytherapy 
the postradiation malignancy developed in soft tissue and 
in four it developed in bone. (One of these patients 
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developed a sarcoma in an irradiated giant cell tumor). In 
three patients who received orthovoltage treatment (250kV 
or 220kV) with or without brachytherapy the postradiation 
malignancy developed in soft tissue and in three in bone 
(one in an irradiated giant cell tumor) . One patient 
developed a tumor in bone after treatment with orthovoltage 
and megavoltage beams and an I-125 implant and one in bone 
after brachytherapy only. 
Thirteen patients developed tumors in the trunk, five in 
the head and neck region and two in the extremities. 
3.2.7. PRESCRIBED DOSES AND DOSES AT SITE OF SECONDARY 
TUMOR DEVELOPMENT 
The initially prescribed doses and the dose ranges and 
points at which the postradiation tumors are estimated to 
have developed can be seen on Tables 1 and 2. Table 1 
includes prescribed doses, and the dose range and point at 
which the tumor is estimated to have grown in Gray. Table 2 
shows the prescribed doses and the prescribed doses in Gray 
(using f-factor conversion). Table 2 also indicates the 




doses ranged from 
14) to 94.94Gy at 
3000R orthovoltage 
Manchester Point A 
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( case 3) in a patient who received mega voltage treatment 
and an intracavitary radium insertion. 
If R/rad corrections are calculated for prescribed doses 
and courses of radiotherapy are added together, no patients 
were prescribed for less than 30Gy, twelve were prescribed 
for 30 to 60Gy and six for more than 60Gy. 
The lowest dose point at which a tumor was estimated to 
have developed was 8Gy (case 11). Excluding the patients 
with retinoblastoma the lowest dose point was 12Gy (Cases 
14 and 15). 
For details of fractionation and duration of treatment see 
Table 1 and case reports. 
The range of estimated dose points at which tumors 
developed was from 8Gy (case 11) to lOOGy (cases 1 and 3). 
The mean estimated dose point was 48Gy (eighteen cases). 
The median was 4 9. The dose point was less than 30Gy in 
three cases, from 30 to less than 60Gy in nine cases and 
60Gy or more in six cases. 
Three of the MMMT developed at estimated dose points of 60, 
100 and lOOGy. In the fourth all radiotherapy details are 
not available. 
In patients who received megavoltage therapy only (seven 
cases) the mean dose point was 42Gy with a range of 12 to 
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60Gy. The median was 45Gy. In the group who received 
orthovoltage therapy only (four cases) the mean dose point 
was 37Gy with a range of 12 to 62Gy. The median was 
36.5 Gy. The difference is not significant (p > 0.05). In 
patients who received orthovoltage with or without 
brachytherapy (five cases) the mean dose point at which the 
PRS is estimated to have developed was 31Gy with a range of 
8 to 62Gy. The median was 35Gy. In the megavoltage group 
(twelve cases) the mean was 54Gy with a range of 12 to 
lOOGy. The median was 50Gy. The difference was not 
significant (p > 0.05). In all patients who received 
brachytherapy (seven cases) the mean was 60Gy and the range 
8 to lOOGy. The median was 50Gy. In those who did not 
receive brachtherapy (eleven cases) the mean was 40Gy with 
a range of 12 to 62Gy. The median was 38Gy. This 
difference was not significant (p > 0.05). 
3.2.8. POSSIBLE PREDISPOSITION TO SECOND MALIGNANCIES 
There is no indication in the case notes that the patient 
with Wilms' tumor had features of the genetic form of the 
disease. In the patients with bilateral retinoblastoma the 
mean dose point at which the PRS was estimated to have 
developed was 31Gy. The median was 35Gy. The points were 
8, 35 and 50Gy. In the non-retinoblastoma patients (15 
cases with information on dose) the mean was 51Gy and the 
range 12 to lOOGy. The median was 50Gy. The difference 
was not significant (p > 0.05). 
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Three other patients (cases 8, 10 and 16) developed three 
malignancies altogether (i.e.triple primary). A fourth 
patient (19) may have had a third primary but the final 
opinion was that the specimens characteristic of malignant 
fibrous histiocytoma and osteosarcoma should be regarded as 
coming from the same tumor. 
3.2.9. PRESENTATION WITH SECONDARY TUMOR 
Sixteen patients presented with clinical features of 
swelling or a mass. In five pain was also present. Three 
presented with x-ray changes and one with a pathological 
fracture. 
3.2.10. PATHOLOGY OF SECONDARY TUMOR 
Four patients developed MMMT. Eight developed osteosarcoma 
of the bone, one after radiotherapy for a giant cell tumor. 
Two developed leiomyosarcomas, one a rhabdomyosarcoma, two 
pleomorphic sarcomas, one a fibrosarcoma and one a sarcoma 
not otherwise specified. A second patient developed a 
radiation induced sarcoma in the site of a previously 
irradiated giant cell tumor and this tumor could not be 
classified further. Four of the sarcomas were of moderate 
grade and sixteen tumors were high grade. The moderate 
grade tumors were [1] a fibrosarcoma of the pelvis, 
occurring more than 30 years after radiotherapy for a low 
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grade stromal sarcoma of the uterus; (2) a sarcoma of the 
axilla which cannot be classified further and which 
occurred at 7 years and 10 months after radiotherapy for 
carcinoma of the breast; [ 3 J a sarcoma of the bone which 
presented 3 years and 2 months after radiation of a Grade 2 
giant cell tumor of the pelvis; and (4) an osteosarcoma in 
fibrous dysplasia, with radiation induced fibrosis noted in 
the specimen, occurring 53 years after irradiation for a 
benign condition of the alveolus. 
3.2.11. TREATMENT OF SECONDARY TUMOR 
In the majority of patients treatment with a curative aim 
could not be carried out for the postradiation tumor due to 
the advanced nature of the disease at the time of 
presentation. 
Four patients received no active therapy. One of these 
declined surgery to establish the nature of a pelvic mass. 
In three no active treatment could be offered. 
In ten patients the initial treatment was surgical. In 
only three of these was a radical resection possible. Case 
8 underwent an excision of a chest wall sarcoma. No 
further therapy was recommended and she was alive with no 
evidence of sarcoma recurrence at the time of the last 
report, 5 years and 2 months after surgery. One patient 
(case 18) underwent amputation of the upper extremity and 
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refused chemotherapy. She is alive with no evidence of 
recurrence at 2 years and 3 months. One (case 2) underwent 
subtotal hysterectomy and bilateral salpingo-oophorectomy 
for a MMMT of the uterus. She refused chemotherapy and was 
lost to follow up. Cure is unlikely as this was a MMMT 
which infiltrated into the outer third of the myometrium. 
A fourth patient (case 3) underwent a subtotal hysterectomy 
and bilateral salpingo-oophorectomy for a MMMT of the 
uterus which invaded almost to the serosa. Macroscopically 
there were ruptured areas which appeared surgical in 
origin. The surgery was described as palliative in nature. 
The patient received postoperative chemotherapy but 
developed a pelvic mass during treatment. She subsequently 
received palliative radiotherapy. 
In two patients the initial surgical procedure was a 
laparotomy and at operation it was found that the tumor was 
inoperable. Case 7 went on to receive neutron radiotherapy 
at a later date and further resection. Case 4 received 
chemotherapy but died early in the course, 2 months after 
presentation with the postradiation tumor. 
Case 1 underwent a hysterectomy but metastases were noted 
at operation. Case 20 had a palliative maxillectomy which 
was followed by two courses of chemotherapy, further 
chemotherapy, packing, radiotherapy and palliative surgery. 
Case 10 had an incomplete resection of a sarcoma in the 
clavicular area which was not followed by further 
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treatment. Case 19 underwent a variety of palliative 
surgical procedures. 
Two patients received radiotherapy as initial treatment of 
the postradiation tumor. Case 9 received a total dose of 
36Gy in 9 fractions after hormonal and chemotherapy had 
been administered for presumed recurrence of breast cancer. 
Although there was an initial regression after irradiation 
the lesion had recurred 3 months after completion of 
treatment. Case 11 underwent a course of radical 
radiotherapy followed by chemotherapy and maxillectomy at 
which time it was thought that the tumor was extending over 
the orbital floor. Extension of tumor had occurred by 2 
months postoperatively. 
Three patients received chemotherapy as initial treatment 
of the postradiation tumor. In only one was there any 
response but this was followed by disease progression and 
chemotherapy was discontinued (Case 13). 
In one patient an initial ernbolization was performed (Case 
17). Approximately 3 years later the patient received two 
cycles of chemotherapy but his condition deteriorated. He 
received palliative radiotherapy. 
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3.2.12. OUTCOME OF TREATMENT OF SECONDARY TUMOR 
The outcome of treatment of the postradiation tumors was 
poor. Two patients are alive and clear of recurrence of 
postradiation sarcoma at 5 years 2 months and 2 years 3 
months after presentation. One is alive with disease 9 
months after presentation. One has been lost to follow-up 
and is presumed dead. One patient died with disease and 
the date of death is unknown. Fifteen patients died with 
disease at an average of 14 months (range 2 months to 3 
years 11 months) after presentation, but in two the cause 
of death may have been metastases from another primary. 
The median survival of the thirteen patients who died with 
sarcoma, in whom the date of death is known, and excluding 
the two patients who may have died from another malignant 
disease, was 12 months and the mean 15 months. 




Table 3 (Addendum 3) shows features of some clinical 
studies reported in the English literature. 
4.1. INCIDENCE 
4.1.1. DIFFICULTIES IN DETERMINING INCIDENCE 
Postradiation sarcoma is a rare condition. Of malignant 
lesions reported in irradiated tissue (carcinoma, leukemia 
and sarcoma) sarcoma is the least common ( 104) . In a 
report published in 1963 Phillips noted that a review of 
the literature produced only thirty cases of bone sarcoma 
occurring in normal bone after radiotherapy. Fifty cases 
had been reported after irradiation of benign bone lesions 
(87). Castro reported in 1967 that a literature survey 
revealed only ninety-three cases of radiation-induced bone 
sarcoma. Including his own cases, 
of radiation-induced sarcoma in 
only thirty-five cases 
normal bone had been 
reported ( 15) . In 1970 Hatfield reported that 
approximately 150 cases of PRS had been reported (46). 
Including five of his own cases eleven cases had been 
reported after radiotherapy for carcinoma of the breast. 
In 1972 Sim mentioned 150 recorded cases of sarcoma in bone 
following irradiation (104). 
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Because of the rarity of the condition and the potentially 
long latent period between irradiation and the development 
of the sarcoma, accurate estimates of the incidence are not 
easily made (94). The number of patients receiving 
radiotherapy is often not reported and the risk in any 
given radiotherapy patient is difficult to establish (94, 
4 9) • 
The paucity of relevant statistics and possibly the failure 
to recognise and report sarcomas occurring in radiation 
fields also renders estimation of risk and incidence 
difficult (46). Most reports do not provide a denominator 
(i.e. the number of patients receiving radiotherapy) for 
assessing risk (122) . In our own department patient data 
is entered on a computer database but it is not possible to 
determine from the database which patients have developed a 
postradiation malignancy. The denominator ( 5- or 10-year 
survivors of radiotherapy) can also not be determined 
except for certain specific primary conditions and 
treatments. 
Some reported incidence rates have not been calculated over 
a long enough period to cover the average latency period 
for postradiation tumors (27). 
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4.1.2. PROPORTION OF SARCOMAS ATTRIBUTABLE TO RADIOTHERAPY 
The proportion of sarcomas which can be attributed to 
previous irradiation varies considerably among different 
institutions. 
At the Roswell Park Memorial Hospital in Buffalo 0.17% of 
sarcomas could be defined as PRS (75). 
Huvos from the Memorial Sloan-Kettering Cancer Centre 
reported that 5.5% of osteosarcomas seen there since 1921 
were PRS (49). 
It was reported from the Mayo Clinic that 1.5% of primary 
malignant bone tumors (including myeloma), 17. 6% of 
fibrosarcomas, 3.4% of osteosarcomas and 0,7% of 
chondrosarcomas were PRS (121). 
At the University of California, Los Angeles Medical Center 
6% of 229 head and neck sarcomas were identified as PRS 
( 6 7) • 
In a comparison of second and single primary sarcomas 
reported from 1973 to 1986 by the Surveillance, 
Epidemiology and End Results ( SEER) Program of the U.S. 
National Cancer Institute (93), 8815 patients were found to 
be registered with sarcoma as a first and 240 with sarcoma 
as a second primary tumor. 7 4 patients 
with sarcoma as the second primary and 
(31% of patients 
0.8% of all the 
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patients with sarcomas) had undergone radiotherapy for the 
first tumor and these patients were assumed to have 
postradiation sarcomas although actually there is no record 
of whether the sarcoma developed in the radiation field or 
not. 
As already discussed I am unable to comment on the 
proportion of sarcomas presenting to Groote Schuur which 
are attributable to radiotherapy. 
Overall the proportion attributable to radiotherapy v~ries 
according to the type of sarcoma. It also appears to vary 
among different institutions which may in part reflect 
referral patterns to certain clinics. 
4.1.3. EVIDENCE FOR NO INCREASE IN RISK OF SARCOMA AFTER 
RADIOTHERAPY 
Because of the difficulty 
the risk of development 
survivor of radiotherapy 
in determining the denominator, 
of a PRS in a 5- or 10-year 
is probably more difficult to 
establish than the proportion of sarcomas which occur in 
radiation fields. Not all clinical studies support 
radiotherapy as a risk factor for sarcoma development. 
Lavey et al (60) reported that among breast cancer patients 
at Duke University Medical Center the relative risk (RR) 
for solid tumors other than breast cancer was not 
significantly different from unity in any treatment group. 
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(Patients were treated with surgery alone, surgery and 
adjuvant chemotherapy, surgery and adjuvant radiotherapy, 
or all three modalities.) 95. 3% of the patients in all 
treatment arms in this study had been followed up for a 
minimum of 5 years or until death. Only 16% were observed 
for more than 10 years. 
Bagshaw ( 6) observed no increase in second cancers after 
radiotherapy in 914 patients treated for carcinoma of the 
prostate. 
Parker and Enstrom (83) found no difference in the 
incidence of second primary cancers in Head and neck cancer 
patients whether they received radiotherapy or not. 
4.1.4. EVIDENCE FOR INCREASE IN RISK OF SARCOMA AFTER 
RADIOTHERAPY 
In spite of evidence from studies such as the ones 
mentioned above, Mark (68) notes in a recent extensive 
literature review that the weight of the evidence suggests 
that radiotherapy does increase the relative risk of 
subsequent sarcomas and second cancers, but that the risk 
appears small. 
Hankey et al (40), reviewing 25 724 cases of breast cancer 
in the Connecticut Tumor Registry, found no difference in 
incidence of second cancers between those who had surgery 
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alone and those who had postoperative radiotherapy. 
However in an update of this analysis it was found that the 
relative risk of soft tissue sarcoma was higher in patients 
who had received radiotherapy (43, 68). 
Mark et al (68) reported a series of patients with PRS from 
the Unversity of California Medical Centre with a review of 
the literature and estimated the risk of PRS with long-term 
follow-up to be O. 03 to O. 8%. Even in this study the 
denominator could not be reliably assessed. 
Phillips (87) reported that at the University of California 
0.03% of irradiated patients and 0.1% of 5-year survivors 
developed bone sarcomas. 
Tountas (114) from the Princess Margaret Hospital in 
Toronto reported that PRS of the bone occurred in 0.02% of 
irradiated patients, and in 0.035% of 5-year survivors. 
A recent report comes from data in the Danish Cancer 
Registry. In a review of second primary malignancies in 
6187 men with testicular carcinoma registered in the Danish 
Cancer Registry from 1943 to 1987 (51) seven patients were 
found who had developed sarcomas within the field of 
radiotherapy and three at the periphery. Eight patients 
had had seminomas. The incidence of sarcoma was four times 
higher than expected. Eight sarcomas occurred in the 2241 
patients who survived 10 years, yielding an absolute risk 
of 0.4%. 
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4.1.4.1) Risk of Postradiation Sarcoma in Irradiated Breast 
Cancer Patients 
Some reports of PRS refer only to patients with specific 
primary tumors such as carc~~oma of the breast or 
gynaecologic malignancy, or evaluate risk separately for 
these patients. In 1948 Cahan (14) reported that of an 
estimated 3 000 to 4 000 patients receiving postoperative 
radiotherapy for breast cancer, of whom approximately forty 
percent survive 5 years, only one developed a radiation-
induced osteogenic sarcoma (i.e.0.07% of an estimated 1400 
5-year-survivors). 
Kurtz reported an incidence of PRS of 0.07% (two cases in 
2850 patients) or 21. 9 cases per 105 patient years for 
survivors beyond the fifth year in breast cancer patients 
treated with radiotherapy alone or following breast-
conserving surgery (57). 
At the Princess Margaret Hospital in Toronto the incidence 
of PRS in 5-year-survivors treated for cancer of the breast 
was 0.05% (114). 
Taghian et al (113) found the cumulative incidence of PRS 
at the Gustave Roussy was 0.2% at 10 years for patients who 
received radiotherapy after mastectomy or breast-conserving 
surgery. It was 0.43% at 20 years and 0.78% at 30 years. 
However two of the eleven sarcomas were attributed to the 
Stewart Treves syndrome. 
observed/expected cases 
population) was 1.81. 
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The relative risk (number of 
in an age-matched control 
At the Massachussetts General Hospital an overall incidence 
of PRS of 0.22% was estimated in breast cancer patients who 
received radiotherapy and survived 10 years (46). Hatfield 
estimates that the incidence of naturally-occurring 
osteosarcoma is only 0.0005%. Irradiated patients do 
appear to be at risk for this condition (75, 46). 
The percentage risk of radiation-induced sarcoma in breast 
cancer patients treated at the Western General Hospital in 
Edinburgh with post-mastectomy radiotherapy or radical 
radiotherapy was 0.26% over 16 years (27). 
Hatlinghus et al (47) reported three cases of postradiation 
sarcoma following radiotherapy for breast cancer in a total 
of 2 764 patients who received radiotherapy for breast 
cancer. Approximately 40% of these patients survived 10 
years so it is estimated that one sarcoma developed per 365 
patients surviving 10 years giving an estimated incidence 
of O. 27% in 10-year survivors. These authors felt that 
some cases are not recognized so this estimate is probably 
a minimum figure. 
0.22 of irradiated survivors of carcinoma of the breast at 
the University of California developed bone sarcomas (87). 
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Pierce (88) observed three (0.18%) cases of breast sarcoma 
in 1624 women undergoing lumpectomy and radiotherapy at the 
Joint Centre for Radiation Therapy in Boston. The 10-year 
actuarial risk was 0.8%. 
Incidence figures are not available from Groote Schuur. 
Overall the incidence 
irradiated breast cancer 
of post radiation sarcoma 
patients is well below 
in 
1%. 
Variation in incidence figures from different institutions 
may be partly due to the difficulties in diagnosing this 
condition and to the difficulties in determining incidence 
figures which will be affected, for example, by the 
duration of follow-up. 
4.1.4.2) Risk of Postradiation Sarcoma in Patients 
Irradiated for Gynaecological Malignancies 
The risk of PRS following radiotherapy for a gynaecological 
malignancy has also been reported by several authors. 
The incidence among 5-year-survivors treated for cancer of 
the cervix at the Princess Margaret Hospital in Toronto was 
reported to be 0.06% (114). 
Boice et al (10) reported a relative risk for bone sarcomas 
of 1.3 among 150 000 patients who had received radiotherapy 
for carcinoma of the cervix. 56% arose in the pelvis in 
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contrast to an expected 15%. The risk of connective tissue 
tumors (not including soft tissue sarcomas arising in 
specific organs) was not increased (RR O. 7) although the 
risk was increased among 10-year survivors receiving 
greater than lOGy and those exposed after age 45. The 
anatomical distribution of soft tissue sarcomas (28% in the 
pelvic and 11% in the abdominal area) did offer some 
support for a radiation aetiology. 
0. 20% of irradiated 5-year-survivors of carcinoma of the 
cervix at the University of California developed bone 
sarcomas (87). 
At the Roswell Park Memorial Hospital O .14% of patients 
with carcinoma of the cervix treated with radiotherapy 
developed sarcoma of the pelvic bones (15, 75). 
0.64% of patients with squamous carcinoma of the cervix who 
were treated with radiotherapy at the University of 
Minnesota Hospital and who survived 9 years developed a 
sarcoma of the irradiated bone. Using previous reports an 
estimation was made that an adult woman has a chance of 
less than 1 in 4 000 000 of developing a spontaneous 
osteosarcoma of the pelvic girdle. In this series one PRS 
arose in 6 000 patient years (31). 
Ruka et al (96) reported that the expected incidence of 
lower trunk soft tissue sarcoma was O. 23/100 000. In 
patients treated for cervical cancer the observed incidence 
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was 10.84/100 000 and the RR 47.13. The incidence in 5-
year survivors who received radiotherapy for endometrial 
cancer was 73.9/100 000, the expected incidence being 
0.23/100 000 and the relative risk 321.3. 
Eleven of Ruka's patients developed soft tissue PRS after 
treatment with radium and orthovoltage external beam 
therapy. This was considered a negligibly small fraction -
0.12% of all the patients treated with orthovoltage therapy 
for cancer of the cervix and 0.25% of the 5-year survivors. 
Two cases occurred among patients irradiated for 
endometrial cancer and this constituted 0.8% of the whole 
group irradiated for endometrial cancer and 1.5% of 5-year 
survivors. These authors point out that if risk is 
calculated for the whole group of patients who received 
radiotherapy, without assuming the minimum latency and 
excluding the patients who died within the first 5 years 
after treatment, the relative risk would be lowered by 
about 10%. However patients who did not survive 5 years 
would represent a small proportion of the person-years 
observed and whether or not minimum latency time is used 
the RR of developing a soft tissue sarcoma in the radiation 
field is markedly increased for cervical as well as 
endometrial cancer patients (96). 
Again there is variation among figures from different 
institutions but overall the incidence appears to be less 
than 1%. 
4.1.4.3) Risk of Postradiation Sarcoma in Survivors of 
Paediatric Malignancy 
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In a series from 10 paediatric oncology centres children 
who developed one malignancy were reported to have an 
approximately tenfold increase in risk of a second 
malignancy in comparison to age-matched populations 5 to 15 
years after the diagnosis of the first malignancy. (This 
report excluded retinoblastoma patients as referrals of 
retinoblastoma patients at high risk of second malignancy 
were particularly likely at these institutions.) (73) In 
another report by the Late Effects Study Group (70) bone 
sarcomas were the most common second malignancies and soft 
tissue sarcomas also occurred frequently. 68% of second 
tumors, and 75% of the sarcomas, were reported to be 
associated with radiotherapy. The most common initial 
primary in this study was retinoblastoma. 81% of the 
retinoblastoma patients had bilateral disease. One third 
of the patients with Wilms' tumor had features associated 
with the genetic form of the Wilms' tumor (70). 
Li ( 61) from the Sidney Farber Cancer Institute reported 
that fifteen patients who had been followed up at that 
institution due to an initial primary, subsequently 
developed another cancer, in contrast to 0.7 expected 
cases. All these patients had had prior irradiation and in 
thirteen with solid malignancies twelve arose in the 
radiation field. Five of the twelve were sarcomas. The 
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cumulative probability of a new malignancy was 12% and for 
patients who had received radiotherapy it was 17%. 
The incidence of PRS in retinoblastoma patients and their 
predispositon to malignancy is discussed in section 4.4. 
4.1.5. PRESENT TRENDS IN INCIDENCE 
The change from orthovoltage to megavoltage radiotherapy 
was expected to lead to a decrease in the incidence of PRS, 
( 4 4) • However this particularly those occurring in bone 
decrease has not been seen (121, 116). 
Finnish Cancer Registry did not 
The analysis of the 
show a decrease in 
incidence and bone tumors were actually more frequent in 
those treated with megavoltage irradiation. However there 
were fewer cutaneous and subcutaneous tumors in this group, 
perhaps because of the skin-sparing effect of megavoltage 
radiotherapy (122). 
Boice (10) found no evidence to support the supposition 
that the incidence of bone tumors may be lower in patients 
treated with megavoltage than with orthovoltage 
radiotherapy. 
Not only has no decrease in incidence been noted with the 
use of megavoltage equipment, but it has also been 
predicted (49) that the incidence of PRS will increase as 
the survival of cancer patients improves. However undue 
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fear that this is a frequent complication of radiotherapy 
is unnecessary (49). 
Robinson, in a review of the subject in 1988, noted that 
PRS had been increasing in frequency but were still rare 
(94). Other authors (5, 109) have also been of the opinion 
that the incidence is increasing. 
Souba noted in 1986 that PRS of the chest wall were being 
reported with increasing frequency and predicted that the 
incidence of PRS would increase as radiotherapy is used 
more frequently in the multidisciplinary treatment of 
malignant disease and as patients survive longer than the 
latency period necessary for a PRS to arise (109). 
With improved survival of cancer patients a higher overall 
incidence of postradiation malignancy should be expected. 
98 
4.2. CRITERIA FOR DIAGNOSIS. LATENCY PERIOD 
4.2.1. CRITERIA FOR DIAGNOSIS 
In 1948, in the first edition of Cancer, Cahan (14) 
published a report of PRS which has been much quoted ever 
since. He reported eleven cases arising in irradiated 
bone. The criteria for case selection were as follows: 
"1. There must have been microscopic or roentgenographic 
evidence of the nonmalignant nature of the initial 
bone condition. 
2. Irradiation must have been given and the sarcoma that 
subsequently developed must have arisen in the area 
included within the radiotherapeutic beam. 
3. A relatively long, asymptomatic period must have 
elapsed after irradiation before the clinical 
appearance of the bone sarcoma. In these cases, this 
has been longer than the so-called five-year-cure 
period. 
4. All sarcomas must have been proved histologically." 
The latent period was calculated from the date of the last 
radiotherapy treatment and appears to have been defined as 
lasting until the onset of clinical change due to the 
sarcoma, although this is not clear from the paper. 
Other authors have 
acceptable. Arlen (5) 
thought shorter latency periods 
suggested in 1971 that a five-year 
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period was not necessary to ensure that a histolo.gically 
independent lesion had developed and proposed an interval 
of 3 to 4 years. According to Robinson (94) these amended 
criteria have been generally accepted. Arlen also 
suggested that the first criterion should be modified so 
that initial bone lesions may have been malignant provided 
they did not have osteoblastic activity. He described two 
cases where an osteogenic sarcoma arose in a radiotherapy 
field used in the treatment of an unrelated sarcoma 
(Ewing's sarcoma and reticulum cell sarcoma of bone). He 
also mentioned a possible fifth criterion of radiation 
osteitis, but noted that in many cases adequate radiologic 
examination of the bone prior to the development of the 
tumor was not available (5). 
Senyszyn et al (100) recommended that in the case of a 
radiation-induced bone sarcoma there should have been x-ray 
evidence of osteodysplasia more than a year before the 
onset of obvious tumor formation as this would in most 






being diagnosed as a 
case of a radiation-
induced malignancy of the soft tissues or skin there may be 
clinical evidence of severe skin atrophy, telangiectasia 
and/or "radiation dermatitis". As is suggested in their 
paper, it is impossible to be sure that a tumor is 
radiation-induced whatever the criteria employed. 
A report from the Mayo Clinic in 1971 (104) criticised 
Cahan's first criterion as roentgenographic criteria of 
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malignancy are not specific and the second as it referred 
only to external therapy. 
Hatlinghhus et al (47) suggested that it seems reasonable 
to apply similar criteria to Cahan' s in the diagnosis of 
postradiation soft tissue sarcoma. Obviously the first 
criterion, which refers to bone sarcomas developing in 
previously benign bone lesions, is an exception. 
In the Groote Schuur study all patients with a sarcoma or 
MMMT in a radiation field have been included provided the 
histology differed from the initial histology. In one case 
(case 18) the initial diagnosis of a giant cell tumor was 
made on the basis of radiological features and a tissue 
not taken. However in view of the initial specimen was 
radiological diagnosis and the long latent period of 42 
years and 7 months before the development of osteosarcoma, 
this has been accepted as being of a different histology. 
(The spontaneous development of sarcomas in giant cell 
tumors is discussed elsewhere.) Latent period was not used 
as an inclusion or exclusion criterion in the Groote Schuur 
study as any such specification is arbitrary and anyway 
does not exclude spontaneously occurring tumors or those 
developing on a genetic basis being classified as 
radiation-induced tumors. In one patient (case 20) no 
radiation details are available. The patient had given a 
history of being irradiated at another institution and this 
was confirmed by her family at the time of this study. 
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Evidence of radiation fibrosis (as well as fibrous 
dysplasia) was present in tissue from the sarcoma. 
4.2.2. REPORTED LATENCIES FOR POSTRADIATION SARCOMAS 
INCLUDING SEPARATE REPORTS FOR BONE AND SOFT TISSUE 
Latency periods reported in various clinical studies can be 
seen on Table 3. 
Latency periods for groups of bone and soft tissue sarcomas 
combined are reported in the following studies: 
1) Hatfield et al from the Massachusetts General Hospital 
(46) reported a range of latency from 3 to 24 years 
with a mean of 12 years in eleven cases of 
postradiation sarcoma. 
2) In an analysis of thirty-three postradiation sarcomas 
from the Finnish Cancer Registry Wiklund et al (122) 
reported a latency of 3.2 to 22.8 years (median 13.2) 
(from start of radiotherapy to the second tumor 
diagnosis, including retrospective diagnoses). No 
interval of more than 35 years could be recorded. 
3) Mindell (75) suggests that some of the reported early 
postradiation sarcomas could be second primaries 
unrelated to the previous radiotherapy. In a review 
of twenty patients with PRS presenting to the Roswell 
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Park Memorial Hospital he recorded a latency range of 
1 to 29 years with a mean of 12.5 years. Three 
occurred before 5 years. 
4) Mark, ( 67) in a report of thirteen PRS of the head and 
neck area, found a latency which ranged from 3 months 
to 50 years with a median of 12 years. All except one 
patient had a latency of more than 4 years. The 
patient with the short latency period had received 
radiotherapy for bony fibrous dysplasia which had more 
than one recurrence. 
5) In nine cases of sarcoma arising in the radiotherapy 
field (excluding Stewart Treves Syndrome) in patients 
who had had treatment for breast carcinoma at the 
Institut Gustave Roussy, 
24 years with a mean 
the latency ranged from 5 to 
of 10 years (113). In the 
accompanying literature review it was noted that most 
second solid tumors occurred after a mean of not less 
than 10 years. This included bone and soft tissue 
sarcomas, with a relative risk slightly increasing in 
relation to the latent period. Only leukemia occurred 
after a latency less than 10 years and had a RR 
inversely related to the latency. 
6) In Scuba's series of sixteen patients with radiation-
induced sarcomas of the chest wall (109) the latency 
ranged from 5 to 28 years with a mean of 13 years and 
a median of 10 years. 
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7) Robinson et al (94), in a literature review and 
analysis of 344 cases of PRS, found the mean time 
interval between first and second neoplasms to be 11 
years with a range of 1.2 to 33 years. 
In the Groote Schuur study ~he average latency was 14 years 
2 months and the median 9 years. The patient with a 
latency of 53 years is unusual, presumably because most 
studies have not included patients followed for such a long 
period. 
More series exist of reports of PRS of bone only than 
reports for soft tissue only. This may be because earlier 
reports included a higher proportion of sarcomas occurring 
after irradiation of benign bone lesions. 
The following studies refer to postradiation bone sarcomas: 
1) In Cahan' s eleven cases of PRS of bone the latency 
ranged from five to twenty-two years and averaged 
eleven and two-tenths years (14). 
2) In the reported series of thirty-four postradiation 
sarcomas of bone of Sim et al (104) the latent period 
(from the date of commencement of radiotherapy to the 
time of diagnosis of sarcoma) ranged from 5 to 42 
years and the mean was 16 years. 
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3) Doherty et al found the latency of forty reported 
cases of sarcoma of the bone following radiotherapy 
for breast cancer to have a range of 4.5 to 20 years. 
The average was 10.9 years (27). 
4) In 10 cases of PRS of bone reported from the Princess 
Margaret Hospital the latent period ranged from 5 to 
23 years and the mean was 15 years (114). 
5) Huvos ( 4 9) from the Memorial Hospital for Cancer and 
Allied Diseases reported sixty-three patients who 
developed postradiation osteogenic sarcoma. Overall 
the range of the latent period was 3. 5 to 33 years, 
the mean 12.8 years and the median 10 years. Latent 
periods were expressed as the time between the start 
of radiation exposure and the diagnosis of osteogenic 
sarcoma. In sixty-three patients who developed 
postradiation osteogenic sarcoma Huvos reported a 
range of latency from 4 to 30 years for patients whose 
bones were normal at the time of irradiation and 3 to 
33 years in those whose bones were 
median in both gioups was 10.5 years. 
diseased. The 
The mean in the 
first group was 12. 5 years and in the second 13. 3 
years. There was no significant difference in the 
mean latency periods in the two groups. 
The following reports refer to postradiation soft tissue 
tumors: 
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1) In a report by the Armed Forces Institute in 1988 
(59), in which fifty-three cases of postradiation soft 
tissue sarcoma were reviewed, Cahan's original 
criteria were modified so that the first was omitted 
(it is not relevant to soft tissue sarcomas), a 
latency period of 2 years was accepted, and the fourth 
was modified so that proof was necessary that the 
sarcoma was histologically different from the 
irradiated primary lesion. (This means that a 
radiation-induced sarcoma can be diagnosed when the 
initial treatment 
sarcoma.) If 
was for a histologically different 
it was not specified that the 
postradiation tumor arose within the radiation field 
these investigators searched for radiation effects in 
surrounding nonneoplastic tissue. In these cases it 
was not possible to prove that the area had been 
irradiated previously if the sarcoma had effaced the 
radiation field. The latency period ranged from 2 to 
40 years with a mean of 10 years and a median of 8 
years. 
2) In a report of seven cases of postradiation soft 
tissue sarcoma in breast cancer patients Kuten found 
the latency ranged from 4 to 26 years with a mean of 
13 years (58). 
3) Ruka ( 96) reported a study of thirteen cases of soft 
tissue PRS in patients treated for uterine cancer 
(mainly cancer of the cervix) at a Warsaw institute. 
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The latent period ranged from 7 to 31 years with a 
mean of 18 years. 
In the Groote Schuur study sarcomas in bone developed after 
a mean latency of 1 7 years 3 months (and a median of 7 
years 7 months) and those in soft tissue after a mean of 11 
years 8 months (and a median of 9 years 10 months) . The 
difference between the groups was not statistically 
signigicant. 
Two patients in the Groote Schuur study had abnormal bone 
at the time of irradiation. (They were irradiated for 
giant cell tumors.) The latent periods were relatively 
long at 17 years 3 months and 42 years 4 months. 
Overall mean or median latencies appear to usually lie 
between 10 and 20 years and no conclusion can be drawn as 
to whether there is a significant difference in latency 
between groups with soft tissue and bone sarcomas. 
4.2.3. LATENCY AND AGE 
Some authors have indicated that that there may be a 
different sensitivity of the immature 
prepubertal children (104, 20, 105). Huvos 
tissues in 
(49) from the 
Memorial Hospital for Cancer and Allied Diseases found a 
significantly shorter latency for postradiation osteogenic 
sarcomas in patients irradiated under the age of 16 years. 
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Weatherby (121), in a report of 78 cases of PRS of bone, 
noted that patients irradiated before the age of 18 tended 
to have longer latent periods than those irradiated after 
18. 
Conversely, in the following series, age at irradiation has 
not been found to affect the latency period: 
1) In Sim's series from the Mayo clinic (104) it was 
found that it made no significant difference whether 
radiotherapy was given in infancy or adulthood 
eleven of the patients in this series were 21 years or 
younger at the time of radiotherapy and a shorter 
latency period in this group was not noted. 
2) In a study of 
malignancy after 
25 patients with postradiation 
treatment of retinoblastoma the 
average latency was more than 10 years among patients 
with sarcoma in whom the latent period was known. In 
a comparison with series of tumors induced by 
irradiation in adults, the author found that the 
latent period was not appreciably different whether 
irradiation occurred in childhood or infancy (108). 
In a comment on this paper Hatfield noted that the 
average latency was overall greater than 10 years in 
spite of a threefold increase in average dose and the 
fact that treatment was given to young, actively 
proliferating bone and cartilage. Therefore Hatfield 
commented that one cannot assume tha·t radiation-
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induced malignancy develops sooner in young than in 
adult bone (46). 
3) Other authors have also found no definite relationship 
between age at the time of the first radiotherapy and 
latency (59, 122) . 
In the Groote Schuur study the difference in latency 
between children (mean 15 years 1 month and median 6 years 
2 months) and adults (mean 13 years 10 months and median 11 
years 5 months) was not statistically significant. The 
latency of 53 years in one paediatric case has of course 
affected the mean which is calculated for a total of only 6 
cases. 
Overall there is no convincing evidence that latent periods 
are significantly different between paediatric and adult 
patients. 
4.2.4. LATENCY IN RELATION TO PRIMARY MALIGNANCY, SEX AND 
GENETIC PREDISPOSITION TO CANCER 
Souba (109) in a report of PRS of the chest wall found no 
difference in latency if patients were stratified according 
to histology of the primary malignancy or sex and Wiklund 
( 122) reported that patients considered to have a genetic 
predisposition to malignancy had a median latency of 13.9 
years and those not having such a predisposition one of 
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12.5 years. This difference was not statistically 
significant. Histologic subtype and treatment with 
chemotherapy were also not associated with a significant 
difference in latency. 
In the Groote Schuur series the retinoblastoma group did 
have a significantly shorter mean latency (4 years 4 
months) than the patients with other primary malignancies 
(15 years 11 months). The median in the former group was 4 
years 7 months and in the latter 11 years. 
4.2.5. LATENCY AND MODALITY 
Some authors have attempted to determine whether the 
latency period is affected by the radiotherapy modality. 
In Wiklund's analysis of thirty-three cases of PRS from the 
Finnish Cancer Registry (122) the median latency was longer 
for patients who had received orthovoltage radiotherapy 
than for those who had received megavoltage treatment (15.9 
versus 7.4 years). In Wilkund's study this difference was 
not significant when patients who had been followed up for 
a short period only were excluded from the analysis, but a 
threshold latency of 11.3 years after orthovoltage and one 
of 3.4 years after megavoltage radiotherapy were noted. 
Two other large studies have found a longer latency after 
orthovoltage than megavoltage therapy. In Robinson's 
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literature review and analysis of 344 cases of PRS (94) the 
difference in latency between those treated with 
orthovoltage therapy (mean 127,84 months) and supervoltage 
(mean 103. 63 months) was statistically significant. The 
longest interval was actually found in those treated with 
brachytherapy (mean 162,21 months) or a combination of 
external beam therapy and brachytherapy (mean 165,43 
months). The interval for the combination was 
significantly longer than for the orthovoltage and 
supervoltage groups. 
In the Armed Forces Institute study (59) most of the 
patients (5/7) who had received orthovoltage radiotherapy 
had latency periods of more than 13 years but those who had 
received megavoltage radiotherapy had latencies less than 
the mean. 
The differences between the orthovoltage and megavoltage 
groups in the Groote Schuur study appear to be consistent 
with those in these other reports with a longer mean and 
median latency after orthovoltage therapy than megavoltage 
therapy, whether or not brachytherapy was given. However 
the differences were not significant and follow-up periods 
had not been taken into account. The group which received 
brachytherapy (with or without external beam therapy) had a 
longer mean latency than the group without brachytherapy, 
but this difference was not statistically significant. In 
view of the combinations of various modalities of external 
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beam treatment with brachytherapy and differences in dose 
it is difficult to assess the relevance of these findings. 
Overall it appears that orthovoltage therapy may be 
associated with a longer latency period than megavoltage 
therapy, but this has not been definitely shown. The 
duration of follow-up should be taken into account when 
differences such as this 
orthovol tage therapy has 
megavoltage therapy. 
4.2.6. LATENCY AND DOSE 
are analysed, particularly as 
been in use longer than 
Hatfield et al (46) could not correlate the length of the 
latent period with the initial radiation dose and found the 
same in other reported series. The latency period did not 
appear to be shortened by higher doses. 
In the analysis based on the Finnish Cancer Registry (122) 
concerning possible influences on the latency period it was 
found that in patients who had received a total dose of 
more than 36Gy the median latency was 7. 4 years with a 
range of 3.4 to 16.1 years. In those who had received less 
than 36Gy the median was 14.4 years with a range of 8.3 to 
22. 8 (p=O. 0 9 Kolmogorov-Smirnov test) . Other reports on 
the association of latency and dose, as discussed by 
Wiklund, have shown conflicting results (122). The maximum 
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single dose per fraction in the Finnish study was not 
associated with a significant difference in latency. 
The quality of radiotherapy, total dose, year of treatment 
and duration of follow-up were closely linked. The number 
of patients and time interval studied was limited. For 
these reason~ the authors of the Finnish analysis did not 
feel they could draw definite conclusions on the 
relationship between latency and dose. 
In the Armed Forces Institute study (59), in the patients 
with malignant fibrous histiocytoma the latency again 
tended to be inversely related to the dose of radiation. 
71% of these patients who had received 3000 rads or more 
had latencies less than the mean. 67% of those who died of 
their sarcoma had latencies less than the mean. These 
authors reported that the mean and median latencies in 
their series correlated with those in other recent reports. 
In the Groote Schuur group the latency was longer in the 
group in whom more than 60Gy was prescribed but the 
difference in latency between this group and the group in 
which less than 60Gy was prescribed was not significant. 
Due to the problems of comparing total doses no comment can 
really be made about association between latency and dose 
::. ~-om this study. 
Overall no conclusions can be drawn on the relationship 
between dose and latency. 
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In conclusion, there is no definite evidence to show that 
tissue type, age, modality, dose, sex, type of primary 
malignancy or a genetic predisposition to malignancy affect 
the latency period. There is some evidence to suggest that 
megavoltage radiotherapy and higher doses may be associated 
with shorter latency periods. 
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4.3. CAUSES OF SARCOMA DEVELOPMENT IN RADIATION FIELDS 
Radiation should be considered carcinogenic for all tissues 




A tumor may appear in a specific tissue in 
population group because that tissue was 
irradiated (for example bone tumors in 
radi urn dial painters) . If radiation is more generalised 
some tissues such as thyroid, breast and lung seem to be 
more susceptible than others. It is estimated that the 
ratio of solid tumors to leukemias will be in the range of 
4 to 6 even though the incidence of leukemia is higher 
earlier after exposure (38). 
Some investigators have reported that doses between 40 to 
60Gy to limited areas in radiotherapy patients do not lead 
to a significantly increased cancer incidence. Others 
report an increase. Assessment of risk is difficult 
because cancer patients are often at increased risk of a 
second cancer because of their lifestyle. Chemotherapy may 
add to the cancer risk. It appears that radiation does 
increase the risk of second malignancy, both in heavily 
irradiated areas and in more distant organs that received a 
few gray. However according to Hall at most approximately 
5% of second cancers can be convincingly associated with 
radiation ( 38) . It will probably remain impossible to be 
certain that a particular malignancy is radiation-induced 
(100). 
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Sarcomas are among the malignancies that may be induced by 
ionizing radiation (15, 14, 38). In the earliest recorded 
cases in man these tumors developed after irradiation for 
benign bone lesions but later were noted to have occurred 
in normal bone and soft tissues in the irradiated areas 
( 4 7) • 
4.3.1. MALIGNANT TRANSFORMATION AT A MOLECULAR LEVEL 
Malignant transformation induced by radiation is thought to 
be related to DNA damage ( 18) but the actual molecular 
mechanisms are not clearly understood (39). In 1980 Borek 
(11) reported for the first time the neoplastic 
transformation in vitro of human diploid cells by x-ray 
irradiation into cells which could progress in vitro into 
advanced stages of neoplastic development, i.e. to form 
colonies in agar and give rise to tumors when injected into 
nude mice. The transformation of human cells has been very 
difficult (8). 
Malignant transformation induced by radiation or chemicals 
appears to be a progressive, multistage process (39, 5, 
113, 38). At least two steps, which have been described as 
initiation and promotion, are involved. These two stages 
may be followed by another period which is less well-
defined and which itself may be made up of different 
components (38). Carcinogenesis extends over many years or 
decades (113). (This may partly explain why tumors as 
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malignant and rapidly progressive as PRS have a relatively 
long latent period). According to Hallahan ionizing 
radiation, like most other known carcinogens, can act as 
both initiator and promoter and is therefore termed a 
complete carcinogen (39). 
Malignant transformation may be due to activation of an 
oncogene, loss of a suppressor gene (as in retinoblastoma 
or Wilms' tumor) or possibly sometimes both (38). 
In radiation carcinogenesis a normal indigenous proto-
oncogene may be changed and activated by the radiation. As 
oncogenes act dominantly, a single copy of the gene in the 
cell is enough to lead to a tr~nsformed phenotype, even if 
normal copies of the same oncogene are present. Proto-
oncogenes may be activated to produce malignant cells by 
point mutations, chromosomal rearrangement, translocation 
(which often places the proto-oncogene next 
promotor sequence), or gene amplification. 
oncogenes are associated with certain 
chromosomal changes (38). 
to a strong 
Some known 
cancers and 
In an analysis of tumor cells derived from seven radiation-
induced tumors, six out of seven of the radation-induced 
human tumors had abnormalities of one or both of the 
suppressor genes Rb and p53 (13). Rb and p53 have been 
implicated in the causation of a variety of tumors, 
including spontaneous sarcomas (77, 91, 38). 
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The development of retinoblastomas is discussed in section 
4. 4. 
Recent studies have supported the concept that multiple 
genetic changes are necessary for tumorigenesis. According 
to Nowell's clonal-evolution model of tumor progression, a 
cell which acquires a specific genetic change may develop a 
proliferative advantage and clonal expansion of the cell, 
driven by successive mutations, could lead to tumor 
progression (78, 92). According to a basic model of 
tumorigenesis reviewed by Renan (92), the age-specific 
incidence rate is proportional to an integral power of age. 
According to this model malignancy only appears as a 
clinical entity after the necessary set of m sequential 
changes has occurred. The number of alterations in a 
particular tumor can be deduced. On double logarithmic 
coordinates, a plot of incidence against age will give a 
straight line of which the slope is (m-1). Renan has taken 
twenty-eight different malignancies and plotted the log of 
the age-specific mortality rate against the log of age in 
years and then determined the best-fit linear regression 
coefficients for each tumor. He thus lists the number of 
mutations calculated to be necessary after birth for the 
developmen~ of the tumor. The mortality rates of commonly 
occurring solid tumors such as stomach and pancreatic 
cancer allowed straight lines in a log-log plot, sometimes 
with a deviation in early childhood or old age. Seven or 
eight mutations appeared to be necessary in this group. 
For prostate cancer twelve mutations appeared necessary, 
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which may explain why it is primarily a disease of old age. 
This may also explain the incidence of "partially 
transformed" lesions of the prostate found at autopsy. It 
may be that the premalignant cells have not undergone the 
full number of alterations necessary for overt neoplasia 
( 92) . 
Relatively high incidences at younger ages for certain 
tumors are thus presumed to be due to inherited defects. 
The final shape of a curve may depend on data from two 
separate groups: patients who develop the tumor in early 
childhood and those who develop it in adulthood. For bone 
cancer there is a peak in the late teenage years and 
another increase after approximately age 35. The high rate 
in teenage years could result from a population group 
susceptible to bone cancer early in life (92), for example 
those with a lesion in the retinoblastoma suppressor locus 
(38, 28). For bone cancers in the younger age group three 
alterations appeared to be necessary, and over 35 years of 
age six. If this is a single disease, these data imply 
that patients with a familial prediposition are born with 
three genetic changes, rather than only one, in the 
precursor tumor cell. It is suggested that one of these, 
the Rb gene lesion, is a germline mutation, and two lesions 
follow rapidly in utero. Renan thus explains why in 
certain tumor types there are early and late onset patient 
groups. The early onset cases may be a re~·.:lt of inherited 
susceptibility, necessitating less genetic alterations 
before malignancy develops (92). 
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If this model is correct, postradiation desmoid tumors or 
aggressive fibromatosis may be due to the same phenomenon 
as suggested for carcinoma of the prostate, with the final 
mutations which would have given rise to definite 
histological evidence of malignancy or to metastasis being 
absent. 
4.3.2. THRESHOLD FOR TUMOR INDUCTION 
Radiation damage may occur according to a deterministic or 
stochastic (random) effect. In general, loss of a large 
number of cells will lead to observable harm. The 
probability of such harm will be nil at small radiation 
doses but above a threshold dose it will increase rapidly 
with dose to 100%. This is called a deterministic effect. 
There is a threshold level and the severity of the effect 
is dose-related. This first outcome could result in, for 
example, a radiation-induced cataract (38). 
Whether or not there is a threshold for radiation 
carcinogenesis has been the subject of controversy. 
According to a report of the United Nations Scientific 
Committee on the Effects of Atomic Radiation reviewed by 
Tountas (114), for external radiation there is a negligible 
probability of radiation induced sarcomas of bone below 
lOGy. In a report on bone sarcomas linked to radiotherapy 
120 
and chemotherapy in children Tucker noted no increased risk 
associated with doses of less than lOGy (116). 
In Wiklund's (122) series of thirty-three cases of PRS from 
the Finnish Cancer Registry, all the patients had received 
doses of more than 15Gy. A higher threshold dose has also 
been suggested (53). Wiklund (122) pointed out that these 
differences probably reflect, in part, the difficulty of 
finding out the dose previously given at the sarcoma site. 
Senyszyn (100) suggested that 30Gy was probably the 
critical dose for tumor induction in bone as doses less 
than this had not been reported to cause bone tumors. 
In the Groote Schuur group the lowest prescribed dose was 
3 OOOR (case 14). Three patients were estimated to have 
developed tumors for which the dose at the estimated tumor 
development point was less than 30Gy (Cases 11, 14 and 
15) . 
According to Hall (38) carcinogenesis is the result of a 
stochastic effect and there is probably no threshold. The 
probability of cancer is dose-related. The severity of the 
cancer is of course not dose-related but a higher dose 
gives a higher probability of cancer (38). 
A relationship between incidence and dose and the rarity of 
the condition overall would account for the fact that it is 
difficult to detect an increase in incidence at very low 
doses as found in the studies discussed. 
4.3.3. GRAY'S HYPOTHESIS AND THE EFFECT OF DOSE 
In small experimental animals a variety of dose-response 
relationships in carcinogenesis have been reported. In the 
characteristic type of curve obtained, if incidence of 
leukemia is plotted against dose, the incidence of 
malignancy increases with dose up to a maximum (usually 
between 3 and lOGy) and this is followed by a decrease in 
incidence with further increases in dose. It is thought 
that the shape of the curve is due to a dose-related 
increase in the proportion of transformed cells and at 
higher doses a dose-related decrease of the probability that 
such cells survive the radiation. The fraction of 
transformed cells is therefore reduced at high doses. It is 
thought that the same effect might well be found in humans 
if enough data were available for a specific tumor type 
(38). This hypothesis has become known as Gray's 
hypothesis. The curves drawn by Gray (37) are reproduced on 
Graph 1. The significance of this effect for most cancers 
other than leukemia remains unclear (63). 
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GRAPH 1 
Dose response relations for the induction of myeloid 










It appears that there is not a single model for the 
description of dose-response curves for tumor induction in 
different tissues (118). For some tumors the mechanism of 
transformation may be mainly a result of direct effects on 
the target cell, perhaps involving one or more mutations. 
A variety of host factors such as endocrine status, immune 
competence and cell population kinetics of the target and 
interacting cells can influence the eventual expression of 
the tumor. In other tumors indirect effects may play a 
major role in the tumor initiation or expression (118). 
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Two different types of model can be used to explain 
radiation carcinogenesis. In the absolute risk model it 
is assumed that the radiation induces a mumber of 
malignancies over and above the natural incidence and 
unrelated to it. This model was favoured in the past. In 
the relative risk model it is assumed that the radiation 
increases the natural incidence of cancer at all ages 
subsequent to exposure. As the spontaneous cancer 
incidence rises in old age, this model predicts a larger 
number of radiation-induced cancers in old age, too. In 
the time-dependent relative risk model, used in the most 
recent assessments of cancer risks in A-bomb survivors, the 
excess incidence was assumed to be a function of dose, 
(dose)-squared, age at radiation exposure, and time since 
exposure (38). 
4.3.4. EVIDENCE FROM CLINICAL STUDIES FOR SARCOMA 
INDUCTION AT LOW DOSES 
Some authors have suggested that PRS develop in low-dose 
areas within radiation fields. 
1) According to Brachman et al (13) it is known that 
second malignancies, usually sarcomas, arise at or 
within the edge of radiation fields several years 
after the radiation. 
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2) Turner and Greenall from the John Radcliffe Hospital 
in Oxford described two cases of sarcoma after breast 
conservation surgery and radiotherapy. They mentioned 
that a distinguishing feature of PRS, as demonstrated 
by their cases, is that the sarcomatous change tends 
to occur at the periphery of the field, whereas a 
recurrence of the breast cancer would often be more 
central (117) . 
3) Arlen et al (5) pointed out that in nineteen cases 
reported or reviewed by Senyszyn (100), six of the PRS 
-eveloped in the scapula although the "apparent" dose 
to this bone appeared to be the least to all sites 
treated. 
4) In children who generally received an exposure of only 
350-400R for tinea capitis the RR for bone and 
connective tissue cancer was 9. Most of these 
occurred in the head and neck area. ( 9. 4% received 
more than one treatment but it was not specified if 
the children who developed bone sarcomas were in this 
group. ) ( 95) 
5) Among patients treated for ankylosing spodylitis an 
excess of deaths due to bone cancer has been reported 
(23) but this report was based on only five deaths. 
Among patients who received a skeletal dose of the 
order of 3Gy for ankylosing spondylitis a RR of 2.96 
after 25 years of follow up was calculated (23). 
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However among atomic bomb survivors, and in a study 
combining results of atomic bomb survivors and 
irradiated spondylitics, there were no excess deaths 
from bone cancers (24). 
Postradiation sarcomas may be found in relatively low dose 
areas in radiation fields but this does not preclude a dose 
effect with higher incidences in higher dose areas. 
It has been speculated that sarcomas appear at the 
periphery of the radiation fields where the radiation 
levels have not been great enough to destroy all viable 
cells (5) or that sarcomatous change occurs in areas of 
intermediate damage, while the more heavily damaged areas 
lack even neoplastic recuperative ability (21). 
4.3.5. EVIDENCE FOR SARCOMA INDUCTION AT HIGHER DOSES AND 
A DOSE-RESPONSE EFFECT 
The frequency of PRS reported in bone as compared to soft 
tissue has been attributed to the greater absorption of 
irradiation by bone, particularly when orthovoltage 
treatment is used (114). This supports the theory that the 
sarcomas occur at higher doses. 
In a review of the literature more studies are found which 
report the development of PRS in conventional or high 
rather than low dose areas: 
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1) In a study of postradiation soft tissue sarcomas at 
the Royal Marsden Hospital in London (25) it was 
found, in patients in whom complete radiotherapy 
details were available, that the mean total dose was 
37.3Gy with a range from 8.8 to 79Gy. Most patients 
had received 20 to 50Gy. Both ortho- and megavoltage 
therapy had been used with conventional and large-
fraction schedules. There was no evidence that the 
sarcomas arose at the edge of the treatment field. It 
had been hoped that full tumoricidal doses of 
radiotherapy might limit the induction of malignancy. 
However in this series it was shown that PRS may occur 
following radical doses and regardless of voltage 
( 2 5) • 
2) In a study of thirteen patients with post irradiation 
sarcoma of the head and neck from the University of 
California, Los Angeles Medical Center, doses were 
known in ten patients and ranged from 30 to 124. 4Gy 
with a mean of 60.03Gy (67). According to this author 
most series report doses in the range of 16-112 Gy 
with most of the sarcomas occurring at doses of about 
55Gy. 
3) In a series of seven postradiation soft tissue 
sarcomas in breast cancer patients from the Northern 
Israel Oncology Centre, the mean dose was 39.14Gy and 
the range from 22 to 54Gy (58). 
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4) Evans and Hughes from the Middlesex Hospital (30) 
reported two cases of PRS of the clavicle. They 
pointed out that, as in most cases previously 
reported, it was not possible for them to calculate 
accurately the dose actually absorbed by the clavicle 
because of insufficient documentation at the time of 
treatment. They estimated the dose to have been in 
excess of 4500rad. Both patients were treated by 
means of an orthodox kilovoltage source. 
5) Meredith and co-workers (72), in their review from the 
Ohio State University, noted that 17% of patients 
6) 
developing uterine malignancy after pelvic 
radiotherapy had mixed mesodermal sarcomas. The 
proportion of sarcomas was higher in those patients 
who developed the malignancy after radiotherapy for a 
malignant condition. Patients who had been irradiated 
for malignant conditions also tended to develop more 
aggressive tumors. 
Souba (109) from the M.D. Anderson has reported 
sarcoma development after doses in the range 42 to 55 
Gy, Doherty (27) after 18 to 100 Gy, and Tountas (114) 
from the Princess Margaret Hospital after 30 to 63 Gy. 
Wiklund (122), in an analysis from the Finnish Cancer 
Registry, reported a range of 16 to 112 Gy with a 
median of 36 Gy. In the latter study only two of the 
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thirty-three patients had received larger doses than 
is usual. 
Referring to a report from the National Research Council 
Committee on the Biological Effects of Ionizing Radiations, 
from the National Academy of Science in Washington, DC, 
Coleman (18) noted that sarcomas require higher doses than 
thyroid or breast cancer with none occurring in the atomic 
bomb population in which the maximum dose was 6Gy. 
There are also many reports of sarcomas occurring in 
particularly heavily irradiated tissue: 
1) Boice et al (10), in a study of dose and second cancer 
risk in patients treated for cancer of the cervix 
(which has been discussed in section 4. 1. 4. 2) found 
that several cancers seem to be related to doses of 
radiation of the order of hundreds of gray. 
Suggestive, but not conclusive, results were obtained 
for cancers of the bone and connective tissue. (High 
doses did not seem to increase the risk of cancers of 
certain organs such as the small intestine and colon. 
Lower radiation doses have been associated with an 
increased risk of colon cancer among atomic bomb 
survivors and these authors suggested that the high 
doses received during the radiotherapy for cervical 
cancer cause cell killing rather than transformation. 
They pointed out that many colon cells proliferate at 
a relatively high rate. Very high doses have also 
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been associated with decreased risk of cancer at other 
sites with a high proliferation rate.) 
High radiotherapy doses appeared to increase the risk 
of cancers of the female genital tract in the order of 
6% per lOGy. 332 cancers of the uterine corpus 
developed. 77% were adenocarcinomas and 17% sarcomas 
(including 6% carcinosarcomas). The others were 
either carcinoma not otherwise specified or unknown 
type. The RR was 6 at 15 or more years after the 
radiation exposure and it appeared that the risk 
increased with increasing dose. The authors (10) 
suggested that for their patients with cervical 
carcinoma the very high doses in the pelvic area are 
likely to have caused severe tissue damage which may 
have contributed to the development of a second cancer 
in a different way from lower doses. The risk may 
have been influenced by the nature of the exposure 
circumstances. Intracavitary radiums were used as well 
as external beam treatments. The authors pointed out 
that the effects of fractionation, protraction and 
nonhomogeneous organ 
predictable. 
exposures are not easily 
2) According to a review by In Sook Seo from the Indiana 
University School of Medicine ( 101) most radiation-
induced tumors in patients treated for benign 
conditions are carcinomas and sarcomas are more common 
after treatment for malignancy. (This would agree 
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with the theory that sarcomas develop after high doses 
as doses for malignant conditions are generally higher 
than for benign ones.) According to In Sook Seo' s 
review most sarcomas occurred in heavily irradiated 
tissues. 
3) Two soft tissue sarcomas in the radiation field 
following breast conservation therapy were reported 
from the Cancer Institute and associated clinics in 
Marseilles. Both occurred in the high dose irradiated 
area, in the region of supplementary electron beam 
irradiation, which had received doses of 70 and 80 Gy 
respectively (57). 
4) Other authors (96, 104, 47, 14, 45) have reported 
sarcoma development in heavily irradiated tissue. 
It has been pointed out (113) that out it is difficult to 
differentiate between the direct role of radiotherapy in 
the induction of sarcomatous changes and its indirect role 
via a chronic post-irradiation ulcer. 
In most studies of PRS where details of radiotherapy are 
available, a prescribed dose is reported rather than the 
dose at the site of tumor development. Corrections for 
dose in bone are not always made. In the Groote Schuur 
study an attempt has been made to estimate the dose level 
at which the tumor developed. This is not very precise due 
to lack of information about the exact situation of the 
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radiation field with respect to the postradiation tumor. 
Corrections have been made for the various modalities 
according to whether bone or soft tissue was affected by 
the postradiation malignancy. The range of dose points at 
which tumor is estimated to have developed is from 8 to 
10 OGy with a mean of 4 8Gy and a median of 4 9 Gy. Only 
three patients were estimated to have developed PRS in 
tissue which received less than 30Gy. The tumor developed 
between 30 and 60Gy in 9 cases and at 60Gy or more in 6 
cases. 
The data from Groote Schuur appear to support the other 
evidence available that sarcomas are more likely to develop 
in higher dose areas. 
lacking. 
However conclusive evidence is 
Boice's results (10) supported the concept of a dose-
response relationship as does work done on children. 
In children with bone sarcomas related to cancer treatment 
a dose response has been reported such that the risk 
reached 40-fold after doses of more than 60Gy to bone. For 
doses less than lOGy the RR was O. 6, for doses of 30-40Gy 
it was 17 and for doses of more than 60Gy it was 38. The 
risk did appear to decrease when the dose was more than 
80Gy (116). 
Experimental work on animals has supported the concept of a 
dose-response relationship (48, 103, 35): 
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1) In an abstract from the Russian literature (102), the 
development of strontium-90 induced osteosarcomas in 
rats is discussed. The highest dose (9.5µCi) yielded 
2-22% osteosarcomas and the incidence was not 
dependent on duration of exposure. 1 and 2µCi yielded 
36 and 60% respectively after 6 months and further 
extension of exposure did not change the process of 
carcinogenesis. In the 4µCi group the yield increased 
from 20% after 1 month to 52% after 3 months and 
further prolongation resulted in inhibition of 
carcinogenesis. 
2) In Gillette I s study (59) of intra-operative 
radiotherapy in dogs the incidence of tumor induction 
increased with increasing dose between 47.5 and 90 Gy 
and decreased at 97.SGy total dose. Two of the dogs 
which did not develop tumors had received 47.5Gy 
intra-operative therapy and 50Gy external beam 
radiotherapy and developed septic osteoradionecrosis 
with very few viable bone cells present (89, 35). 
It is possible that the curve for sarcoma induction would 
be similar to that described by Gray for leukemia induction 
but that the dose levels at which maximum malignant 
transformation and decreased transformation occur would 
fall at higher dose levels. This could be due to slower 
turnover of connective tissue and bone cells allowing cells 
to survive and be transformed at higher dose levels. 
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Another possible explanation for sarcoma development at 
high doses is that malignant cells grow in from the 
periphery of the field (where lower doses have been 
received) ( 5) to produce tumors more centrally in higher 
dose areas. The tissue damage in these areas may promote 
tumor growth but this is controversial as will be discussed 
later (82, 74). Some connective tissue and bone cells must 
survive in high dose areas and it seems more likely, 
considering the differences in dose reported in patients 
developing leukemia, breast and thyroid cancer and 
sarcomas, that sarcomas develop in higher dose areas than 
these other tumors, but perhaps with a fall-off in 
induction at doses at which cell kill overtakes malignant 
transformation. 
4.3.6. THE EFFECT OF TISSUE DAMAGE 
Sarcomas may arise in surgical sites where no radiotherapy 
has been given. Several authors have reported such sarcomas 
(50, 29). These and other reports support a role for 
mechanical damage in tumor development (66, 15). According 
to one hypothesis reviewed by Gillette in Cancer Research 
in 1990 (35), radiation has a direct and indirect effect on 
tumor induction. The direct effect is the malignant change 
in the regenerating cells and the indirect the creation of 
an environment for expression of malignant change. Stromal 
damage, more severe with large single doses, may have 
contributd to the incidence of tumor induction after intra-
operative radiotherapy. Repetitive irradiation has been 
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reported to be more effective at tumor induction in ,a study 
on radiation-induced osteosarcomas in mice (80). 
Thus even where there is no other reason, such as previous 
surgery, for mechanical damage, it is possible that 
radiation alone may have a mechanical effect which 
influences tumor development. It has been suggested that 
the reason for the development of PRS in the scapula after 
radiotherapy for breast carcinoma may be radiation damage 
to vessels which have their origin in the radiation fields. 
The scapula may be more radiosensitive because of a 
relatively better oxygen supply due to the rich blood 
supply (100). 
Papaioannou presents evidence from the literature that 
breast cancer recurrence may be facilitated by the injury 
caused by mastectomy or radiotherapy through local, 
regional and systemic mechanisms which promote tumor 
growth. Both local and systemic relapse may be affected 
and the effect appears to be proportional to the degree of 
injury (82). Similar factors may have a role in sarcoma 
development, with prior tissue irradiation promoting tumor 
growth. 
According to the theory of the tumor bed effect, tumor 
cells transplanted into pre-irradiated subcutaneous tissue 
need more time to establish tumors than those transplanted 
into non-irradiated tissue, and further tumor growth in the 
irradiated tissue is reduced. The phenomenon is thought to 
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be due to the reduced blood supply to tumor in irradiated 
tissue as the tissue has a decreased ability to provide 
blood vessels to tumors. The effect is dose-dependent. 
The tumor type is an important factor in the tumor bed 
effect with carcinomas showing a more pronounced effect 
than fibrosarcomas. Experimental work using murine tumors 
has shown that pre-irradiation of the tumor bed can 
influence the therapeutic response to Cyclophosphamide in a 
deleterious or advantageous way, depending on whether the 
endpoint for assessing anti-tumor activity is tumor cure 
(which was reduced) or regrowth delay (which was 
increased). It is explained that the reduced blood supply 
may account for the reduced curability but the same effect 
accounts for the delayed regrowth (74). 
There has been much speculation as to whether bone injury 
and reparative proliferation are necessary as an initiating 
factor in tumor development. In a report from the Memorial 
and James Ewing Hospitals many patients did have evidence 
of radiation osteonecrosis before signs of sarcoma 
development but the authors did not feel there was clinical 
evidence at the time of their report to support the concept 
described. There had been relatively few reports of the 
phenomenon (5). 
Several patients in the Groote Schuur study had undergone 
surgery as well as radiotherapy in the treatment of the 
initial tumor and had received more than one course of 
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radiotherapy to the relevant area before the development of 
a postradiation tumor. 
In general it appears that mechanical factors may affect 
sarcoma development. It is impossible to assess the 
magnitude of this effect in the clinical setting. 
4.3.7. THE EFFECT OF AGE 
It has already been noted (section 4.2.3.) that tissues in 
children may respond differently to radiation from those in 
adults. 
Age at the time of radiation exposure is thought to be 
important in the development of bone cancer. It is 
suggested by Hall that in exposure to a fetus or young 
person the rapid deposition of the bone-seeking 
radioisotopes during active bone growth might confer a 
higher risk of cancer induction than in adults (38). Other 
authors (12 4, 5) have noted that doses greater than 50Gy 
are likely to cause complete devitalization of adult bone, 
but the bones of children survive higher doses. A greater 
likelihood of cell survival would increase the risk of 
malignant transformation. It is difficult to estimate the 
effect of age in view of the large numers of paediatric 
cases with a genetic predisposition to malignancy. 
4.3.8. THE EFFECT OF MODALITY 
4.3.8.1) THE EFFECT OF MODALITY ON THE DEVELOPMENT OF 
POSTRADIATION SARCOMAS 
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The effect of radiation modality on the development of 
malignancy should be related to radiobiological effects as 
well as the dose absorbed by different tissues with 
different modalities. In 1970 Hatfield (46) stated that 
the issue of the incidence of sarcomas as a function of the 
energy of the external beam has not been resolved. This 
statement still holds true today. The absence of the 
expected decrease in incidence of PRS with the increasing 
use of megavoltage therapy has already been mentioned 
(section 4.1.5.). 
finding (10) . 
Boice's survey also supported this 
Laskin (59) suggested that a possible increase in PRS may 
be due to the profound mutagenic effect of megavoltage 
treatment on deep mesenchymal soft tissue. The 
transformation may be due to the effect on undifferentiated 
mesenchymal stem cells and result in malignant 
transformation along primitive fibrohistiocytic lines. 
Transformation into osteoid-producing cells may occur under 
the influence of increased oxygen tension in congested 
tissue (7). 
In the Groote Schuur study thirteen patients had received 
megavoltage therapy. One of these had also received 
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orthovol tage therapy and brachytherapy. One had received 
electron beam treatment (not at the site of sarcoma 
development) and five had received radium insertions. Six 
had been treated with orthovoltage and no megavoltage 
therapy. Of these, two were also treated by means of 
brachytherapy. 
The evidence from the literature and our study suggests 
that PRS have not become less common with the introduction 
of megavoltage therapy. 
4.3.8.2) THE EFFECT OF MODALITY ON THE DOSE AT WHICH 
POSTRADIATION SARCOMAS DEVELOP 
A further question relating to modality is whether the dose 
at which a PRS develops is related to the type of 
radiotherapy employed. In Wiklund' s analysis of thirty-
three cases of PRS the median total dose for megavoltage 
therapy was 36Gy (range 31 to 112Gy) and orthovoltage 24Gy 
( range 16 to 90Gy, pO. 02) . Whether or not the patients 
received intracavi tary treatment was also not significant 
(122) . 
In the Groote Schuur study, if f-factor corrections are 
made, the patients who received orthovoltage treatment 
developed tumors at a lower mean dose point (31Gy) and 
range of dose point (8 to 62Gy) than in the megavoltage 
group (mean 54Gy and range 12 to 10 OGy) . This difference 
was however not statistically significant and there is 
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insufficient data in the literature to draw conclusions 
regarding this point. 
4.3.9. GENETIC FACTORS AND THEIR RELATIONSHIP TO THE DOSE 
AT WHICH POSTRADIATION SARCOMAS DEVELOP 
Several authors have discussed the relationship between 
genetic factors and the development of second malignancies. 
Even in the absence of a family history of malignancy there 
may be a genetic factor which increases the susceptibility 
to malignancy in the radiation field (110). 
There are hereditary or familial disorders with an 
increased risk of cancer development and an association 
between hereditary retinoblastoma and osteogenic sarcoma in 
children has been shown (28). This will be discussed in 
more detail in section 4.4. 
Coleman (18) notes that between 25 and 50% of second tumors 
in a paediatric popul~tion may be due to a genetic syndrome 
or some other hereditary predisposition and thus may not be 
truly treatment-related. 
Approximately 5% of the second malignant neoplasms in a 
report from the Late Effects Study Group were not 
associated with radiotherapy, chemotherapy or genetic 
disease. If, as previously suggested, the incidence of 
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second malignancies in children is tenfold greater than 
that of cancer ~n the age-matched general population, this 
fraction of cases would be expected to occur by chance 
alone (70). 
It has been suggested that a fraction of patients with 
Wilms' tumor also carry a genetic predisposition to the 
disease (55) . In a report by Meadows on second malignant 
neoplasms in survivors of paediatric cancer (70), almost 
30% of the Wilms' group had characteristics of the genetic 
form of that embryonal tumor although the age at diagnosis 
of Wilms' was not earlier than expected. This suggests 
that, as in retinoblastoma, second malignancies occurred 
excessively in patients with the genetic form of Wilms' 
tumor. Ionising radiation was associated with the majority 
of second malignancies reported in this study. 
In Wiklund's study the mean and median total dose was lower 
for patients with a genetic predisposition to malignant 
disease than for those without such a predisposition (30). 
In the Groote Schuur study the retinoblastoma patients 
the non-developed PRS at an average of 31Gy. 
retinoblastoma group the mean was 51Gy. 
In 
This result was 
not statistically significant but the trend is in keeping 
with Wiklund's finding. It is impossible to determine 
whether the PRS in retinoblastoma patients developed due to 
genetic factors alone and what role the radiotherapy 
played. 
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In conclusion, genetic factors may increase the risk of a 
second malignancy but the relationship between genetic 
factors and dose is not clear. 
4.3.10. CHEMOTHERAPY AND CHEMICALS 
Various chemicals have also been associated with sarcoma 
development (67). 
An association between the use of chemotherapy and sarcoma 
development has been shown in the following studies: 
(1) A higher incidence of bone sarcomas has been noted in 
survivors of paediatric malignancies who received 
chemotherapy as well as radiotherapy, than in patients 
who received radiotherapy alone (116). 
(2) Cyclophosphamide may play a role in the induction of 
second tumors in retinoblastoma patients (28). Of the 
eight patients with sarcomas occurring within the 
radiation field in Draper's study of second primary 
neoplasms in retinoblastoma patients, three patients 
had been given Cyclophosphamide. Of the thirteen who 
developed tumors out of the field, five had received 
Cyclophosphamide. Of the two who developed soft 
tissue sarcomas within the field one patient had 
received Cyclophosphamide, and one of the four who 
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developed a soft tissue sarcoma outside the field. 
The incidence of second primary tumors overall was 
greater among patients given chemotherapy than among 
those not given it (28). 
In the Groote Schuur study six patients had received 
chemotherapy as well as radiotherapy before the development 
of the PRS. In this report no comment can be made on the 
effect of chemotherapy on the incidence of PRS. It appears 
from reports in the literature that chemotherapy may 
further increase the risk of a sarcoma developing in a 
radiation field. 
4.3.11. OTHER FACTORS IN THE DEVELOPMENT OF SARCOMAS IN 
RADIATION FIELDS 
4 . 3. 11 . 1) "SPONTANEOUS" SARCOMAS AND UNKNOWN 
PREDISPOSITIONS TO SARCOMA DEVELOPMENT 
A sarcoma may occur by chance in the irradiated area (34, 
84). It should be remembered that patients with primary 
malignant tumors are statistically more at risk of second 
unrelated tumors than the general population. If the risk 
of a double primary has been outlived, patients who have 
been irradiated are at risk from "spontaneous" sarcomas 
just as the rest of the population is (46). 
292 patients with 308 second malignancies were reported by 
the Late Effects Study Group in 1985 (70) . It was noted 
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that although most cases of second malignancy in survivors 
of childhood cancer can be attributed to radiation, genetic 
disease, chemotherapy or combinations of these, 
unrecognized predisposition or chance may also play a role. 
25% of the patients in this series had a known cancer-prone 
condition. 
It has been suggested that there is an "unknown 
predisposing factor" implicated in the rare development of 
sarcomas in breast cancer patients (115). 
Reports of third neoplasms in patients with PRS are rare. 
Hatlinghus and co-workers (47), in a report of three PRS, 
noted that two had multiple primaries and others have been 
noted (3, 34). Hatlinghus (47) pointed out that the 
presence of multiple primaries might suggest that the 
sarcomas were actually spontaneous tumors but he and his 
co-authors felt there was good reason to regard them as 
radiation-induced tumors in patients with an increased 
disposition to develop cancer. 
4.3.11.2) UNDERLYING BONE DISEASE 
Benign conditions including fibrous dysplasia and giant 
cell tumor of bone have been associated with later sarcoma 
development, even in the absence of radiotherapy (121). It 
is possible that the development of sarcoma in these cases 
may be associated with the tissue damage effect as 
discussed earlier (5). 
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In patients with diseased bone at the time of irradiation 
in Huvos' series the median dose was 59Gy with a range of 
16.60 to 115.00 Gy and in those with normal bone the median 
was 45Gy with a range of 25 to llOGy (49). 
In the Groote Schuur study the two sarcomas which developed 
in diseased bone were estimated to have developed in tissue 
which had received 48 and 62Gy. No conclusions can be 
drawn regarding these patients due to the small number. 
4.3.11.3) THE CAUSE OF TUMOR DEVELOPMENT CANNOT BE 
ASCERTAINED IN INDIVIDUAL LESIONS 
Hatfield (46) pointed out that postirradiation sarcomas 
occur later than unrelated second primaries and should be 
considered as a separate group of lesions. He also noted 
that sarcomas do occur spontaneously and absolute proof of 
radiation as a cause is lacking in man. Statistical 
evidence is available. Hatfield stated that it is prudent 
to assume that tumors which have been called PRS are 
causally related to the previous radiation and are not 
spontaneously-occurring second primaries. 
As can be seen from the preceding discussion, although 
sarcomas developing in postradiation fields may be termed 
radiation-induced sarcomas in some reports, they may have 
developed spontaneously. Genetic, chemical or mechanical 
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factors, or disease in the underlying bone, may also have 
played a part in their development. 
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4.4. POSTRADIATION SARCOMAS IN RETINOBLASTOMA PATIENTS 
4.4.1. HISTORICAL BACKGROUND AND CLINICAL STUDIES 
In 1969 Sagerman from the Columbia-Presbyterian Medical 
Centre of New York wrote a report (97) on radiation-induced 
tumors following external beam treatment for 
retinoblastoma. It was not the first report of tumors 
following radiotherapy for this condition but it is an 
interesting paper and particularly interesting in 
retrospect. Among 243 retinoblastoma patients followed up 
for 5 or more years, second malignant neoplasms occurred in 
twenty-three. Two were osteosarcomas outside the field. 
Therefore twenty-one postradiation tumors were available 
for analysis. Sixteen were sarcomas and nine of these 
osteosarcomas. The incidence figures for second 
malignancies in patients surviving 5 or more years ranged 
from 2. 5 to 32% and appeared to depend on the dose of 
radiotherapy the patients had received. 
Sagerman noted that in other large series of radiation-
induced tumors the incidence had only been about 0.1% and 
he referred to reports by Castro and Phillips. These are 
actually both reports of postradiation sarcomas (15, 87), 
and do not include other postradiation malignancies. 
However Sagerman' s patients had an incidence of 6. 6% for 
sarcomas, so even if only sarcomas are considered the 
incidence in Sagerman' s series was higher than in other 
series. Sagerman suggested several factors to explain the 
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discrepancy. He pointed out that a high proportion of 
patients at his unit were cured of retinoblastoma and 
therefore at risk of a second tumor for many years. He also 
pointed out that generally higher doses of radiation were 
used in his patients than in most patients in other series 
and that patients in his series were young and therefore the 
effect of the radiation might be more pronounced. Sagerman 
did note that the two cases of osteosarcoma of the femur, 
one in a patient who had not been irradiated, raised the 
possibility of an increased susceptibility to neoplasia in 
retinoblastoma patients which was being investigated. 
No mention was made in the paper of whether Sagerman' s 
patients had a family history of retinoblastoma. 
An interesting aspect of Sagerman's work was that he found a 
significant reduction in the risk of developing a radiation 
tumor with lower doses. He noted a gradual decrease in 
the tumor dose which had been used to control retinoblastoma 
from about 14 OOOR before 1945 to 3 500 - 4 500R at the 
time of reporting. The risk of damage to irradiated bone 
decreased by a factor of approximately 2 when mega voltage 
equipment was introduced, and the incidence of all tumors 
and of osteosarcoma alone appeared to be significantly 
decreased. It was not possible to determine what the true 
incidence of radiation-induced tumors would eventually be in 
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Sagerman's patients with the schedule in use at the time of 
reporting as of course new cases were expected to develop. 
10 years after Sagerman's report, Tountas from the Princess 
Margaret Hospital used the results in a further analysis 
(114). Tountas calculated the absorbed bone dose in rad in 
the cases of PRS of bone and compared this with the 
incidence of bone sarcomas produced, expressed as a 
percentage of 5-year survivors. He produced a graph (Graph 
2) with on the X-axis the log% incidence of radiation-
induced sarcomas among 5-year survivors and on the Y-axis 
the absorbed bone dose in rad which produced these sarcomas. 
It appears from the graph that Sagerman' s patients had a 
higher incidence of sarcoma with higher dose. Tountas 
included on the graph figures for PRS of bone in patients 
treated for cancer of the breast and cervix at his own 
institution and figures from the series of Castro and 
Phillips. These were the only series he could use, as in 
general techniques are not well reported for these patients. 
Tountas thus produced convincing evidence for an increased 
incidence of sarcoma with increasing dose. However he did 
not take into account the effect of duration of follow-up 
( 1) • 
GRAPH 2 
Graph showing the relationship of log% incidence of 
irradiation induced sarcomas (X-axis) amongst five year 
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It had already been recognised that there was a 15 to 20% 
incidence of second, non-ocular tumors, most commonly 
osteosarcoma in long bones, in patients with bilateral 
retinoblastoma. A mean latency of 13 years was reported 
from Columbia University. These tumors were reported to 
appear on average 10 years after the treatment of the 
original tumor and occured almost exclusively in patients 
with bilateral disease. Second primaries were rare in 
patients with unilateral disease (54, 9, 90). A review of 
over 2 000 cases of retinoblastoma indicated that survivors 
of bilateral disease are about 300 times more likely than 
the rest of the population to develop osteosarcoma of the 
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femur and over 10 0 0 times more likely to develop 
osteosarcoma of the skull (90). 
Patients with genetic retinoblastoma are at substantial 
risk of developing oseosarcoma and other tumors (28). 
Meadows reported 65% of the second tumors to have occurred 
within the irradiated field and 64% of these to be 
osteosarcomas (71). Other tumors including soft tissue 
sarcomas were much less common than osteosarcoma (71). 
The question arose whether the genetic predisposition did 
not account for all the so-called radiation-induced tumors 
in these patients as well as the tumors outside the field. 
Abramson (2) like Sagerman wrote from the Columbia-
Presbyterian Medical Centre in New York. He described 
twenty-two patients who survived and were followed up after 
bilateral enucleation alone for retinoblastoma. Three of 
the twenty-two developed second tumors and this was at a 
mean of 15 years after bilateral enucleation. The 
incidence of second tumors in patients who survived 
bilateral retinoblastoma treated without radiation was 14% 
which was noted to be comparable to figures reported for 
patients treated with enucleation and radiotherapy. 
Because of the long latent period involved, Abramsom 
estimated that the incidence of second neoplasms would 
probably be between 15 and 20% in patients with bilateral 
retinoblastoma who survived treatment. The role of 
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radiation in inducing any of the tumors was not certain 
( 2) • 
Draper from Oxford University (28) reported a series of 882 
retinoblastoma patients in 198 6. 384 had genetic disease 
and 4 98 sporadic. Thirty developed second malignancies. 
The incidence was 2% at 12 years and 4.2% a~ 18 years. 
Most of the second tumors (26/30) occurred among patients 
with the genetic type of disease. For patients with 
genetic disease t~~ cumulative incidence rate after 18 
years was 8.4% for all second neoplasms and 6% for 
osteosarcoma alone. 
For patients with genetic disease the cumulative incidence 
of all second neoplasms within the radiation field after 18 
years was 6. 6% and for osteosarcoma alone 3. 7%. 46% of 
second primaries among the cases of genetic retinoblastoma 
developed outside the radiation field. Nine of twelve were 
osteosarcomas, two soft tissue sarcomas and one an 
epithelial tumor. The estimated cumulative incidence rate 
of second malignancies outside the field for genetic cases 
18 years after the diagnosis of retinoblastoma was 3%, all 
the second tumors observed within this time period being 
osteosarcomas. The estimate of risk for patients with the 
genetic form of retinoblastoma developing osteosarcoma, 
excluding any risk from treatment, was about 200 times that 
for the general population. 
152 
Osteosarcomas of the orbit are rare and probably less than 
10% of all osteosarcomas usually occur at any site in the 
skull and jaw bones in this age-group. It would be 
expected that less than one person in 100 000 would develop 
such a tumor in the first 20 years of life. The observed 
rate in this study was of the order of 4 000 times as great 
as this. 
Among the 498 patients with non-genetic retinoblastoma only 
four second primaries were recorded. The incidence rate 
for second malignancies outside the field at 18 years was 
therefore 0.4% or 0% (as the one patient in this category 
may have actually had the genetic form of the disease). 
The corresponding rate for the genetic cases as we have 
seen was 3%. For tumors inside the field the contrast 
between the rates for genetic and non-genetic disease was 
also striking. Among 100 patients with non-genetic disease 
only one developed a tumor in the field. This was a 
meningioma of the brain at 31 yrs. The corresponding 
estimated rates for the patients with genetic disease were 
3.4% at 12 and 6.6% at 18 years. 
Draper's results suggested that patients with genetic 
retinoblastoma may be more susceptible to the induction of 
second tumors by radiation and, as has been discussed in 
section 4.3.10, that Cyclophosphamide may be implicated in 
the induction of second primary cancers in these patients 
( 2 8) • 
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It is difficult to test the hypothesis that patients with 
the genetic form of retinoblastoma may have an increased 
susceptibility to the induction of second tumors by 
radiation since other individuals exposed to radiation 
differ from retinoblastoma patients in respect of the doses 
received, the area irradiated and the type of tissue 
exposed. The most direct test of the hypothesis is to 
compare patients with the genetic and non-genetic forms of 
retinoblastoma treated by irradiation. In Draper's series 
the rate of second tumors among the eyes of patients with 
the genetic form is greater than the rate among the eyes of 
patients with the non-genetic form of the disease. (28) 
Abramson (1) used actuarial methods of analysis and 
calculated the incidence of second tumors in patients with 
genetic retinoblastoma to be 20% after 10 and 90% after 30 
years survival. In patients treated without radiation or 
where tumors developed outside the field the incidence was 
10% at 10 years and 68% at 32 years. 
A further study providing evidence for the genetic origin 
of second malignancies, and particularly sarcomas, in 
retinoblastoma patients was reported by Meadows et al of 
the Late Effects Study Group (70) . 292 patients had had 
cancer in childhood and developed second malignancies. 
(Altogether there were 308 second malignant neoplasms.) 
The most common primary was retinoblastoma (52 patients), 
followed by Hodgkin's disease, soft tissue sarcoma and 
Wilms' tumor. 68% of second malignancies in retinoblastoma 
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patients were bone or soft tissue sarcomas. 67% of these 
sarcomas arose in an irradiated site and 33% were not 
associated with radiation (70). 
Smith (106) from the Stanford University Medical Centre 
reported the actuarial incidence of second non-ocular 
malignancies among patients with heritable retinoblastoma 
to be 6% at 10 years, 19% at 20 years and 38% at 30 years. 
The latent period from treatment of retinoblastoma to the 
diagnosis of second malignancy ranged from 5 to 36 years 
with a median of 16 years. 
The cumulative risk in Smith's study lies between that 
reported by Abramson in 1984 of 20, 50 and 90% and the risk 
reported by Draper of 4.3% at 12 years and 8.4% at 18 years 
(1, 28, 106). 











retinoblastoma as more second malignancies developed within 
than outside the irradiated field. 
4.4.2. GENETIC ALTERATIONS AND THEIR EFFECTS IN 
RETINOBLASTOMA PATIENTS 
Retinoblastoma appears to occur because of two separate 
mutations in all the tumor cells. It has been proposed 
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that in sporadic cases both mutations occur in the same 
retinal precursor cell during in utero life or early 
childhood. In the absence of a functioning ret inoblastoma 
(Rb) gene a tumor develops. In the inherited form it is 
proposed that one of the mutations is inherited and is 
therefore present in all the cells. 
spontaneously (38). 
The second occurs 
The retinoblastoma gene was located on the short arm of 
chromosome 13 in the early 1980's and has been cloned and 
sequenced. It appears to be associated with several other 
human cancers such as osteosarcoma, small cell lung cancer 
and breast cancer, but other changes in addition to the 
loss of the Rb gene are necessary for these tumors to 
develop. The Rb gene therefore may have a role in growth 
suppression in various tissues (38). 
In the sporadic form of retinoblastoma there may be two 
independent mutations in the two alleles, but actually 
homozygosi ty is more likely. In this process a single 
deletion occurs in one chromosome and the second is lost 
completely. The chromosome with the deletion replicates so 
the cell has both alleles from one parent with the piece 
containing the suppressor gene missing. (38) 
The observation that children with hereditary 
retinoblastoma frequently develop second malignancies, 
principally sarcomas, 
gene deletions in 
led to the detection of similar Rb 
some osteosarcomas. Reissman ( 91) 
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studied forty-four unselected sarcomas from patients with 
no antecedent retinoblastoma to determine the prevalence 
and nature of Rb gene alterations. In total eight of 
thirty-eight sarcomas were found to have alterations of the 
Rb gene. These data indicate that the Rb gene is 
inactivated in a number of sarcomas unrelated to 
retinoblastoma, and that the potential role of the gene in 
the pathogenesis of human malignancy may not be limited to 
retinoblastoma. 
Draper's data suggested that the mutation predisposing 
patients so predictably to retinoblastoma might predispose 
patients in a less predictable manner to osteosarcoma and 
that the development of osteosarcoma was influenced further 
by environmental factors such as radiotherapy ( 111) . The 
frequent onset of osteosarcoma during adolescence, with a 
latent period of 10 to 20 years after radiotherapy, and the 
much-reduced penetrance for osteosarcoma, suggested that 
additional events might be necessary for tumor development 
( 111) . Current molecular genetic data on sporadic 
osteosarcoma suggest the development may be considered a 
"two-hit" phenomenon, requiring mutations at both allelles 
of the Rb locus and at the tumor suppressor p53 gene locus 
(41). Inheritance of a mutation at Rb predisposes a person 
to osteosarcoma, but several additional mutational events 
must occur. The same genetic loci, Rb and p53, appear to 
be mutated in the more common sporadic osteosarcoma. 
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Strong (111) notes in a review that the Rb gene is involved 
in the development of many different tumor types, but for 
most tumor types it is only one of several genetic 
alterations necessary for tumor development. Therefore, 
although germline mutations in this gene predictably give 
rise to heritable retinoblastoma, they less predictably 
increase the risk of at least some of these other tumors. 
In conclusion, patients with heritable retinoblastoma have 
a genetic predispostion to second malignancies, 
particularly sarcomas. They appear to be particularly 
susceptible to the carcinogenic effects of radiotherapy, 
but a dose-response relationship has not been definitely 
proved. 
The three retinoblastoma patients in the Groote Schuur 
series of patients with PRS all had bilateral disease and 
had received chemotherapy. Two had received 
Cyclophosphamide. The latency in the three cases was 
relatively short at 3 years 7 months, 4 years 7 months and 
4 years 10 months. Schwarz (98) reported an average 
sarcomas following radiotherapy 
Therefore the role of 
development of these tumors must be 
years. 
latency for head and neck 
for retinoblastoma of 10 
radiotherapy in the 
more in doubt than in other cases of PRS with longer 
latency periods. The latent period was significantly 
shorter than the period for non-retinoblastoma patients. 
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4.5. PATHOLOGY OF POSTRADIATION SARCOMAS 
4.5.1. HISTOLOGICAL TYPES OF POSTRADIATION SARCOMA 
Osteosarcoma has probably been the most commonly reported 
P RS ( 9 4 , 4 7 , 115 , 1 0 0 , 112 , 4 2 , 7 9, 114 , 121 , 14 , 21 , 2 7 , 
36, 65, 101). 
unusual with 
The Groote Schuur study is therefore not 
eight (40%) cases of osteosarcoma. 
Extraskeletal osteosarcomas have also been reported ( 4 7, 
122, 59) but all our cases included involvement of bone. 
In a report published in 1945 Hatcher (45) reviewed the 
world literature on PRS of bone and found nine of twenty-
four to be chondrosarcomas. However Fitzwater (32) noted 
in 197 6 that only 9% of reported cases since 194 8 were 
chondrosarcoma and of the remainder 62% were osteosarcoma, 





several of the 
classifiable. 
osteosarcomas 
included chondroid elements as a prominent feature. Even 
allowing for differences in classification Fitzwater noted 
that chondrosarcoma is a relatively infrequent type of PRS 
of bone. 
Fibrosarcoma has also been relatively frequently reported 
(47, 75, 115, 42, 36). Some early studies reported a high 
percentage of fibrosarcomas and extraskeletal 
osteosarcomas, probably 
criteria and nomenclature 
was a fibrosarcoma. 
reflecting earlier diagnostic 
(59). Only one case in our study 
This occurred in ~oft tissue. 
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Nomenclature of sarcomas has changed periodically (57, 59). 
For example cases earlier diagnosed as fibrosarcoma would 
later have been classified as malignant fibrous 
histiocytomas (57, 113). In a recent report of PRS from 
the Finnish Cancer Registry there were ten osteosarcomas, 
ten malignant fibrous histiocytomas and six fibrosarcomas 
(122). Malignant fibrous histiocytoma was the most common 
tumor ( 68%) in a review of fifty-three postradiation soft 
tissue sarcomas submitted to the Armed Forces Institute of 
Pathology from 1954 to 1986 (59). 
A literature review reveals a host of sarcoma types to have 
occurred in radiation fields. These include 
rhabdomyosarcoma (47), 
spindle cell sarcoma 
malignant mesenchymoma (115, 47), 
(65, 67, 112, 15, 27), angiosarcoma 
(67, 58, 117, 
122, 59), 
122, 26, 59), malignant schwannoma 
chondrosarcoma (104, 114, 15, 
(67, 112, 
27, 65), 
extraskeletal chondrosarcoma (59), undifferentiated sarcoma 
(100, 122, 114, 58), osteochondrosarcoma 
leiomyosarcoma (122), pleomorphic sarcoma (4), 
(113, 14), 
meningeal 
fibrosarcoma ( 3 4) , cutaneous 
hemangiosarcoma ( 64, 96) , malignant 




( 81) , 
( 65) , 
soft 
part sarcoma (following radiotherapy for a spinal 
hemangioma) (120), lymphangiosarcoma (25), sarcoma not 
otherwise specified ( 25) , gastric leiomyosarcoma ( 62, 12 0) 
and cutaneous sarcoma (101). The tumors in our series were 
not of particularly unusual histological type for tumors 
occurring in radiation fields. 
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It is not possible to determine from histological 
examination whether a sarcoma occurring in a radiation 
field has been induced by radiation or not (5, 35, 36, 59) 
although the proportion of different types may differ from 
that found among spontaneously occurring tumors (122) and 
there may be some variation in morphology (5, 59). 
4.5.2. HISTOLOGICAL CHANGES IN IRRADIATED TISSUE AND 
HISTOGENESIS OF POSTRADIATION SARCOMAS 
There may be evidence of radiation damage in soft tissue or 
bone adjacent to a tumor occurring in a radiation field (5, 
59, 96, 36) and this may be used to confirm the origin of 
the sarcoma within the field if radiation details are 
lacking (59). The field may however be completely effaced 
by the sarcoma (59). 
The location and extent of radiation cha_ es in adjacent 
tissue have been noted to depend on the radiation source 
and the latency period (96). 
PRS may simply represent one end of a spectrum of changes 
wh~-~ may occur in a radiation field. Pettit noted in 1954 
( 8 6) that fibromatosis following radiation was more 
frequent than fibrosarcoma and that the two entities had 
often been confused. He stated that irradiation 
fibromatosis may blend into fibrosarcoma, which is usually 
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a low-grade lesion and is peculiar in that it kills by 
local infiltration rather than by distant metastases. 
In 1986 Gossner (36) reviewed data on the pathology of 
radiation-induced bone tumors. Fibre-osseous lesions may 
represent early or transitional stages between the 
radiation reaction and radiation sarcoma. As well as 
hyperplastic processes the lesions can show different 
degrees of osteodysplasia. Intraosseous osteosarcomas (the 
earliest malignant lesions) were found less frequently than 
overt osteosarcomas, indicating rapid progression of 
osteosarcoma. 
In our series case 6 is of interest in that thickening in 
the irradiated area was noted more than 3 years before the 
patient presented with a mass. She was diagnosed as having 
a leiomyosarcoma of the abdominal wall. Biopsy of the 
postradiation tumor in case 20 revealed osteosarcoma in 
fibrous dysplasia and also fibrosis without fibrous 
dysplasia. The fibrous dysplasia may have been a 
premalignant event in this patient. 
4.5.3. GRADE OF POSTRADIATION SARCOMAS 
Many postradiation tumors are described as poorly 
differentiated or high grade (59, 94). Only four (5%) 
tumors in the Groote schuur study were of moderate grade 
and the rest were high grade. 
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4.5.4. GIANT CELL TUMOR AND POSTRADIATION SARCOMA 
Sarcoma complicates the course of 10% of giant cell tumors, 
particularly if radiation has been used in treatment. 
Malignant change usually occurs 10 to 15 years after 
primary treatment but has been known to occur after 40 
years. (22) 
In Cahan' s report in 1948 (16), in two cases giant cell 
tumor had been the initial diagnosis. In one the sarcoma 
was seen adjacent to a fibrosed area, presumably old giant-
cell tumor. In the other the osteogenic sarcoma merged 
with residual giant-cell tumor but was still a distinct new 
entity. 
In the Mayo clinic series (22) twenty-three of twenty-eight 
malignancies in giant cell tumors occurred after treatment 
of typical giant cell tumors. In twenty-one the treatment 
of the benign giant cell tumor had included radiotherapy. 
The average interval from treatment to the appearance of 
sarcoma was 13. 5 years. In only one case was residual 
giant cell tumor present when the sarcoma was diagnosed. 
In two cases sarcoma developed without previous 
radiotherapy - one 1. 5 years after curettage and one 15 
years after second curettage. Overall in seven cases no 
radiation had been used and in five both giant cell tumor 
and sarcoma were present at the time of the first 
operation. In this series seventeen of the secondary 
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tumors were fibrosarcomas, five osteosarcomas and one a 
malignant fibrous histiocytoma. 
Histologically one cannot determine the precise site of 
origin of the sarcoma, that is, whether it arises within a 
pre-existing lesion or in the surrounding normal bone 
(104). In a report from the Mayo Clinic in 1971 Sim (104) 
accepted long latency as evidence of benignness and the 
indolent course of the initial lesion. Four of eight 
verified initial benign lesions in his series of thirty-
four PRS of bone were giant cell tumors. There is no doubt 
that spontaneous malignant transfromation can occur, but 
there is evidence to support the importance of previous 




from the University of Bologna reported that 
who received more than 40Gy for giant cell 
incidence of malignancy was 29%. No 
malignancies developed in patients who received less than 
30Gy. 
Mirra (76) reported that three forms of radiation-induced 
sarcomas in the site of a previously irradiated 
conventional giant cell tumor may be identified 
histologically. These are 





induced anaplastic transformation of host bone mesenchyme, 
and osteoclastic sarcoma, which is related to radiation 
induced anaplastic transformation of residual· conventional 
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giant cell tumor. In the Groote Schuur series two PRS 
developed in the site of irradiated giant cell tumors. In 
neither case was the initial diagnosis of giant cell tumor 
absolutely certain as one (case 18) was diagnosed 
radiologically, and in the other a diagnosis of possible 
aneurysmal bone cyst was made initially. Case 18 developed 
an osteogenic sarcoma. In case 17 a more specific 
diagnosis than sarcoma could not be made on review. Both 
patients had received a total of more than 40Gy. In the 
patient treated with a 220kV beam (case 18) the total 
prescribed dose was 5 OOOR, but the Roentgens to rad 
conversion factor of 1.5 for the 220kV beam in bone 
indicates that the dose in bone was actually 75Gy. 
4.5.5. PELVIC SARCOMA AFTER RADIOTHERAPY FOR LOW-GRADE 
ENDOMETRIAL STROMAL SARCOMA 
In 198 9 Chumas et al ( 1 7) reported a case of high-grade 
heterologous pelvic sarcoma in a 60-year-old woman 15 years 
after she received whole-pelvic radiation for a low-grade 
endometrial stromal sarcoma. Approximately 50% of patients 
with low grade stromal sarcoma will develop recurrence 
although it is a relatively indolent sarcoma. 
Smith (107) noted that late recurrence and spread are the 
rule in endolymphatic stromal myosis (another term for low 
grade stromal sarcoma) (56) with survival at 10 years being 
close to 100%, often after multiple excisions, but a death 
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rate of 20% at 20 years (107) . Smith reports a case of 
frank sarcoma developing from endolymphatic stromal myosis. 
He notes that this is an unusal occurrence. In the Groote 
Schuur series one patient (case 7) with PRS developed a 
sarcoma of the pelvis 30 years after radiotherapy and 
surgery for a low grade stromal sarcoma of the uterus. 
Initial histology of the recurrence was undifferentiated 
sarcoma. Subsequent resection almost 2 years later 
revealed a moderate grade fibrosarcoma. We have therefore 
considered this to be a separate tumor of different 
histology rather than a progression of the low grade 
stromal sarcoma, although the possibility of the latter 
diagnosis must be borne in mind. 
4.5.6. MALIGNANT MIXED MULLERIAN TUMOR AFTER PELVIC 
RADIOTHERAPY 
MMMT's have generally been classified with the sarcomas in 
publications concerning uterine neoplasms (19) and have 
been included in studies of PRS ( 17, 72) . Therefore in 
this dissertation they have been included under the general 
heading of postradiation sarcomas. However it must be 
noted that in discussions of poorly differentiated ovarian 
tumors MMMT's are grouped with carcinomas and it has 
recently been suggested that MMMT's probably represent 
"metaplastic" (sarcomatoid) carcinomas rather than true 
carcinosarcomas (19). 
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In a report of thirty cases of uterine corpus malignancies 
after pelvic radiotherapy from the Ohio State University 
Hospitals (72), five sarcomas were noted. These were mixed 
mesodermal sarcomas and four were stage 3 or 4 at 
diagnosis. Four occurred in patients initially treated for 
malignancy while most of the adenocarcinomas occurred in 
patients initially treated with radiotherapy for benign 
conditions. Most of the patients with adenocarcinomas had 
stage 1 disease. 
In the Groote Schuur series four out of six patients who 
developed PRS after radiotherapy for carcinoma of the 
cervix developed MMMT. The four cases were all advanced at 
presentation, one having omental metastases (case 1) and 
one being irresectable with possible metastases (case 4). 
All the tumors were high grade. In case 2 the tumor 
infiltrated into the outer third of the myometrium and in 
case 3 almost to the serosa. Three patients died within a 
year of surgery and one has been lost to follow-up. 
In conclusion, the Groote Schuur series does not appear to 
differ markedly from other reported series with respect to 
histological types of PRS, grade or extent of tumor at 
presentation. 
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4.6. CLINICAL CHARACTERISTICS OF POSTRADIATION SARCOMA 
Clinical characteristics of patients in some series 
reported in the English literature are summarised on Table 
3. 
4.6.1. PRIMARY TUMOR 
Some authors have included all PRS in their reports ( 94), 
as has been done in our study. In others the report has 
been limited to PRS after a specific primary tumor such as 
breast cancer (27, 58, 113) or uterine cancer (96). In 
these and other reports a certain tissue (bone or soft 
tissue) may have been specified. In Wiklund's report (122), 
for example, visceral sarcomas were excluded. These 
specifications affect the apparent incidence of certain 
primary tumors preceding PRS. Sundaresan (112) chose 
spinal involvement as the common denominator in his series. 
Up to 30% of PRS arise in or around the axial skeleton. 
Common primary tumors after which PRS have occurred can be 
seen on Table 3. In Wiklund' s report from the Finnish 
Cancer Registry (122) most of the first primary tumors were 
of breast and female genital origin. According to Wiklund 
this agreed with previous reports and was probably a 
reflection of the frequency of these tumors, the use of 
radiotherapy in treatment and the long survival of many of 
the patients. These factors also explained the 
predominance of females in the series (122). Robinson et 
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al (93) noted that in a review of sarcomas in the SEER 
(Surveillance, Epidemiology and End Results) Program of the 
United States National Cancer Institute there was a higher 
proportion of females in the PRS group than in the group 
with sarcomas as a single primary, as more females receive 
radiotherapy for their first primary tumors, probably 
reflecting a large fraction of breast and gynaecological 
tumors. 
In his extensive literature review of PRS Robinson (94) 
noted that the sarcoma site depended on the location of the 
first primary and the treatment portals. The most common 
first primary was breast cancer (30.8%) and the second most 
common cancer arising in the female genital organs (22%). 
The third most common was retinoblastoma (19.5%) with 76% 
of retinoblastoma patients having bilateral retinoblastoma. 
The multiple other sites included the head and neck, 
thyroid, spine, abdomen and limbs. 
Gessner (36) noted in a review on the pathology of PRS of 
bone that when these had been reported after radiotherapy 
for extraskeletal tumors they most commonly followed 
for retinoblastoma. After treatment 
carcinomas of the breast or uterus were 
primary conditions. 
retinoblastoma, 
the most common 
Wiklund (122) explained the comparative rarity of lymphomas 
in his report as probably reflecting the poor prognosis of 
lymphomas during the first decades of the study period. 
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However this study included patients whose first primary 
was diagnosed after January 1, 1953 and in two reports 
which included patients from earlier years Hodgkin's 
disease was a common primary (59, 49). A previous poor 
prognosis of lymphomas therefore may not account for the 
disparity in the frequency of this primary in different 
reports but comment is difficult due to the rarity of PRS 
overall and problems in obtaining true incidence figures. 
If the incidence of PRS is dose-related this would also 
affect the relative incidence of primaries such as 
Hodgkin's disease. 
Reports of the site and type of the primary tumor become 
very important when radiotherapy is not the only treatment 
option available. An example is early stage breast cancer, 
a condition in which the trend is to treat greater numbers 
of relatively young women with potentially curable cancers 
with conservation treatment including radiotherapy (25). 
Turner et al ( 11 7) from the John Radcliffe Hospital in 
Oxford reported two cases of sarcoma complicating breast 
conservation radiotherapy. These authors were not aware of 
sarcoma having previously been reported as a complication 
of radiotherapy in breast conservation. However reports of 
this complication had previously appeared (57, 109). This 
complication must be considered in patients developing 
abnormalities within the radiation fields after breast 
conservation treatment. The sarcoma tends to occur after a 
longer period than is generally the case for local 
recurrence ( 11 7) . In the Groote Schuur patients the only 
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PRS after breast conservation treatment (Case 8) apP,ears to 
have developed below the breast rather than in irradiated 
breast tissue. The latency of less than 2 years is not in 
accordance with Cahan's criteria (14) and would have 
excluded this patient from many studies of PRS. 
The most common primary in our series was carcinoma of the 
cervix followed by carcinoma of the breast. Three patients 
in our series were retinoblastoma patients. They all had 
bilateral disease. We are not aware of any PRS in patients 
treated with lymphoma at Groote Schuur since 1964. 
Therefore it appears that overall tumors of the female 
genital tract and breast may relatively frequently precede 
PRS. Retinoblastoma is another common primary. Some 
authors report lymphoma as a relatively common primary. 
4.6.2. PRESENTATION AND DIAGNOSIS OF POSTRADIATION SARCOMAS 
In the Groote Schuur series sixteen patients presented with 
clinical features of swelling or a mass. In five pain was 
also a presenting symptom. Three patients presented with 
x-ray changes and one with a pathological fracture. In 
other studies swelling or a mass has also been the most 
common symptom (109, 122, 96, 49). Pain is a common 
symptom (122, 49). In Sundaresan's series of thirteen PRS 
involving the spine all the patients complained of pain and 
in four a mass was present (112). 
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In Huvos' series (49) of osteogenic sarcomas, lesions which 
were predominantly sclerotic, mostly lytic, and mixed were 
equally represented radiologically among bone sarcomas. 
Permeative osseous changes were rarely seen on x-rays. 
Sundaresan ( 112) noted that in PRS involving the spine 
plain radiographic findings included nonspecific lytic 
destruction of the spine with little reactive sclerosis. 
The distinction between a radiation osteitis or malignancy 
could not be made. Calcification was noted in one patient 
with a paraspinal soft tissue mass. CT scan was the most 
useful test and often revealed extensive soft tissue tumor 
as well as osseous destruction of the spine. 
Mindell (75) noted that PRS should be suspected whenever a 
patient who has previously received radiotherapy presents 
with increasing pain or swelling in the irradiated area. 
On examination oedema, tenderness and a palpable mass may 
be evident. The skin in the irradiated area may show 
changes due to the previous irradiation and often the 
differential diagnosis may rest between radiation osteitis 
and PRS. Increasing pain, the clinical presence of a mass 
and a radiographic mass may suggest the presence of 
sarcoma. 
Many of the tumors in the Groote Schuur study were advanced 
at presentation. Robinson et al (94) noted in a literature 
review that PRS are generally of advanced stage at 
diagnosis. These authors noted that PRS tend to be 
diagnosed in a more advanced stage than other sarcomas. 
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Possible explanations put forward are that the second tumor 
may be more aggressive leading to a more advanced stage at 
diagnosis, and that there may be a delay in the diagnosis 
of a PRS (94). 
Wiklund (122) noted that in his series in many cases there 
was delay from the date of first discovery of a second 
primary to the date of the final histological diagnosis or 
start of treatment (median O. 2 years but in 8 the delay 
exceeded 1 year) . In some cases the tumor was at first 
regarded as benign clinically or histologically and in some 
as a recurrence of the first primary. In many cases the 
therapy was adversely affected by an incorrect original 
diagnosis and this may have had an impact on treatment 
outcome. Souba (109) also noted that delay in diagnosis 
may be caused by the attending doctor. These tumors are 
grossly often difficult to differentiate from radiation 
changes. Biopsy in an irradiated field carries the risk of 
poor healing (109). O'Neill (79) pointed out that time is 
lost while the patient undergoes further radiotherapy to 
control a PRS misdiagnosed as a local recurrence and that 
biopsy may further delay initiation of treatment as 
radiation-induced changes may lead to an erroneous 
diagnosis of radiation-induced fibrosis. 
Cahan (14) stated that when a patient had pain with or 
without swelling in an area previouly irradiated for a 
benign bone lesion 5 or more years previously, suspicion of 
malignant change should be aroused. X-rays and biopsy 
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should be immediately performed, the latter preferably by 
aspiration to avoid incision of irradiated tissues. 
A high index of suspicion is necessary to pursue the 
finding of a new swelling or pain that develops in an 
irradiated field at least 5 years after radiation 
treatment. It has been recommended that any new pain or 
swelling that occurs in an irradiated field 5 years after 
radiation should be promptly evaluated (109). As there is 
a risk of second malignancies before 5 years, and in any 
case differentiation must be made as to whether the lesion 
is benign or malignant and appropriate treatment 
instituted, the specification as to 5 years seems unwise. 
For clinically suspicious lesions repeat biopsy is 
necessary despite a benign pathological diagnosis. In some 
patients multiple recurrent excisions have been necessary 
to make the diagnosis (79). 
4.6.3. TREATMENT OF POSTRADIATION SARCOMAS 
4.6.3.1) Surgery 
Several authors have stressed the importance of early 
diagnosis in PRS (113, 112, 79). Sundaresan ( 112) noted 
that prompt recognition and early surgery for postradiation 
bone sarcomas are important because these tumors grow 
quickly and respond poorly to conventional radiation and 
chemotherapy. In a report of soft tissue ·postradiation 
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fibrosarcomas of the chest wall, O'Neil noted that adequate 
palliation and potential cure depend on awareness of these 
lesions, early diagnosis, persistent repeat biopsies in 
suspicious cases, early aggressive radical excision without 
fear of the resultant defect and adequate reconstruction 
( 7 9) • 
Surgery, when feasible, is the basis of treatment (109, 75, 
58, 79). In fact in cases of fibrous proliferation 
following postmastectomay radiotherapy, aggressive surgical 
resection may have to be considered even if the microscopic 
appearance of the biopsied tissue does not appear malignant 
( 3 4) • 
In a review of 344 cases of PRS in the English literature 
(94) Robinson et al noted that only 46% were reported to be 
operable. It appeared that in 28% the disease was too 
advanced for surgery to be used. In 27% no information 
regarding treatment was available. Most of the tumors were 
located in areas where radical surgery could not be 
performed. Other authors have also found that the extent 
of surgery may be limited by the site of the tumor and the 
proximity of vital structures (109, 104, 75). 
In the Groote Schuur series ten (50%) of patients underwent 
surgery as initial treatment but in only three could it be 
described as radical. A further patient underwent 
maxillectomy after radiotherapy and chemotherapy. 
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It appears that surgery is employed whenever possible in 
the treatment of postradiation sarcomas but frequently the 
disease is too advanced for radical resection to be 
possible. 
4.6.3.2) Radiotherapy 
Both radiotherapy and chemotherapy have been used as 
adjuncts to surgery in the treatment of PRS. 
In a case of prostatic PRS isolated pelvic perfusion with 
Cisplatin and pelvic exenteration was used (99). Outcome 
is not reported, presumably because it was too early for 
this to be relevant. 
Several patients 
Cancer Registry 






treatment of PRS although many tumors were in previously 
heavily irradiated tissues. In general this appears to 
have been postoperative radiotherapy and presumably that is 
the reason reponse is not mentioned. One of these patients 
later developed severe chronic radiation sequelae leading 
to death (122) . 
In a series of PRS involving the spine, brachytherapy was 
used after resection as most patients had already received 
radiation dosages approaching spinal cord tolerance. The 
three patients who survived more than 2 years had all 
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undergone extensive resection as well as brachytherapy. 
None were cured and completely disease-free. Five of six 
who underwent extensive resecton and brachytherapy were 
thought to have adequate local control but eventually 
distant metastases were noted {112). 
The role of radiotherapy in the treatment of PRS is limited, 
as apart from the problem of exceeding tissue tolerance in 
related structures it has been noted that PRS of bone 
responds poorly to conventional radiation and chemotherapy 
(112). 
In the Groote Schuur series radiotherapy was used in six 
patients. Data on reponse were available in four cases. 
One progressed in spite of palliative radiotherapy (case 3), 
one responded initially to treatment but was noted to have 
progressed at 3 months ( case 9) and in one there was a 
response to a combination of chemotherapy and radiotherapy 
(case 11). In the fourth patient (case 7) there was 
virtually no response to two courses of neutron 
radiotherapy. 
Thus radiotherapy is used in the treatment of PRS, in spite 
of previous irradiation to the tissues, but no promising 
results have been noted. 
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4.6.3.3) Chemotherapy 
Several other authors have noted that results using 
Poor results chemotherapy are poor (49, 






attributed to the 
fibrotic changes due to previous radiotherapy resulting in 
an inadequate blood supply for the chemotherapy to produce 
significant concentrations in the target organ (58). 
Robinson (94) recommended that more aggressive and 
investigative chemotherapy regimens are warranted because 
of the poor prognosis of PRS. 
Souba 
might 
suggested =hat more 
be more effective. 
modern chemotherapy regimens 
In patients with primary 
sarcomas, preoperative chemotherapy has been helpful in 
determining which 
adjuvant therapy 
patients will benefit from continued 
as well as allowing good disease-free 
survival. However chemotherapy cannot take the place of 
good surgery with wide resection (109). 
In the Groote Schuur series nine patients with PRS received 
chemotherapy. One patients was treated for a presumed 
breast recurrence and the disease progressed (case 9). In 
case 11, as has been mentioned, there was a repsonse to a 
combination of chemotherapy and radiotherapy. In case 13 
there was an initial response but subsequent progression of 
disease. In cases 3, 14 and 17 there was either no 
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response or deterioration. Cases 4 and 15 did not receive 
more than one cycle. In case 20 the response is unknown. 
Thus, as in the case of radiotherapy, chemotherapy is used 
in the treament of PRS, but results have been 
disappointing. 
4.6.4. PROGNOSIS OF POSTRADIATION SARCOMAS 
4.6.4.1) Comparison of Prognosis of Postradiation and 
Spontaneously-occurring Sarcomas 
It is controversial whether the prognosis of postradiation 
sarcomas is poorer than that of spontaneously-appearing 
lesions. 
Some authors, including Robinson (94) and Laskin (59) (who 
analysed fifty-three cases of soft tissue PRS and reported 
a 32% 2-year survival), state that the prognosis of PRS is 
worse than that of primary sarcomas. Robinson noted that 
this applied to primary sarcomas of similar stage to the 
PRS. (94, 59, 75) 
Meredith (72) noted that survival in irradiation-induced 
MMMT is poorer than that reported for the same tumors not 
necessarily occurring post radiation. However in 
Meredith's series the patients with radiation-induced 
tumors tended to present with late stage disease and 
received less aggressive therapy. 
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Others have not found there to be a worse prognosis for a 
sarcoma which develops in a radiation field. 
In a University of Minnesota study comparing uterine 
sarcomas developing in previously irradiated women with 
those among unirradiated controls, a significant difference 
in survival was not shown (119). However the patients who 
had been previously irradiated presented at a younger age 
with symptoms of more advanced disease. 
Arlen (5) reported a relatively good disease-free survival 
rate in that nine out of twenty-eight (32%) of the patients 
in his series of PRS of bone were alive and disease-free 
over 5 years. He assessed the results as being 
"surprisingly good considering the poor overall survival 
rate for osteogenic sarcoma". All the patients in whom the 
PRS was apparently cured had developed these tumors in the 
long bones. Among four patients with sarcomas of the head 
and neck region only one survived. Arlen reported a more 
favourable prognosis for postradiation osteosarcomas than 
for the spontaneously appearing lesions (5). 
Wiklund, in his series of PRS from the Finnish Cancer 
Registry ( 122) , reported overall 2- and 5-year survival 
rates of 45 and 29%. Wiklund noted that in his study the 
prognosis was "fairly good" in the radically treated group 
and also that four patients achieved long-term remission 
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and perhaps cure after salvage therapy for, local 
recurrence. 
In 1992 Robinson reported a population-based study 
comparing the clinical characteristics of second primary 
and single primary sarcomas and noted there was no 
difference in survival time between the PRS group and the 
non-PRS group (single primary and second primary in non-
radiation-exposed area) overall nor for any stage (93). 
Thus there is not agreement as to whether postradiation 
sarcomas have a poorer outlook than sarcomas arising in 
unirradiated tissue. 
4.6.4.2) Assessment of potential prognostic factors 
Various factors have been analysed to determine whether 
they affect the prognosis of PRS. In two studies there were 
reported to be no significant survival differences between 
males and females (109, 49). 
It is controversial whether the outcome is affected by the 
site of the saroma (68, 121). It has been reported that 
central lesions have a worse prognosis than those of the 
extremities (121). 
Robinson found that for PRS occurring after orthovol tage 
treatment the mean survival was 19.98 months, after 
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external beam treatment combined with brachytherapy it was 
17.34 months, after supervoltage 10.13 months and after 
brachytherapy 11. 2 8 months ( 94) . According to his review 
patients with fibrosarcoma, angiosarcoma and carcinosarcoma 
had a better survival than those with osteosarcoma or 
chondrosarcoma. Patients with lymphangiosarcoma had a 
better survival than those in the other histologic groups 
( 94) . 
Overall there is inadequate data to assess the impact of 
these factors on the prognosis of PRS. 
4.6.4.3) Poor Prognosis of Postradiation Sarcomas and 
Reasons for Poor Prognosis 
The poor prognosis of PRS has been confirmed by many 
reports (25, 94, 104, 114,59). Meredith (72) reported that 
four out of five patients with postradiation MMMT in her 
study died within 7 months. 
In Robinson's extensive literature review (94) the median 
survival of the 266 PRS patients for whom survival 
information was available was 12 months, with a 2-year 
survival of 22% and a 5-year survival of 11%. 73.5% of 
patients died of disease and 12.8% were alive at the time 
of reporting. In 9. 6% follow-up data were not available. 
4.1% were alive with disease at the time of reporting. 
Death was almost always due to recurrent or metastatic 
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sarcoma. An indication of the poor survival generally 
reported can be obtained from Table 3. 
The dismal outlook for this condition has been attributed 
to a variety of factors, some of which have already been 
discussed. Factors may include delay in presentation, 
difficulty in diagnosis when a soft tissue sarcoma arises 
in an indurated irradiated field (25) and unfavourable site 
(trunk and limb girdle) (25). The anatomical site of the 
primary, such as in retinoblastoma or pelvic tumors, may 
make adequate radical surgery for the PRS impossible. 
According to Robinson's review however it seems that the 
prognosis of sarcomas in retinoblastoma patients is also 
poor for sarcomas outside the radiation field. Therefore 
the site cannot be the sole reason for the poor prognosis 
( 94) . Another adverse factor may be the preclusion of 
further radiotherapy in patients already treated to tissue 
tolerance (25). 
Delay in diagnosis because symptoms are considered related 
to the original disease or radiation necrosis may 
contribute to a poorer outlook for PRS as opposed to 
primary sarcomas (75). Tumors in areas with prior chronic 
irradiation changes may behave in a more malignant way due 
to local factors and therefore progress more rapidly, 
similarly to the manner in which chest wall recurrences of 
breast cancer in irradiated areas progress rapidly and are 
more resistant to therapy ( 94) . Lymphatic obstruction, 
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vascular compromise and fibrosis from radiation may shield 
potentially malignant cells from immune surveillance (33). 
The immunosuppressive effect of the initial tumor or 
chemotherapy (85, 59) as well as the aggressive nature of 
the tumor, grade (94, 109) and stage may all contribute to 
the poor prognosis. Where data were available in Robinson's 
review (94) (which was not often) many tumors were noted to 
be high grade. In Scuba's study of PRS of the chest wall 
all the sarcomas were of high grade (109). In 39% of cases 
in Robinson's review stage was mentioned and most of these 
were diagnosed at an advanced stage. 
Robinson (94) states that all PRS, regardless of the 
histologic appearance, should be considered as poor 
prognosis. Because of the poor prognosis and malignant 
behaviour of these tumors a more aggressive approach to 
their treatment is warranted. More radical surgery should 
be done where possible, together with innovative 
radiotherapy and systemic therapy. Currently a radical 
surgical approach offers the best means of palliation and 
the only chance for cure (94). The planned combined 
approach advocated for secondary sarcomas in the head and 
neck region (106) should probably be used when it is 
feasible for all postradiation sarcomas. 
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4.7. CONCLUSIONS AND RECOMMENDATIONS 
4.7.1. SUMMARY 
Overall it appears that the incidence of PRS is certainly 
less than 1% (68, 94, 122), except in certain groups where 
a genetic predisposition to sarcoma development also exists 
( 2 8) • The latency period which must have passed between 
radiotherapy and presentation with the tumor for it to be 
classifiable as a postradiation sarcoma is controversial, 
but in general a shorter latency period than the 5 years 
initially proposed by Cahan has been accepted (14, 5, 94). 
The median latency in our study was 9 years. 
It is impossible to determine in an individual case of 
sarcoma arising in an irradiated field whether or not the 
irradiation was completely or even partly responsible for 
the development of the tumor (100). A very wide variety of 
sarcomas have been reported to arise in radiation fields as 
described in section 4. 5 .1. Histological features cannot 
be used to differentiate between a primary sarcoma and one 
occurring due to irradiation (50, 35, 36, 59). Factors 
such as the previous use of chemotherapy (116, 28) and 
genetic factors (28, 110) may also contribute to the 
development of sarcomas as second malignancies. The dose-
relationship in the development of PRS is not clear. It is 
possible that the tumor is more likely to arise at 
relatively high therapeutic doses but that the incidence 
falls when cell kill exceeds the transforming effect of the 
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irradiation ( 3 8) . The median dose at which tumors were 
estimated to have developed in our study was 49Gy. 
The treatment of PRS includes surgery if this is feasible 
(109, 75, 58, 79). The response to radiotherapy and 
chemotherapy has generally been poor but this does not 
preclude their use in the treatment of the condition (122, 
10 9) . The prognosis of PRS is poor ( 94) but there is not 
agreement as to whether it is poorer than for spontaneous 
sarcomas (72, 93, 94, 59). 
4.7.2. RECOMMENDATIONS 
4.7.2.1) Awareness and Record-keeping 
Heightened awareness of the condition is essential so that 
unnecessary radiation is avoided and an early diagnosis is 
made when a sarcoma does arise in a previously irradiated 
field. Careful records must be kept so that true incidence 
figures can be assessed. Record-keeping systems should 
allow the numerator (number of cases) and the denominator 
(in this case possibly 5-year-survivors of radiotherapy) to 
be determined. 
In view of the rarity of the condition a multicentre study 
should be performed. In the absence of this, literature 
reviews such as that by Robinson et al ( 94) form a very 
useful part of our database on this condition. 
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The reporting of radiotherapy treatment regimens in patents 
in whom PRS has arisen is also important if further clarity 
about the cause of this condition is to be obtained. The 
risk of tumor induction must be included in the evaluation 
of new therapeutic modalities such as intraoperative 
radiotherapy (35). 
For such a review as Robinson's ( 94) to be feasible, each 
report of a series must include details of previous 
treatment. Further understanding of this condition should 
contribute to our understanding of carcinogenesis (51, 70). 
4.7.2.2) Primary Malignancies: Treatment Decisions 
An awareness of the likelihood of the condition arising in 
different circumstances is important if balanced decisions 
regarding the use of different treatment modalities are to 
be made. 
Every effort should be made to avoid the occurrence of PRS 
by avoiding unnecessary radiation, such as radiotherapy for 
benign conditions when it is not strictly necessary (75, 
14, 112), particularly if surgery without severe morbibity 
is an option (87). This warning also applies to the use of 
postoperative radiotherapy for low grade endometrial 
stromal sarcoma. In this condition an option is to use 
progesterone therapy ( 1 7) . As PRS is generally a rare 
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complication of radiotherapy it should not be considered a 
contraindication to the use of radiotherapy for treating 
malignant tumors (15). Coleman (18) has stated that all 
possible efforts should be made to avoid second tumors if 
cures will not be compromised. 
In a literature review that compared mortality risks of 
chemotherapy, general surgery and anesthesia, Mark et al 
( 68) noted that the risk of PRS and second cancers after 
radiotherapy in general did not appear worse than risks of 
other treatments. Thus they felt that, given the large 
number of patients cured or palliated by radiotherapy, this 
potential complication should not be a major factor 
influencing treatment decisions in cancer patients. 
This still leaves unanswered the question of the use of 
radiotherapy for conditions such as early breast cancer 
when other modalities of therapy are available. Davidson 
(25) has noted that induced malignancy may be considered an 
acceptable complication when radiotherapy is the only, or 
most appropriate, treatment for a patient with a life-
threatening cancer; and that an induced tumor would be 
unlikely in a radiotherapy failure. However where the 
choice between radiotherapy and other treatments is more 
finely balanced, such as in early breast carcinoma, the 
morbidity and mortality of radiation-induced malignancies 
must be borne in mind (25). Choy (16) has suggested that 
it is unlikely that radiation-induced secondary tumors will 
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emerge as a significant complication of the breast-
conserving treatment of breast cancer. 
Further evidence in favour of radiotherapy in early breast 
cancer is 1) the possibility of sarcoma development 
complicating mastectomy (29) and 2) the extreme rarity of 
reports of PRS after breast conservation radiotherapy. 
The use of radiotherapy is not as problematic in paediatric 
cancers, where its application may be essential to improve 
the cure rate, as in early breast cancer. 
children survive cancer potential 
However as more 
complications of 
treatment such as second tumor development do become more 
important in initial treatment decisions (44). 
With improvement in methods of delivering radiation and 
protecting tissues as well as improved case selection it 
has been hoped that the incidence of PRS will decrease 
( 7 5) • 
A further question is the problem of explaining this 
possible complication to a patient without arousing 
unnecessary anxiety. It has been suggested in relation to 
the treatment of uterine malignancies that only the 
absolute risk should be discussed with the patient, making 
her aware of the problem but avoiding unnecessary fears 
( 9 6) • 
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4.7.2.3) The Importance of Follow-up after Radiotherapy 
It has been recommended that if patients are irradiated for 
benign uterine disorders, they should be indefinitely 
followed up and educated as to the signs and symptoms of 
uterine cancer (72). Permanent follow-up has also been 
recommended after radiotherapy for 





patients who have received radical radiotherapy (109, 99). 
4.7.2.4) The Development of Postradiation Sarcoma in 
relation to Dose 
It should be clarified as urgently as possible whether or 
not there is a dose-relationship between radiotherapy and 
sarcoma development. The relative tissue dose and bone 
absorption with different modalities should be considered 
when deciding upon treatment. It has been suggested in the 
case of uterine malignancy that if only selected patients 
can receive Co-60 radiotherapy rather than orthovoltage 
therapy, young women with longer life expectancy, more 
sensitive to postirradiation effects, and patients with 
greater antero-postero diameter, should be selected for the 
higher energy treatment ( 96) . High energy radiation has 
been recommended if radiotherapy is to be used in the case 
of giant cell tumor of bone (76). The relative absorption 
in bone from, for example, I-125, should be borne in mind 
when this isotope is used in the treatment of 
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retinoblastoma patients who appear to be particulary 
susceptible to postradiation sarcomas. 
4.7.2.5) Treatment Approach to Postradiation Sarcomas 
It has been seen in the previous chapter that the poor 
prognosis of PRS should lead to a more aggressive approach 
rather than a less aggressive one (106). The dismal 
outlook for the condition overall does not always preclude 
cure and careful investigation and staging should be 
performed, followed by an aggressive radical planned 
combined modality treatment approach where feasible (106). 
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Figures 1-20 
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Tumor 
Maximum dose point 
Field centre 
Centre of field entrance 
Centre of field entrance 
Centre of field exit 





PRIMARY TUMOR: Ca cervix 
RADIOTHERAPY: 4 planned fields and radium insertion 




L I so doses 
POST. 
Total Gray Distribution 1.5 cm inferior to central axis. Secondary tumor 











PRIMARY TUMOR: Ca cervix 
RADIOTHERAPY: 4 planned fields and radium insertion. 
Secondary tumor in anterior field. 













A FIGURE 3 
Lt. 
PRIMARY TUMOR: Ca cervix 
RADIOTHERAPY: 8 planned fields and 2 radium insertions. 
B 
Rt. 












Total Gray Distribution central axis. Secondary tumor 4 cm above the 






PRIMARY TUMOR: Ca cervix 
RADIOTHERAPY: 4 planned fields and radium insertion. Secondary 















Total Gray Distribution central axis. Secondary tumor at this level 
at time of presentation. 
Rt. 
FIGURE 4 
Sup. margin of angled fields 
Inf. margin of angled fields 
PRIMARY TUMOR: Ca cervix 
Lt. 
9ADIOTHERAPY: 2 radium insertions and 4 planned fields. Secondary 




PRIMARY TUMOR: Ca cervix 
RADIOTHERAPY: Anterior and posterior fields and 2 
radium insertions. Secondary tumor 






















A Sup. margin of angled fields 
Lt. 
Inf. margin of angled fields 
PRIMARY TUMOR: Low grade stromal sarcoma uterus 
RADIOTHERAPY: 8 planned fields. Secondary tumor in anterior fields. 
























PRIMARY TUMOR: Ca left breast 
boost 
field 
RADIOTHERAPY: 2 tangential fields and electron boost left (previous treatment 





Total Gray Distribution 6.5 cm inferior to central axis. Level through secondary 




















PRIMARY TUMOR: Ca left breast 
Posterior field 
RADIOTHERAPY: Anterior and posterior planned fields. Secondary 

















Total Gray Distribution 2 cm inferior to central axis (edge of Pb.) 




PRIMARY TUMOR: Ca right breast 
RADIOTHERAPY: Anterior and posterior planned fields. 
Secondary tumor in relation to fields. 



















PRIMARY TUMOR: Bilateral retinoblastoma 
RADIOTHERAPY: 5 planned fields, 2 Tantalum-182 applicators. Secondary 





















A co60 fields 
Lt. 
PRIMARY TUMOR: Bilateral retinoblastoma. 
RADIOTHERAPY: Two 250 kV fields, 1-125 implant, 2 courses of Co-60. 
Rt. 
Secondary tumor in the 250 kV fields. Centres of Co-60 
fields are shown. 
Body outline level 












Total Gray Distribution 1 cm inferior to central axis of 250 kV fields. Level 
through mid-secondary tumor. 
FIGURE 13 
A 
Inf. margin of fields 
PRIMARY TUMOR: Bilateral retinoblastoma 











rn I auditory meatus 
Total Gray Distribution central axis. Level through mid-secondary tumor. 
FIGURE 14 




PRIMARY TUMOR: Wilms' tumor right kidney 
RADIOTHERAPY: Anterior and posterior fields pre- and post-operatively. 
Secondary tumor in relation to anterior fields. 




Total Gray Distribution inferior border of pre-operative fields. Level through 
superior iliac crest. 
A FIGURE 15 
margin ot ~\~ ---
I Exit 2 .e-- -
' ' -----
PRIMARY TUMOR:Ca left parotid. 
C --
-
RADIOTHERAPY: 2 planned fields left parotid area. Secondary tumor on RIGHT 











Total Gray Distribution through inferior margin of fields. Body of mandible 
superimposed. 
A FIGURE 16 
Lt. 
Rt. 
PRIMARY TUMOR:Synovial sarcoma left thigh 
RADIOTHERAPY: Anterior and posterior fields. 
B 
Secondary tumor in anterior field. 
ANT. 
POST. 







Total Gray Distribution 7.5 cm superior to central axis. Level through centre of 




PRIMARY TUMOR: Giant cell tumor right pelvis 
RADIOTHERAPY: Anterior and posterior fields. 
Secondary tumor in anterior field. 













Total Gray Distribution central axis. Level centre of secondary tumor. 
A FIGURE 18 
Rt. Lt. 
Fracture 
PRIMARY TUMOR: Giant cell tumor right humerus 
RADIOTHERAPY: Right and left lateral fields. 2 courses. 
ANT. 
Secondary tumor in relation to fields. 
Rt. 

















A Second course 
First course 
PRIMARY TUMOR: Fibromatosis left buttock 
Posterior pelvis 
Rt. 
RADIOTHERAPY: 1. Posterior field. 2. Anterior and posterior fields. 
B 
Secondary tumor in relation to posterior fields. 









l-#-1-+-+-+----~-"n1r'f' ......... .....,...,....,...._:-t-t--+---<----,.,.--+---t---1--"1 Rt. 
40.~ .o (medial) 
ANT. 






PRIMARY TUMOR: Benign tumor right alveolus 
RADIOTHERAPY: Radium implant. Secondary tumor as shown. 
Lt. 
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